Differential expression of molecules associated with acute stroke

ABSTRACT

Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.

CROSS REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. application Ser. No. 11/155,835 filed Jun.17, 2005, now U.S. Pat. No. 7,749,700 issued Jul. 6, 2010, which is acontinuation-in-part of PCT/US2005/018744 filed May 27, 2005, whichclaims priority to U.S. Provisional Application No. 60/575,279 filed May27, 2004, all herein incorporated by reference in their entirety.

FIELD

This application relates to methods of evaluating an ischemic stroke,methods of identifying a treatment modality for a subject who has had anischemic stroke, methods of identifying compounds that alter theactivity of an ischemic stroke-related molecule, as well as arrays andkits that can be used to practice the disclosed methods.

BACKGROUND

Stroke is the third leading cause of death and the leading cause ofadult disability in developed countries (Simons et al., Stroke29:1341-6, 1998; Adams et al., Ischemic Cerebrovascular Disease. NewYork: Oxford, 2001). Strokes are caused by an interruption of blood flowto the brain, by either an intravascular occlusion (such as an arterialthrombus) or a hemorrhage. The American Heart Association estimates thatthere are approximately three million stroke survivors in the UnitedStates, most of whom are disabled. Despite the prevalence and burden ofthis disease, stroke precipitants and pathophysiological mechanisms inindividual patients are often unknown. It is also difficult toaccurately predict whether a stroke will lead to only minor neurologicalsequelae or more serious medical consequences.

Gene expression profiling involves the study of mRNA levels in a tissuesample to determine the expression levels of genes that are expressed ortranscribed from genomic DNA. Animal experiments in focally ischemicbrain tissue have indicated that there are alterations in geneexpression following a stroke (Stenzel-Poore et al., Lancet 362:1028-37,2003; Lu et al., J. Cereb. Blood Flow. Metab. 23:786-810, 2003; Tang etal., Eur J Neurosci 15:1937-52, 2002; Tang et al., Ann. Neurol.50:699-707, 2001; and Tang et al., J Cereb Blood Flow Metab 23:310-9,2003). However, gene expression profiling has not yet been applied toclinical human stroke, primarily because brain tissue samples areinaccessible and rarely justified. Therefore, an assay that can allowone to determine the genetic expression profile of ischemic strokewithout the need for brain tissue samples is needed.

Currently, there is no specific blood marker of acute stroke. Followinga stroke, released brain antigens can be detected in the blood. Suchantigens include S100B, neuron specific enolase (NSE), and glialfibrillary acid protein (GFAP), although S100B and GFAP are of lowsensitivity for early stroke diagnosis, and NSE and myelin basic protein(MBP) MBP are non-specific (Lamers et al., Brain. Res. Bull. 61:261-4,2003). Four soluble factors that have demonstrated moderate sensitivityand specificity for the diagnosis of stroke include two markers ofinflammation (matrix metalloproteinase-9 and vascular cell adhesionmolecule), one marker of glial activation (S100beta) and one thrombosismarker (von Willebrand factor) (Lynch et al., Stroke 35:57-63, 2004).However, a panel of markers which allow one to diagnose and prognoseischemic stroke with high diagnostic sensitivity and specificity isstill needed.

SUMMARY

Although stroke is one of the leading causes of morbidity and mortalityin developed countries, methods for rapidly and accurately determiningwhether a subject has had a stroke are expensive and invasive.Therefore, new methods are needed for evaluating a stroke, for examplefor determining whether an ischemic stroke has occurred, for determiningthe severity of the stroke or the likely neurological recovery of thesubject who had an ischemic stroke, or combinations thereof. Inparticular examples, the disclosed methods offer a potentially lowercost alternative to expensive imaging modalities (such as MRI and CTscans), can be used in instances where those imaging modalities are notavailable (such as in field hospitals), and can be more convenient thanplacing individuals in scanners (for example for subjects who can not besubjected to MRI, such as those having certain types of metallicimplants in their bodies).

Using these methods, appropriate therapy protocols for subjects who havehad an ischemic stroke can be identified and administered. For example,because the results of the disclosed methods are highly reliablepredictors of the ischemic nature of the stroke, the results can also beused (alone or in combination with other clinical evidence and brainscans) to determine whether thrombolytic therapy designed to lyse aneurovascular occlusion such as a thrombus (for example by using tissueplasminogen activator or streptokinase) should be administered to thesubject. In certain examples, thrombolytic therapy is given to thesubject once the results of the differential expression assay are knownif the assay provides an indication that the stroke is ischemic innature.

The inventors have identified changes in gene expression in peripheralblood mononuclear cells (PBMCs) that allow one to evaluate a stroke, forexample to determine whether a subject has had an ischemic stroke, todetermine the severity of an ischemic stroke, to determine the likelyneurological recovery of the subject, or combinations thereof. Thedisclosed methods allow one to screen many genes simultaneously andserially and only a relatively small amount of cell or tissue sample isneeded. Changes in gene expression were observed in at least 22 genes,at least 82 genes, at least 190 genes, or even at least 637 genesdepending on sensitivity and specificity used. In particular examples,subjects who had an ischemic stroke showed increased gene expression inCD163; hypothetical protein FLJ22662 Laminin A motif; bone marrowstromal cell antigen 1 (BST-1, also known as CD157); Fc fragment of IgG,high affinity Ia, receptor for (FcγRI, also known as CD64); baculoviralIAP repeat-containing protein 1 (also referred to in the literature asneuronal apoptosis inhibitory protein); or KIAA0146, or any combinationsthereof, such as a change in expression in at least 1, at least 2, atleast 3, at least 4, at least 5, or all 6 of these genes. In someexamples, subjects who had an ischemic stroke showed increased geneexpression in four classes of genes: genes involved in white blood cellactivation and differentiation, genes related to hypoxia, genes involvedin vascular repair, and genes related to a PBMC response to the alteredcerebral microenvironment.

The disclosed gene expression fingerprint of ischemic stroke enablesmethods of evaluating a stroke, for example determining whether asubject had an ischemic stroke, determining the prognosis of a subjectwho had an ischemic stroke, as well as determining an appropriatetreatment regimen for a subject who had an ischemic stroke. In someexamples, the disclosed methods are at least 78% sensitive and at least80% specific for identifying those subjects who have suffered anischemic stroke, for example within the past 72 hours. In otherexamples, the disclosed methods are at least 80% sensitive (such as atleast 85% sensitive or at least 90% sensitive) and at least 80% specific(such as at least 85% specific or at least 90% specific) for identifyingthose subjects who have suffered an ischemic stroke, for example withinthe past 72 hours. In particular examples, the disclosed methods are atleast 80% sensitive for predicting the likelihood of neurologicalrecovery of the subject.

In some examples, the method involves detecting patterns of increasedprotein expression, decreased protein expression, or both. Such patternsof expression can be detected either at the nucleic acid level (such asquantitation of mRNAs associated with protein expression) or the proteinlevel (such as quantitative spectroscopic detection of proteins).Certain methods involve not only detection of patterns of expression,but detection of the magnitude of expression (increased, decreased, orboth), wherein such patterns are associated with the subject having hadan ischemic stroke, or is associated with predicted clinical sequelae,such as neurological recovery following an ischemic stroke.

The disclosed methods are the first that permit accurate diagnosis of anischemic stroke using PBMCs with high sensitivity and specificity. PBMCsinfiltrate the evolving cerebral infarct as part of the tissueremodeling process. Release of brain antigens from damaged neural cellsmay allow sensitization of PBMCs followed by changes in functional geneexpression.

The disclosed methods can be performed on a subject who is suspected ofhaving had a stroke, for example prior to radiographic investigation. Inanother example, the method is performed on a subject known to have hada stroke, as the disclosed assays permit early and accuratestratification of risk of long-lasting neurological impairment.

In one example, the method of evaluating a stroke includes determiningwhether a subject has changes in expression in four or more ischemicstroke-associated molecules that comprise, consist essentially of, orconsist of, sequences (such as a DNA, RNA or protein sequence) involvedin white blood cell activation and differentiation, sequences related tohypoxia, sequences involved in vascular repair, and sequences related toa PBMC response to the altered cerebral microenvironment, such as thoselisted in Table 5.

In other examples, ischemic stroke-associated molecules comprise,consist essentially of, or consist of, CD163; hypothetical proteinFLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; and KIAA0146, or any 1, 2, 3, 4, 5, or 6 ofthese molecules. For example, ischemic stroke-associated molecules cancomprise, consist essentially of, or consist of, 4 or more, such as 5 ormore, 10 or more, 20 or more, 22 or more, 50 or more, 75 or more, 80 ormore, 82 or more, 100 or more, 150 or more, 190 or more, 200 or more,300 or more, 500 or more, 600 or more, or 637 or more of the nucleicacid or protein sequences listed in Tables 2-5. Any of the identifiedsequences can be used in combination with such sets or subsets ofsequences.

In a particular example, evaluating a stroke includes detectingdifferential expression in at least four ischemic stroke-relatedmolecules of the subject, such as any combination of at least four genes(or the corresponding proteins) listed in any of Tables 2-5, wherein thepresence of differential expression of at least four ischemic-strokerelated molecules indicates that the subject has had an ischemic stroke.Therefore, such methods can be used to diagnose an ischemic stroke. Inparticular examples, the at least four ischemic-stroke related moleculesinclude at least one of CD163; hypothetical protein FLJ22662 Laminin Amotif; BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; orKIAA0146, such as at least 2, at least 3, at least 4, at least 5 or atleast 6 of such molecules. For example, the method can includedetermining if the subject has increased gene (or protein) expression ofat least one of CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; or KIAA0146,optionally in combination with determining if the subject has alteredgene (or protein) expression of any other combination of other ischemicstroke-associated molecules, such as any combination of at least 3 othergenes (for example any combination of at least 5, at least 10, at least20, at least 50, at least 100, at least 200, or even at least 500 genes)listed in Tables 2-5.

In a particular example, differential expression is detected bydetermining if the subject has increased gene (or protein) expression ofat least one of CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; or KIAA0146,and determining if the subject has decreased gene (or protein)expression of at least one of intercellular adhesion molecule 2, proteinkinase D2, GATA binding protein 3, hypothetical protein FLJ20257, orprotein kinase C, theta. For example, differential expression can bedetected by determining if the subject has increased gene (or protein)expression of CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; and KIAA0146,and determining if the subject has decreased gene (or protein)expression of intercellular adhesion molecule 2, protein kinase D2, GATAbinding protein 3, hypothetical protein FLJ20257, and protein kinase C,theta.

In one example, the method includes determining if the subject has anincrease in gene expression in any combination of at least four of thegenes listed in Table 5, for example an increase in at least 5, at least10, at least 15, at least 20, or at least 22 of the genes listed inTable 5. An increase in expression in any combination of four or more ofthe genes listed in Table 5 (or the corresponding proteins), andparticularly any combination of at least one gene (or protein) from eachof the four classes of genes listed in Table 5 (such as any combinationof at least 2 or at least 3 sequences from each of the four classes ofgenes listed in Table 5) indicates that the subject has had an ischemicstroke. Any one of the set of genes (or proteins) can be identified by asingle one or the genes (or proteins) listed in Table 5. Any one of thegenes (or proteins) in Table 5 can be combined with any othercombination of the genes (or proteins) in Table 5 to produce acombination or subcombination of genes (or proteins).

In one example, the method of evaluating a stroke includes determiningif the subject has a change in gene expression (such as an increase ordecrease) in any combination of at least 150 of the 190 of the geneslisted in Table 3, for example a change in expression in at least 160,at least 170, at least 175, at least 180, or at least 185 of the geneslisted in Table 3. Any one of the set of genes can be identified by asingle one or the genes listed in Table 3. Any one of the genes (orproteins) in Table 3 can be combined with any other combination of thegenes (or proteins) in Table 3 to produce a combination orsubcombination of genes. A change in expression in any combination of150 or more of the genes listed in Table 3 (or the correspondingproteins) indicates that the subject has had an ischemic stroke.

In another example, the method of evaluating a stroke includesdetermining if the subject has a change in gene expression (such as anincrease or decrease) in any combination of at least 510 of the 637 ofthe genes listed in Table 2, for example an increase or decrease in anycombination of at least 510, at least 550, at least 575, at least 600,at least 620, or at least 630 of the genes listed in Table 2. Any one ofthe set of genes (or proteins) can be identified by a single one or thegenes (or proteins) listed in Table 2. Any one of the genes (orproteins) in Table 2 can be combined with any other combination of thegenes (or proteins) in Table 2 to produce a combination orsubcombination of genes. A change in expression in any combination of510 or more of the genes listed in Table 2 (or the correspondingproteins) indicates that the subject has had an ischemic stroke.

In some examples, the amount of gene (or protein) expression in thesubject is compared to a control, such as the gene (or protein)expression of a subject who has not had an ischemic stroke, wherein anincrease or decrease in expression in any combination of four or moreischemic stroke related genes listed in Tables 2-5 compared to thecontrol indicates that the subject has experienced an ischemic stroke.For example, an increase in expression in any combination of four ormore ischemic stroke related genes (or the corresponding proteins)listed in Table 5, such as at least one gene (or the correspondingprotein) from each class listed in Table 5, compared to the controlindicates that the subject has experienced an ischemic stroke.

In particular examples evaluating the stroke includes predicting alikelihood of severity of neurological sequelae of the ischemic stroke.In some examples, evaluating the stroke includes predicting a likelihoodof neurological recovery of the subject. For example, if there isdifferential expression (such as increased expression) in at least the22 ischemic-stroke related molecules listed in Table 5, indicates thatthe subject has a higher risk of long-term adverse neurological sequelaeand therefore a lower likelihood of neurological recovery. In anotherexample, detecting a change in expression in any combination of 150 ormore of the genes listed in Table 2 or 3 (or the corresponding proteins)indicates that the subject has a higher risk of long-term adverseneurological sequelae and therefore a lower likelihood of neurologicalrecovery. In yet another example, detecting a change in expression inany combination of at least 500 of the 637 of the genes listed in Table2, for example an increase or decrease in any combination of at least510, at least 550, at least 575, at least 600, at least 620, or at least630 of the genes listed in Table 2 indicates that the subject has ahigher risk of long-term adverse neurological sequelae and therefore alower likelihood of neurological recovery. In some examples,differential expression in the subject is compared to differentialexpression of a subject who has not had an ischemic stroke, wherein achange in expression in at least the 22 ischemic-stroke relatedmolecules listed in Table 5, such as any combination of 150 or more ofthe genes listed in Tables 2 or 3 (or the corresponding proteins)compared to the control indicates that the subject has a higher risk oflong-term adverse neurological sequelae and therefore a lower likelihoodof neurological recovery.

The disclosed methods can further include administering to a subject atreatment to avoid or reduce ischemic injury if the presence ofdifferential expression indicates that the subject has had an ischemicstroke. For example, a change in expression in at least four ischemicstroke related molecules, such as a combination that includes at leastfour of the molecules listed in Tables 2-5, indicates that the subjecthas had an ischemic stroke (and not a hemorrhagic stroke) and is in needof thrombolytic therapy (such as t-PA or heparin), anticoagulant therapy(such as coumadin), or combinations thereof. Therefore, the disclosedmethods differentiate ischemic from hemorrhagic stroke, and allow one toadminister the appropriate therapy to the subject. In some examples, theamount of differential expression in the subject is compared to theexpression of a subject who has not had an ischemic stroke, wherein achange in expression in at least four ischemic stroke related moleculeslisted in Table 2-5 (or the corresponding proteins), such as at leastthose 22 listed in Table 5, compared to the control indicates that thesubject would benefit from thrombolytic therapy, anticoagulant therapy,or combinations thereof.

In some examples the presence of differential expression is evaluated bydetermining a t-statistic value that indicates whether a gene or proteinis up- or down-regulated. For example, an absolute t-statistic value canbe determined. In some examples, a negative t-statistic indicates thatthe gene or protein is downregulated, while a positive t-statisticindicates that the gene or protein is upregulated. In particularexamples, a t-statistic less than −3 indicates that the gene or proteinis downregulated, such as less than −3.5, less than −3.6, less than −3.7or even less than −3.8, while a t-statistic of at least 3, such as atleast 3.5, at least 3.7, or at least 3.8 indicates that the gene orprotein is upregulated.

Differential expression can be detected at any time following the onsetof clinical signs and symptoms that indicate a potential stroke, such aswithin 24 hours, within 7-14 days, or within 90 days of onset ofclinical signs and symptoms that indicate a potential stroke. Examplesof such signs and symptoms include, but are not limited to: headache,sensory loss (such as numbness, particularly confined to one side of thebody or face), paralysis (such as hemiparesis), pupillary changes,blindness (including bilateral blindness), ataxia, memory impairment,dysarthria, somnolence, and other effects on the central nervous systemrecognized by those of skill in the art.

In particular examples, the disclosed methods include isolating nucleicacid molecules from PBMCs of a subject suspected of having had anischemic stroke (or known to have had an ischemic stroke), such as mRNAmolecules. The isolated nucleic acid molecules are contacted with orapplied to an array, for example an array that includes oligonucleotideprobes capable of hybridizing to ischemic stroke-associated genes. Inanother particular example, the disclosed methods include purifyingproteins from PBMCs of a subject suspected of having had an ischemicstroke (or known to have had an ischemic stroke). The isolated proteinsare contacted with or applied to an array, for example an array thatincludes antibody probes capable of hybridizing to ischemicstroke-associated proteins. In some examples, PBMCs are obtained withinat least the previous 72 hours of a time when the stroke is suspected ofoccurring, such as within the previous 24 hours.

Also provided herein are arrays that include molecules that permitevaluation of a stroke. Such arrays in particular examples permitquantitation of ischemic stroke-related nucleic acid or proteinsequences present in a sample, such as a sample that includes PBMCnucleic acid molecules or proteins.

In one example, the array includes oligonucleotide probes capable ofhybridizing to nucleic acid molecules (such as gene, cDNA or mRNAsequences) involved in white blood cell activation and differentiation,nucleic acid molecules related to hypoxia, nucleic acid moleculesinvolved in vascular repair, and nucleic acid molecules related to aPBMC response to the altered cerebral microenvironment, such as at leastthose listed in Table 5. Examples of particular genes are provided inTables 2-5. In particular examples, the array includes probes thatrecognize any combination of at least 4 of the genes listed in any ofTables 2-5, for example at least 10, at least 20, at least 50, at least100, at least 150, at least 160, at least 170, at least 175, at least180, at least 185, at least 200, at least 400, at least 500, at least510, at least 550, at least 575, at least 600, at least 620, or at least630 of the genes listed in any of Tables 2-5. For example, the array caninclude oligonucleotide probes capable of hybridizing to a sequence thatencodes at least CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; and KIAA0146,or any one of these. In one example, the array includes oligonucleotideprobes capable of hybridizing to a sequence that encodes one or more ofCD163; hypothetical protein FLJ22662 Laminin A motif; BST-1; FcγRI;baculoviral IAP repeat-containing protein 1; or KIAA0146, such as atleast 2, at least 3, at least 4, at least 5 or at least 6 of suchmolecules. In some examples, the array includes probes that recognizeany combination of at least one gene from each of the four classeslisted in Table 5, such as at least 2, at least 3, at least 5, or atleast 10 genes from each class.

The isolated nucleic acid molecules are incubated with the array for atime sufficient to allow hybridization between the isolated nucleic acidmolecules and oligonucleotide probes, thereby forming isolated nucleicacid molecules:oligonucleotide probe complexes. The isolated nucleicacid molecules:oligonucleotide probe complexes are then analyzed todetermine if there are changes in gene expression (such as increases ordecreases), for example changes in expression of any combination of fouror more of the genes listed in Table 5, such as 20 or more of the geneslisted in Tables 2-5, or such as 150 or more of the genes listed inTables 2-4. In particular examples, changes in gene expression arequantitated. The presence of increased expression of four or more geneslisted in Tables 2-5 with a positive t-statistic value, or decreasedexpression of four or more genes listed in Tables 2-4 with a negativet-statistic value (or any combination thereof, such as decreasedexpression of at least one gene and increased expression of at least 3genes listed in Tables 2-4), after multiple comparison correction,indicates that the subject has had an ischemic stroke.

In another example, the method includes isolating proteins from PBMCs ofa subject suspected of having had an ischemic stroke, or known to havehad an ischemic stroke. In particular examples the assay is performed onsubstantially purified or isolated PBMCs that have been separated, forexample, for other leukocytes in the blood. The isolated proteins arecontacted with or applied to an array.

Arrays that can be used to detect and quantitate proteins for evaluatingstroke are also provided. For examples, the array, such as aprotein-binding array, can include probes (such as an oligonucleotideprobes or antibodies) capable of hybridizing to ischemic-stroke relatedproteins, such as proteins involved in white blood cell activation anddifferentiation, proteins related to hypoxia, proteins involved invascular repair, and proteins related to a PBMC response to the alteredcerebral microenvironment. Examples of particular ischemic-strokerelated proteins are provided in Tables 2-5. The isolated proteins areincubated with the array for a time sufficient to allow hybridizationbetween the proteins and probes on the array, thereby formingprotein:probe complexes.

The protein:probe complexes are then analyzed and in some examplesquantitated to determine if there are changes in gene expression (suchas increases or decreases) in any combination of four or more of themolecules listed in any of Tables 2-5, such as changes in expression ofone or more of CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-vcontaining protein 1; andKIAA0146, or 2, 3, 4, or 5 of these. In a specific example,protein:probe complexes are analyzed (for example quantitated) todetermine if there are increases in expression in any combination of atleast one protein from each of the four classes listed in Table 5, suchas at least 2, at least 3, at least 5, or at least 10 genes from each ofthe classes listed in Table 5. The presence of increased or decreasedexpression of any combination of four or more proteins listed in Tables2-4 (or increased expression of any combination of four or more proteinslisted in Table 5), indicates that the subject has had an ischemicstroke.

In particular examples, the disclosed arrays are capable of evaluating astroke, for example for determining whether a subject has had anischemic stroke, determining the severity of the ischemic stroke,determining the likelihood of neurological recovery of a subject who hadan ischemic stroke, determining how to treat a subject who had anischemic stroke, or combinations thereof. Such arrays includeoligonucleotides that are complementary to ischemic stroke-relatedgenes, such as those involved in white blood cell activation anddifferentiation, genes related to hypoxia, genes involved in vascularrepair, and genes related to a PBMC response to the altered cerebralmicroenvironment. Examples of particular genes are provided in Tables2-5. Kits including such arrays are also disclosed.

In one example, proteins a biological sample are quantitated, forinstance by quantitative mass spectroscopy, to determine whetherproteins associated with ischemic stroke or prognosis of ischemic strokeare upregulated, downregulated, or both.

Also provided in the present disclosure are methods of identifying oneor more agents that alter the activity (such as the expression) of anischemic stroke-related molecule (for example a gene or protein), suchas one or more of those listed in Tables 2-5. If desired, multiple testagents and multiple ischemic stroke-related molecules can be screened atthe same time. In one example, the method is used to screen the effectof one test agent on multiple ischemic stroke-related moleculessimultaneously (such as all of the ischemic stroke-related moleculeslisted in Table 2 or Table 3). In another example, the method is used toscreen the effect of multiple test agents on one ischemic stroke-relatedmolecule, such as one of the molecules listed in Tables 2-5. Inparticular examples, the identified agent alters the activity of anischemic stroke-related molecule that is upregulated or downregulatedfollowing an ischemic stroke. For example, the agent can normalizeactivity of an ischemic stroke-related molecule that is upregulated ordownregulated following an ischemic stroke, such as by increasing theactivity of an ischemic stroke-related molecule that is downregulatedfollowing an ischemic stroke, or decreasing activity of an ischemicstroke-related molecule that is upregulated following an ischemicstroke. The disclosed methods can be performed in vitro (for example ina cell culture) or in vivo (such as in a mammal).

In one example, the test agent is an agent in pre-clinical or clinicaltrials or approved by a regulatory agency (such as the Food and DrugAdministration, FDA), to treat ischemic stroke. For example, the methodcan be used to determine if the agent alters the activity of one or moreischemic stroke-related molecules that modifies response to treatmentand can predict the best responders.

In another example, the method is used to identify a particular class ofagents, such as those that are effective against hypoxia. For example,one or more test agents can be screened using the methods disclosedherein, and differential expression of the disclosed hypoxia-relatedgenes (or proteins) measured. Test agents that alter the activity of oneor more disclosed hypoxia-related molecules are candidates for treatmentof hypoxia.

The disclosed methods can also be used in toxicogenomics, for example toidentify genes or proteins whose expression is altered in response tomedication-induced toxicity and side-effects. In one example, thedisclosed ischemic stroke-related molecules are screened to identifythose whose activity is altered in response to an agent. For example,the disclosed ischemic stroke-related molecules can be used determine ifan agent promotes or induces ischemic stroke. Briefly, the test agent iscontacted with a normal cell (such as a PBMC, endothelia, or neuronalcell), such as a cell that has not been exposed to conditions that mimican ischemic stroke, and differential expression of one or more ischemicstroke molecules measured using the methods disclosed herein. If theagent promotes or induces differential expression of one or more, suchas at least 4 of the disclosed ischemic stroke-related molecules (suchas those listed in Tables 2-5) in an otherwise normal cell or mammal(for example as compared to a similar cell cultured in similarconditions without the test agent), this indicates that the agent maycause or promote an ischemic stroke in vivo. Such a result may indicatethat further studies of the agent are needed. In another example, cellsfrom a subject who is to receive a pharmaceutical agent are obtained(such as PBMCs), and the pharmaceutical agent incubated with the cellsas described above, to determine if the pharmaceutical agent causes orpromotes differential expression of one or more ischemic stroke-relatedmolecules. Such a result would indicate that the subject may reactadversely to the agent, or that a lower dose of the agent should beadministered.

The disclosure also provides methods of generating a brain imagingtracer or white blood cell tracers for molecular imaging, such asimaging to determine if a subject has had an ischemic stroke. Briefly, alabeled antibody that recognizes an ischemic stroke-related molecule,such as those involved in white blood cell activation anddifferentiation, those involved in the response to altered cerebralmicroenvironment, or combinations thereof (see Table 5). In one example,the label is a fluorophore, radioisotope, or other compound that can beused in diagnostic imaging, such as a nuclear medicine radio-isotope(for example ^(99m)Technetium for use with single photon emissioncomputed tomography, ¹⁸Fluorodeoxyglucose (¹⁸FDG) for use with positronemission tomography, or a paramagnetic contrast agent for magneticresonance imaging). The labeled antibody can be administered to thesubject, for example intravenously, and the subject imaged usingstandard methods.

The foregoing and other features and advantages of the disclosure willbecome more apparent from the following detailed description of aseveral embodiments.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1 is a graph showing the effects of various multiple comparisoncorrection techniques on the ischemic stroke microarrays.

SEQUENCE LISTING

The nucleic acid sequences listed in the accompanying sequence listingare shown using standard letter abbreviations for nucleotide bases. Onlyone strand of each nucleic acid sequence is shown, but the complementarystrand is understood as included by any reference to the displayedstrand.

SEQ ID NOS: 1-2 are oligonucleotide sequences used to perform RT-PCR todetermine expression levels of adrenomedullin.

SEQ ID NOS: 3-4 are oligonucleotide sequences used to perform RT-PCR todetermine expression levels of CD14.

SEQ ID NOS: 5-6 are oligonucleotide sequences used to perform RT-PCR todetermine expression levels of CD36.

SEQ ID NOS: 7-8 are oligonucleotide sequences used to perform RT-PCR todetermine expression levels of caspase 1.

SEQ ID NOS: 9-10 are oligonucleotide sequences used to perform RT-PCR todetermine expression levels of a-Catenin.

SEQ ID NOS: 11-12 are oligonucleotide sequences used to perform RT-PCRto determine expression levels of FcR2a.

SEQ ID NOS: 13-14 are oligonucleotide sequences used to perform RT-PCRto determine expression levels of FcER1a.

SEQ ID NOS: 15-16 are oligonucleotide sequences used to perform RT-PCRto determine expression levels of cathepsin B.

SEQ ID NOS: 17-18 are oligonucleotide sequences used to perform RT-PCRto determine expression levels of TRL2.

SEQ ID NOS: 19-20 are oligonucleotide sequences used to perform RT-PCRto determine expression levels of INFGR1.

DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS Abbreviations and Terms

The following explanations of terms and methods are provided to betterdescribe the present disclosure and to guide those of ordinary skill inthe art in the practice of the present disclosure. The singular forms“a,” “an,” and “the” refer to one or more than one, unless the contextclearly dictates otherwise. For example, the term “comprising a nucleicacid molecule” includes single or plural nucleic acid molecules and isconsidered equivalent to the phrase “comprising at least one nucleicacid molecule.” The term “or” refers to a single element of statedalternative elements or a combination of two or more elements, unlessthe context clearly indicates otherwise. As used herein, “comprises”means “includes.” Thus, “comprising A or B,” means “including A, B, or Aand B,” without excluding additional elements.

Unless explained otherwise, all technical and scientific terms usedherein have the same meaning as commonly understood to one of ordinaryskill in the art to which this disclosure belongs. Although methods andmaterials similar or equivalent to those described herein can be used inthe practice or testing of the present disclosure, suitable methods andmaterials are described below. The materials, methods, and examples areillustrative only and not intended to be limiting.

PBMC: peripheral blood mononuclear cell

Real time-PCR: real time polymerase chain reaction

Administration: To provide or give a subject an agent by any effectiveroute. Exemplary routes of administration include, but are not limitedto, oral, injection (such as subcutaneous, intramuscular, intradermal,intraperitoneal, and intravenous), sublingual, rectal, transdermal,intranasal, vaginal and inhalation routes.

Amplifying a nucleic acid molecule: To increase the number of copies ofa nucleic acid molecule, such as a gene or fragment of a gene, forexample a region of a ischemic stroke-associated gene. The resultingproducts are called amplification products.

An example of in vitro amplification is the polymerase chain reaction(PCR), in which a biological sample obtained from a subject (such as asample containing PBMCs) is contacted with a pair of oligonucleotideprimers, under conditions that allow for hybridization of the primers toa nucleic acid molecule in the sample. The primers are extended undersuitable conditions, dissociated from the template, and thenre-annealed, extended, and dissociated to amplify the number of copiesof the nucleic acid molecule. Other examples of in vitro amplificationtechniques include quantitative real-time PCR, strand displacementamplification (see U.S. Pat. No. 5,744,311); transcription-freeisothermal amplification (see U.S. Pat. No. 6,033,881); repair chainreaction amplification (see WO 90/01069); ligase chain reactionamplification (see EP-A-320 308); gap filling ligase chain reactionamplification (see U.S. Pat. No. 5,427,930); coupled ligase detectionand PCR (see U.S. Pat. No. 6,027,889); and NASBATM RNAtranscription-free amplification (see U.S. Pat. No. 6,025,134).

Quantitative real-time PCR is another form of in vitro amplifyingnucleic acid molecules, enabled by Applied Biosystems (TaqMan PCR).Real-time quantitative TaqMan PCR has reduced the variabilitytraditionally associated with quantitative PCR, thus allowing theroutine and reliable quantification of PCR products to producesensitive, accurate, and reproducible measurements of levels of geneexpression. The 5′ nuclease assay provides a real-time method fordetecting only specific amplification products. During amplification,annealing of the probe to its target sequence generates a substrate thatis cleaved by the 5′ nuclease activity of Taq DNA polymerase when theenzyme extends from an upstream primer into the region of the probe.This dependence on polymerization ensures that cleavage of the probeoccurs only if the target sequence is being amplified. The use offluorogenic probes makes it possible to eliminate post-PCR processingfor the analysis of probe degradation. The probe is an oligonucleotidewith both a reporter fluorescent dye and a quencher dye attached. Whilethe probe is intact, the proximity of the quencher greatly reduces thefluorescence emitted by the reporter dye by Förster resonance energytransfer (FRET) through space. Probe design and synthesis has beensimplified by the finding that adequate quenching is observed for probeswith the reporter at the 5′ end and the quencher at the 3′ end.

Anti-coagulants: Agents that decrease or prevent blood clotting.Anticoagulants can avoid the formation of new clots, and preventexisting clots from growing (extending), for example by decreasing orstopping the production of proteins necessary for blood to clot.Examples include, but are not limited to, aspirin, heparin,ximelagatran, and warfarin (Coumadin). Administration of anticoagulantsis one treatment for ischemic stroke, for example to prevent furtherstrokes. A particular type of anti-coagulant are anti-platelet agents,which can also be used to prevent further strokes from occurring andinclude aspirin, clopidogrel (Plavix), aspirin/dipyridamole combination(Aggrenox), and ticlopidine (Ticlid). Other agents used to preventstroke recurrence are antihypertensive drugs and lipid-lowering agentssuch as statins.

Array: An arrangement of molecules, such as biological macromolecules(such as peptides or nucleic acid molecules) or biological samples (suchas tissue sections), in addressable locations on or in a substrate. A“microarray” is an array that is miniaturized so as to require or beaided by microscopic examination for evaluation or analysis. Arrays aresometimes called DNA chips or biochips.

The array of molecules (“features”) makes it possible to carry out avery large number of analyses on a sample at one time. In certainexample arrays, one or more molecules (such as an oligonucleotide probe)will occur on the array a plurality of times (such as twice), forinstance to provide internal controls. The number of addressablelocations on the array can vary, for example from at least four, to atleast 10, at least 20, at least 30, at least 50, at least 75, at least100, at least 150, at least 200, at least 300, at least 500, least 550,at least 600, at least 800, at least 1000, at least 10,000, or more. Inparticular examples, an array includes nucleic acid molecules, such asoligonucleotide sequences that are at least 15 nucleotides in length,such as about 15-40 nucleotides in length. In particular examples, anarray includes oligonucleotide probes or primers which can be used todetect ischemia stroke-associated sequences, such as any combination ofat least four of those listed in Table 5, such as at least 10, at least20, at least 50, at least 100, at least 150, at least 160, at least 170,at least 175, at least 180, at least 185, at least 200, at least 400, atleast 500, at least 510, at least 550, at least 575, at least 600, atleast 620, or at least 630 of the sequences listed in any of Tables 2-5.In some examples, an array includes oligonucleotide probes or primerswhich can be used to detect at least one gene from each of the fourclasses of genes listed in Table 5, such as at least 2, at least 3, atleast 5, or even at least 10 genes from each of the four classes ofgenes listed in Table 5.

Within an array, each arrayed sample is addressable, in that itslocation can be reliably and consistently determined within at least twodimensions of the array. The feature application location on an arraycan assume different shapes. For example, the array can be regular (suchas arranged in uniform rows and columns) or irregular. Thus, in orderedarrays the location of each sample is assigned to the sample at the timewhen it is applied to the array, and a key may be provided in order tocorrelate each location with the appropriate target or feature position.Often, ordered arrays are arranged in a symmetrical grid pattern, butsamples could be arranged in other patterns (such as in radiallydistributed lines, spiral lines, or ordered clusters). Addressablearrays usually are computer readable, in that a computer can beprogrammed to correlate a particular address on the array withinformation about the sample at that position (such as hybridization orbinding data, including for instance signal intensity). In some examplesof computer readable formats, the individual features in the array arearranged regularly, for instance in a Cartesian grid pattern, which canbe correlated to address information by a computer.

Protein-based arrays include probe molecules that are or includeproteins, or where the target molecules are or include proteins, andarrays including nucleic acids to which proteins are bound, or viceversa. In some examples, an array contains antibodies to ischemicstroke-associated proteins, such as any combination of at least four ofthose listed in Table 5, such as at least 10, at least 20, at least 50,at least 100, at least 150, at least 160, at least 170, at least 175, atleast 180, at least 185, at least 200, at least 400, at least 500, atleast 510, at least 550, at least 575, at least 600, at least 620, or atleast 630 of the sequences listed in any of Tables 2-5. In particularexamples, an array includes antibodies or proteins that can detect atleast one protein from each class listed in Table 5, such as at least 2,at least 3, at least 5, or even at least 10 genes from each class listedin Table 5.

Baculoviral IAP repeat-containing protein 1 (Birc1): A protein thatincludes one or more baculoviral IAP repeat (BIR) domains, which iscapable of decreasing (an in some examples inhibiting) the biologicalactivity of caspases, and in some examples thereby decreasing orinhibiting apoptosis. The term baculoviral IAP repeat-containing protein1 includes any Birc1 gene, cDNA, mRNA, or protein from any organism andthat is a Birc1 that can decrease or inhibit caspase biologicalactivity. Also referred to in the literature as neuronal apoptosisinhibitory protein (Naip).

Birc1 sequences are publicly available. For example, GenBank AccessionNos: NM_(—)004536 and NP_(—)004527 disclose human Birc1 nucleic acid andprotein sequences, respectively and GenBank Accession Nos: NM_(—)010870and NP_(—)035000 disclose mouse Birc1 nucleic acid and proteinssequences, respectively.

In one example, a Birc1 sequence includes a full-length wild-type (ornative) sequence, as well as Birc1 allelic variants, variants,fragments, homologs or fusion sequences that retain the ability todecrease or inhibit caspase biological activity. In certain examples,Birc1 has at least 80% sequence identity, for example at least 85%, 90%,95%, or 98% sequence identity to a native Birc1. In other examples,Birc1 has a sequence that hybridizes under very high stringencyconditions to a sequence set forth in GenBank Accession No. NM_(—)010870or NM_(—)004536, and retains Birc1 activity.

Binding or stable binding: An association between two substances ormolecules, such as the hybridization of one nucleic acid molecule toanother (or itself), the association of an antibody with a peptide, orthe association of a protein with another protein or nucleic acidmolecule. An oligonucleotide molecule binds or stably binds to a targetnucleic acid molecule if a sufficient amount of the oligonucleotidemolecule forms base pairs or is hybridized to its target nucleic acidmolecule, to permit detection of that binding.

Binding can be detected by any procedure known to one skilled in theart, such as by physical or functional properties of the target:oligonucleotide complex. For example, binding can be detectedfunctionally by determining whether binding has an observable effectupon a biosynthetic process such as expression of a gene, DNAreplication, transcription, translation, and the like.

Physical methods of detecting the binding of complementary strands ofnucleic acid molecules, include but are not limited to, such methods asDNase I or chemical footprinting, gel shift and affinity cleavageassays, Northern blotting, dot blotting and light absorption detectionprocedures. For example, one method involves observing a change in lightabsorption of a solution containing an oligonucleotide (or an analog)and a target nucleic acid at 220 to 300 nm as the temperature is slowlyincreased. If the oligonucleotide or analog has bound to its target,there is a sudden increase in absorption at a characteristic temperatureas the oligonucleotide (or analog) and target disassociate from eachother, or melt. In another example, the method involves detecting asignal, such as a detectable label, present on one or both nucleic acidmolecules (or antibody or protein as appropriate).

The binding between an oligomer and its target nucleic acid isfrequently characterized by the temperature (T_(m)) at which 50% of theoligomer is melted from its target. A higher (T_(m)) means a stronger ormore stable complex relative to a complex with a lower (T_(m)).

Bone marrow stromal cell antigen 1 (BST-1): Aglycosylphosphatidylinositol (GPI)-anchored protein involved in adhesionto extracellular matrix proteins and in chemotaxis induced in vitro byformyl-methionyl-leucyl-phenylalanine (fMLP), as well as activation ofwhite blood cells. Also known in the art as CD157. The term bone marrowstromal cell antigen 1 (BST-1) includes any BST-1 gene, cDNA, mRNA, orprotein from any organism and that is a BST-1 that has BST-1 biologicalactivity. BST-1 sequences are publicly available. For example, GenBankAccession Nos: BT019502 and AAV38309 disclose human BST-1 nucleic acidand proteins sequences, respectively.

In one example, a BST-1 sequence includes a full-length wild-type (ornative) sequence, as well as BST-1 allelic variants, variants,fragments, homologs or fusion sequences that retain the ability tofunction in adhesion and chemotaxis. In certain examples, BST-1 has atleast 80% sequence identity, for example at least 85%, 90%, 95%, or 98%sequence identity to a native BST-1. In other examples, BST-1 has asequence that hybridizes under very high stringency conditions to asequence set forth in GenBank Accession No. BT019502, and retains BST-1activity.

CD163: A hemoglobin scavenger receptor. The term CD163 includes anyCD163 gene, cDNA, mRNA, or protein from any organism and that is a CD163that can function as a hemoglobin scavenger receptor. CD163 sequencesare publicly available. For example, GenBank Accession Nos: Y18388 andCAB45233 disclose human CD163 nucleic acid and protein sequences,respectively and GenBank Accession Nos: NM_(—)053094 and NP_(—)444324disclose mouse CD163 nucleic acid and proteins sequences, respectively.

In one example, a CD163 sequence includes a full-length wild-type (ornative) sequence, as well as CD163 allelic variants, variants,fragments, homologs or fusion sequences that retain the ability tofunction as a hemoglobin scavenger receptor. In certain examples, CD163has at least 80% sequence identity, for example at least 85%, 90%, 95%,or 98% sequence identity to a native CD163. In other examples, CD163 hasa sequence that hybridizes under very high stringency conditions to asequence set forth in GenBank Accession No. Y18388 or NM_(—)053094, andretains CD163 activity.

cDNA (complementary DNA): A piece of DNA lacking internal, non-codingsegments (introns) and regulatory sequences which determinetranscription. cDNA can be synthesized by reverse transcription frommessenger RNA extracted from cells.

Clinical indications of stroke: One or more signs or symptoms that areassociated with a subject having (or had) a stroke, such as an ischemicstroke. Particular examples include, but are not limited to: headache,sensory loss (such as numbness, particularly confined to one side of thebody or face), paralysis (such as hemiparesis), pupillary changes,blindness (including bilateral blindness), ataxia, memory impairment,dysarthria, somnolence, and other effects on the central nervous systemrecognized by those of skill in the art.

Complementarity and percentage complementarity: Molecules withcomplementary nucleic acids form a stable duplex or triplex when thestrands bind, (hybridize), to each other by forming Watson-Crick,Hoogsteen or reverse Hoogsteen base pairs. Stable binding occurs when anoligonucleotide molecule remains detectably bound to a target nucleicacid sequence under the required conditions.

Complementarity is the degree to which bases in one nucleic acid strandbase pair with the bases in a second nucleic acid strand.Complementarity is conveniently described by percentage, that is, theproportion of nucleotides that form base pairs between two strands orwithin a specific region or domain of two strands. For example, if 10nucleotides of a 15-nucleotide oligonucleotide form base pairs with atargeted region of a DNA molecule, that oligonucleotide is said to have66.67% complementarity to the region of DNA targeted.

In the present disclosure, “sufficient complementarity” means that asufficient number of base pairs exist between an oligonucleotidemolecule and a target nucleic acid sequence (such as an ischemicstroke-related sequence, for example any of the sequences listed inTables 2-5) to achieve detectable binding. When expressed or measured bypercentage of base pairs formed, the percentage complementarity thatfulfills this goal can range from as little as about 50% complementarityto full (100%) complementary. In general, sufficient complementarity isat least about 50%, for example at least about 75% complementarity, atleast about 90% complementarity, at least about 95% complementarity, atleast about 98% complementarity, or even at least about 100%complementarity.

A thorough treatment of the qualitative and quantitative considerationsinvolved in establishing binding conditions that allow one skilled inthe art to design appropriate oligonucleotides for use under the desiredconditions is provided by Beltz et al. Methods Enzymol. 100:266-285,1983, and by Sambrook et al. (ed.), Molecular Cloning: A LaboratoryManual, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., 1989.

DNA (deoxyribonucleic acid): A long chain polymer which includes thegenetic material of most living organisms (some viruses have genesincluding ribonucleic acid, RNA). The repeating units in DNA polymersare four different nucleotides, each of which includes one of the fourbases, adenine, guanine, cytosine and thymine bound to a deoxyribosesugar to which a phosphate group is attached. Triplets of nucleotides,referred to as codons, in DNA molecules code for amino acid in apolypeptide. The term codon is also used for the corresponding (andcomplementary) sequences of three nucleotides in the mRNA into which theDNA sequence is transcribed.

Deletion: The removal of one or more nucleotides from a nucleic acidsequence (or one or more amino acids from a protein sequence), theregions on either side of the removed sequence being joined together.

Differential expression: A difference, such as an increase or decrease,in the conversion of the information encoded in a gene (such as anischemic stroke related gene) into messenger RNA, the conversion of mRNAto a protein, or both. In some examples, the difference is relative to acontrol or reference value, such as an amount of gene expression that isexpected in a subject who has not had an ischemic stroke or an amountexpected in a subject who has had an ischemic stroke. Detectingdifferential expression can include measuring a change in geneexpression.

Downregulated or inactivation: When used in reference to the expressionof a nucleic acid molecule, such as a gene, refers to any process whichresults in a decrease in production of a gene product. A gene productcan be RNA (such as mRNA, rRNA, tRNA, and structural RNA) or protein.Therefore, gene downregulation or deactivation includes processes thatdecrease transcription of a gene or translation of mRNA.

Examples of processes that decrease transcription include those thatfacilitate degradation of a transcription initiation complex, those thatdecrease transcription initiation rate, those that decreasetranscription elongation rate, those that decrease processivity oftranscription and those that increase transcriptional repression. Genedownregulation can include reduction of expression above an existinglevel. Examples of processes that decrease translation include thosethat decrease translational initiation, those that decreasetranslational elongation and those that decrease mRNA stability.

Gene downregulation includes any detectable decrease in the productionof a gene product. In certain examples, production of a gene productdecreases by at least 2-fold, for example at least 3-fold or at least4-fold, as compared to a control (such an amount of gene expression in anormal cell). In one example, a control is a relative amount of geneexpression or protein expression in a PBMC in a subject who has notsuffered an ischemic stroke.

Evaluating a stroke: To determine whether an ischemic stroke hasoccurred in a subject, to determine the severity of an ischemic stroke,to determine the likely neurological recovery of a subject who has hadan ischemic stroke, or combinations thereof.

Expression: The process by which the coded information of a gene isconverted into an operational, non-operational, or structural part of acell, such as the synthesis of a protein. Gene expression can beinfluenced by external signals. For instance, exposure of a cell to ahormone may stimulate expression of a hormone-induced gene. Differenttypes of cells can respond differently to an identical signal.Expression of a gene also can be regulated anywhere in the pathway fromDNA to RNA to protein. Regulation can include controls on transcription,translation, RNA transport and processing, degradation of intermediarymolecules such as mRNA, or through activation, inactivation,compartmentalization or degradation of specific protein molecules afterthey are produced.

The expression of a nucleic acid molecule can be altered relative to anormal (wild type) nucleic acid molecule. Alterations in geneexpression, such as differential expression, includes but is not limitedto: (1) overexpression; (2) underexpression; or (3) suppression ofexpression. Alternations in the expression of a nucleic acid moleculecan be associated with, and in fact cause, a change in expression of thecorresponding protein.

Protein expression can also be altered in some manner to be differentfrom the expression of the protein in a normal (wild type) situation.This includes but is not necessarily limited to: (1) a mutation in theprotein such that one or more of the amino acid residues is different;(2) a short deletion or addition of one or a few (such as no more than10-20) amino acid residues to the sequence of the protein; (3) a longerdeletion or addition of amino acid residues (such as at least 20residues), such that an entire protein domain or sub-domain is removedor added; (4) expression of an increased amount of the protein comparedto a control or standard amount; (5) expression of a decreased amount ofthe protein compared to a control or standard amount; (6) alteration ofthe subcellular localization or targeting of the protein; (7) alterationof the temporally regulated expression of the protein (such that theprotein is expressed when it normally would not be, or alternatively isnot expressed when it normally would be); (8) alteration in stability ofa protein through increased longevity in the time that the proteinremains localized in a cell; and (9) alteration of the localized (suchas organ or tissue specific or subcellular localization) expression ofthe protein (such that the protein is not expressed where it wouldnormally be expressed or is expressed where it normally would not beexpressed), each compared to a control or standard. Controls orstandards for comparison to a sample, for the determination ofdifferential expression, include samples believed to be normal (in thatthey are not altered for the desired characteristic, for example asample from a subject who has not had an ischemic stroke) as well aslaboratory values, even though possibly arbitrarily set, keeping in mindthat such values can vary from laboratory to laboratory.

Laboratory standards and values may be set based on a known ordetermined population value and can be supplied in the format of a graphor table that permits comparison of measured, experimentally determinedvalues.

Fc fragment of IgG, high affinity Ia, receptor for (high affinityimmunoglobulin G receptor Fc gamma RI, FcγRI): One of three classes ofreceptors for the Fc fragment of IgG (FcγR) that participates in immunecomplex clearance. Binding of ligand to FcγRI initiates multiple immuneactivation events, such as phagocytosis, expression of proinflammatorycytokines, and cytotoxicity against Ig-coated target cells. Also knownin the art as CD64. The term FcγRI includes any FcγRI gene, cDNA, mRNA,or protein from any organism and that is a FcγRI that can function inimmune complex clearance. FcγRI sequences are publicly available. Forexample, GenBank Accession Nos: NM_(—)000566 (nucleic acid) and CAI12557(protein) and NP_(—)000557 (protein) disclose human FcγRI sequences.

In one example, a FcγRI sequence includes a full-length wild-type (ornative) sequence, as well as FcγRI allelic variants, variants,fragments, homologs or fusion sequences that retain the ability tofunction in immune complex clearance. In certain examples, FcγRI has atleast 80% sequence identity, for example at least 85%, 90%, 95%, or 98%sequence identity to a native FcγRI. In other examples, FcγRI has asequence that hybridizes under very high stringency conditions to asequence set forth in GenBank Accession No. NM_(—)000566 and retainsFcγRI activity.

Gene expression profile (or fingerprint): Differential or altered geneexpression can be detected by changes in the detectable amount of geneexpression (such as cDNA or mRNA) or by changes in the detectable amountof proteins expressed by those genes. A distinct or identifiable patternof gene expression, for instance a pattern of high and low expression ofa defined set of genes or gene-indicative nucleic acids such as ESTs; insome examples, as few as one or two genes provides a profile, but moregenes can be used in a profile, for example at least 3, at least 4, atleast 5, at least 10, at least 20, at least 25, at least 50, at least80, at least 100, at least 190, at least 200, at least 300, at least400, at least 500, at least 550, at least 600, or at least 630 or more.A gene expression profile (also referred to as a fingerprint) can belinked to a tissue or cell type (such as PBMCs), to a particular stageof normal tissue growth or disease progression (such as ischemicstroke), or to any other distinct or identifiable condition thatinfluences gene expression in a predictable way. Gene expressionprofiles can include relative as well as absolute expression levels ofspecific genes, and can be viewed in the context of a test samplecompared to a baseline or control sample profile (such as a sample froma subject who has not had an ischemic stroke). In one example, a geneexpression profile in a subject is read on an array (such as a nucleicacid or protein array).

Hybridization: To form base pairs between complementary regions of twostrands of DNA, RNA, or between DNA and RNA, thereby forming a duplexmolecule. Hybridization conditions resulting in particular degrees ofstringency will vary depending upon the nature of the hybridizationmethod and the composition and length of the hybridizing nucleic acidsequences. Generally, the temperature of hybridization and the ionicstrength (such as the Na+ concentration) of the hybridization bufferwill determine the stringency of hybridization. Calculations regardinghybridization conditions for attaining particular degrees of stringencyare discussed in Sambrook et al., (1989) Molecular Cloning, secondedition, Cold Spring Harbor Laboratory, Plainview, N.Y. (chapters 9 and11). The following is an exemplary set of hybridization conditions andis not limiting:

Very High Stringency (Detects Sequences that Share 90% Identity)

Hybridization: 5×SSC at 65° C. for 16 hours

Wash twice: 2×SSC at room temperature (RT) for 15 minutes each

Wash twice: 0.5×SSC at 65° C. for 20 minutes each

High Stringency (Detects Sequences that Share 80% Identity or Greater)

Hybridization: 5×-6×SSC at 65° C.-70° C. for 16-20 hours

Wash twice: 2×SSC at RT for 5-20 minutes each

Wash twice: 1×SSC at 55° C.-70° C. for 30 minutes each

Low Stringency (Detects Sequences that Share Greater than 50% Identity)

Hybridization: 6×SSC at RT to 55° C. for 16-20 hours

Wash at least twice: 2×-3×SSC at RT to 55° C. for 20-30 minutes each.

Hypothetical protein FLJ22662 Laminin A motif: The term hypotheticalprotein FLJ22662 Laminin A motif sequence includes any hypotheticalprotein FLJ22662 Laminin A motif sequence gene, cDNA, mRNA, or proteinfrom any organism and that is a hypothetical protein FLJ22662 Laminin Amotif sequence. In particular examples, hypothetical protein FLJ22662Laminin A motif is part of a basement membrane.

Hypothetical protein FLJ22662 Laminin A motif sequences are publiclyavailable. For example, GenBank Accession Nos: BC063561 (nucleic acid),BC000909 (nucleic acid), AAH00909 (protein) and AAH63561 (protein)disclose human sequences. In one example, a hypothetical proteinFLJ22662 Laminin A motif sequence includes a full-length wild-type (ornative) sequence, as well as hypothetical protein FLJ22662 Laminin Amotif allelic variants, variants, fragments, homologs or fusionsequences. In certain examples, CD163 has at least 80% sequenceidentity, for example at least 85%, 90%, 95%, or 98% sequence identityto a native hypothetical protein FLJ22662 Laminin A motif. In otherexamples, hypothetical protein FLJ22662 Laminin A motif has a sequencethat hybridizes under very high stringency conditions to a sequence setforth in GenBank Accession No. BC063561 or BC000909, and retainsFLJ22662 activity.

Insertion: The addition of one or more nucleotides to a nucleic acidsequence, or the addition of one or more amino acids to a proteinsequence.

Ischemic stroke: An ischemic stroke occurs when a blood vessel thatsupplies blood to the brain is blocked or narrowed (as contrasted with ahemorrhagic stroke which develops when an artery in the brain leaks orruptures and causes bleeding inside the brain tissue or near the surfaceof the brain). The blockage can be a blood clot that forms or lodgesinside the blood vessel (thrombus) or an object (such as an air bubbleor piece of tissue) that moves through the blood from another part ofthe body (embolus).

Ischemic Stroke-related (or associated) molecule: A molecule whoseexpression is affected by an ischemic stroke. Such molecules include,for instance, nucleic acid sequences (such as DNA, cDNA, or mRNAs) andproteins. Specific examples include those listed in Tables 2-5, as wellas fragments of the full-length genes, cDNAs, or mRNAs (and proteinsencoded thereby) whose expression is altered (such as upregulated ordownregulated) in response to an ischemic stroke.

Examples of ischemic stroke-related molecules whose expression isupregulated following an ischemic stroke include sequences involved inwhite blood cell activation and differentiation, sequences related tohypoxia, sequences involved in vascular repair, and sequences related toa specific PBMC response to the altered cerebral microenvironment, suchas those genes listed in Table 5. Specific examples of ischemicstroke-related molecules whose expression is upregulated following anischemic stroke include CD163; hypothetical protein FLJ22662 Laminin Amotif; bone marrow stromal cell antigen 1 (also known as CD157); Fcfragment of IgG, high affinity Ia, receptor for (CD64); baculoviral IAPrepeat-containing protein 1 (also known as neuronal apoptosis inhibitoryprotein); and KIAA0146, or any one of these.

Ischemic stroke-related molecules can be involved in or influenced by anischemic stroke in different ways, including causative (in that a changein an ischemic stroke-related molecule leads to development of orprogression to an ischemic stroke) or resultive (in that development ofor progression to an ischemic stroke causes or results in a change inthe ischemic stroke-related molecule).

Isolated: An “isolated” biological component (such as a nucleic acidmolecule, protein, or cell) has been substantially separated or purifiedaway from other biological components in the cell of the organism, orthe organism itself, in which the component naturally occurs, such asother chromosomal and extra-chromosomal DNA and RNA, proteins and cells.Nucleic acid molecules and proteins that have been “isolated” includenucleic acid molecules and proteins purified by standard purificationmethods. The term also embraces nucleic acid molecules and proteinsprepared by recombinant expression in a host cell as well as chemicallysynthesized nucleic acid molecules and proteins. For example, anisolated cell, such as an isolated PBMC is one that is substantiallyseparated from other cells, such as other blood cells.

KIAA0146: The term KIAA0146 includes any KIAA0146 gene, cDNA, mRNA, orprotein from any organism and that is a KIAA0146 sequence. KIAA0146sequences are publicly available. For example, GenBank Accession Nos:AAH15561 (protein), BAA09767 (protein), D63480 (nucleic acid), andBC015561 (nucleic acid) disclose human KIAA0146 sequences.

In one example, a KIAA0146 sequence includes a full-length wild-type (ornative) sequence, as well as KIAA0146 allelic variants, variants,fragments, homologs or fusion sequences. In certain examples, KIAA0146has at least 80% sequence identity, for example at least 85%, 90%, 95%,or 98% sequence identity to a native KIAA0146. In other examples,KIAA0146 has a sequence that hybridizes under very high stringencyconditions to a sequence set forth in GenBank Accession No. D63480 orBC015561, and retains KIAA0146 activity.

Label: An agent capable of detection, for example by ELISA,spectrophotometry, flow cytometry, or microscopy. For example, a labelcan be attached to a nucleic acid molecule or protein, therebypermitting detection of the nucleic acid molecule or protein. Examplesof labels include, but are not limited to, radioactive isotopes, enzymesubstrates, co-factors, ligands, chemiluminescent agents, fluorophores,haptens, enzymes, and combinations thereof. Methods for labeling andguidance in the choice of labels appropriate for various purposes arediscussed for example in Sambrook et al. (Molecular Cloning: ALaboratory Manual, Cold Spring Harbor, N.Y., 1989) and Ausubel et al.(In Current Protocols in Molecular Biology, John Wiley & Sons, New York,1998).

Neurological sequelae: Any abnormality of the nervous system (such asthe central nervous system) following or resulting from a disease orinjury or treatment, for example following an ischemic stroke.

Nucleic acid array: An arrangement of nucleic acids (such as DNA or RNA)in assigned locations on a matrix, such as that found in cDNA arrays, oroligonucleotide arrays.

Nucleic acid molecules representing genes: Any nucleic acid, for exampleDNA (intron or exon or both), cDNA, or RNA (such as mRNA), of any lengthsuitable for use as a probe or other indicator molecule, and that isinformative about the corresponding gene.

Nucleic acid molecules: A deoxyribonucleotide or ribonucleotide polymerincluding, without limitation, cDNA, mRNA, genomic DNA, and synthetic(such as chemically synthesized) DNA. The nucleic acid molecule can bedouble-stranded or single-stranded. Where single-stranded, the nucleicacid molecule can be the sense strand or the antisense strand. Inaddition, nucleic acid molecule can be circular or linear.

The disclosure includes isolated nucleic acid molecules that includespecified lengths of an ischemic stroke-related nucleotide sequence, forexample those listed in Tables 2-5. Such molecules can include at least10, at least 15, at least 20, at least 25, at least 30, at least 35, atleast 40, at least 45 or at least 50 consecutive nucleotides of thesesequences or more, and can be obtained from any region of an ischemicstroke-related nucleic acid molecule.

Nucleotide: Includes, but is not limited to, a monomer that includes abase linked to a sugar, such as a pyrimidine, purine or syntheticanalogs thereof, or a base linked to an amino acid, as in a peptidenucleic acid (PNA). A nucleotide is one monomer in a polynucleotide. Anucleotide sequence refers to the sequence of bases in a polynucleotide.

Oligonucleotide: A plurality of joined nucleotides joined by nativephosphodiester bonds, between about 6 and about 300 nucleotides inlength. An oligonucleotide analog refers to moieties that functionsimilarly to oligonucleotides but have non-naturally occurring portions.For example, oligonucleotide analogs can contain non-naturally occurringportions, such as altered sugar moieties or inter-sugar linkages, suchas a phosphorothioate oligodeoxynucleotide.

Particular oligonucleotides and oligonucleotide analogs can includelinear sequences up to about 200 nucleotides in length, for example asequence (such as DNA or RNA) that is at least 6 nucleotides, forexample at least 8, at least 10, at least 15, at least 20, at least 21,at least 25, at least 30, at least 35, at least 40, at least 45, atleast 50, at least 100 or even at least 200 nucleotides long, or fromabout 6 to about 50 nucleotides, for example about 10-25 nucleotides,such as 12, 15 or 20 nucleotides.

Oligonucleotide probe: A short sequence of nucleotides, such as at least8, at least 10, at least 15, at least 20, at least 21, at least 25, orat least 30 nucleotides in length, used to detect the presence of acomplementary sequence by molecular hybridization. In particularexamples, oligonucleotide probes include a label that permits detectionof oligonucleotide probe:target sequence hybridization complexes.

Open reading frame (ORF): A series of nucleotide triplets (codons)coding for amino acids without any internal termination codons. Thesesequences are usually translatable into a peptide.

Peripheral blood mononuclear cells (PBMCs): Cells present in the bloodthat have one round nucleus. Examples include lymphocytes, monocytes,and natural killer cells. PBMCs do not include neutrophils, eosinophilsor basophils.

Primers: Short nucleic acid molecules, for instance DNA oligonucleotides10-100 nucleotides in length, such as about 15, 20, 25, 30 or 50nucleotides or more in length. Primers can be annealed to acomplementary target DNA strand by nucleic acid hybridization to form ahybrid between the primer and the target DNA strand. Primer pairs can beused for amplification of a nucleic acid sequence, such as by PCR orother nucleic acid amplification methods known in the art.

Methods for preparing and using nucleic acid primers are described, forexample, in Sambrook et al. (In Molecular Cloning: A Laboratory Manual,CSHL, New York, 1989), Ausubel et al. (ed.) (In Current Protocols inMolecular Biology, John Wiley & Sons, New York, 1998), and Innis et al.(PCR Protocols, A Guide to Methods and Applications, Academic Press,Inc., San Diego, Calif., 1990). PCR primer pairs can be derived from aknown sequence, for example, by using computer programs intended forthat purpose such as Primer (Version 0.5, ©1991, Whitehead Institute forBiomedical Research, Cambridge, Mass.). One of ordinary skill in the artwill appreciate that the specificity of a particular primer increaseswith its length. Thus, for example, a primer including 30 consecutivenucleotides of an ischemic stroke-related nucleotide molecule willanneal to a target sequence, such as another homolog of the designatedischemic stroke-related protein, with a higher specificity than acorresponding primer of only 15 nucleotides. Thus, in order to obtaingreater specificity, primers can be selected that include at least 20,at least 25, at least 30, at least 35, at least 40, at least 45, atleast 50 or more consecutive nucleotides of a ischemic stroke-relatednucleotide sequence. Purified: The term “purified” does not requireabsolute purity; rather, it is intended as a relative term. Thus, forexample, a purified protein preparation is one in which the proteinreferred to is more pure than the protein in its natural environmentwithin a cell. For example, a preparation of a protein is purified suchthat the protein represents at least 50% of the total protein content ofthe preparation. Similarly, a purified oligonucleotide preparation isone in which the oligonucleotide is more pure than in an environmentincluding a complex mixture of oligonucleotides. In addition, a purifiedcell, such as a purified PBMC, is one that is substantially separatedfrom other cells, such as other blood cells. In one example, purifiedPBMCs are at least 90% pure, such as at least 95% pure, or even at least99% pure.

Recombinant: A recombinant nucleic acid molecule is one that has asequence that is not naturally occurring or has a sequence that is madeby an artificial combination of two otherwise separated segments ofsequence. This artificial combination can be accomplished by chemicalsynthesis or by the artificial manipulation of isolated segments ofnucleic acid molecules, such as by genetic engineering techniques.

Sample: A biological specimen containing genomic DNA, RNA (includingmRNA), protein, or combinations thereof, obtained from a subject.Examples include, but are not limited to, peripheral blood, urine,saliva, tissue biopsy, surgical specimen, amniocentesis samples andautopsy material. In one example, a sample includes peripheral bloodmononuclear cells (PBMCs).

Sequence identity/similarity: The identity/similarity between two ormore nucleic acid sequences, or two or more amino acid sequences, isexpressed in terms of the identity or similarity between the sequences.Sequence identity can be measured in terms of percentage identity; thehigher the percentage, the more identical the sequences are. Sequencesimilarity can be measured in terms of percentage similarity (whichtakes into account conservative amino acid substitutions); the higherthe percentage, the more similar the sequences are. Homologs ororthologs of nucleic acid or amino acid sequences possess a relativelyhigh degree of sequence identity/similarity when aligned using standardmethods. This homology is more significant when the orthologous proteinsor cDNAs are derived from species which are more closely related (suchas human and mouse sequences), compared to species more distantlyrelated (such as human and C. elegans sequences).

Methods of alignment of sequences for comparison are well known in theart. Various programs and alignment algorithms are described in: Smith &Waterman, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, J. Mol.Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp,CABIOS 5:151-3, 1989; Corpet et al., Nuc. Acids Res. 16:10881-90, 1988;Huang et al. Computer Appls. in the Biosciences 8, 155-65, 1992; andPearson et al., Meth. Mol. Bio. 24:307-31, 1994. Altschul et al., Mol.Biol. 215:403-10, 1990, presents a detailed consideration of sequencealignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J.Mol. Biol. 215:403-10, 1990) is available from several sources,including the National Center for Biological Information (NCBI, NationalLibrary of Medicine, Building 38A, Room 8N805, Bethesda, Md. 20894) andon the Internet, for use in connection with the sequence analysisprograms blastp, blastn, blastx, tblastn and tblastx. Additionalinformation can be found at the NCBI web site.

BLASTN is used to compare nucleic acid sequences, while BLASTP is usedto compare amino acid sequences. To compare two nucleic acid sequences,the options can be set as follows: −i is set to a file containing thefirst nucleic acid sequence to be compared (such as C:\seq1.txt); −j isset to a file containing the second nucleic acid sequence to be compared(such as C:\seq2.txt); −p is set to blastn; −o is set to any desiredfile name (such as C:\output.txt); −q is set to 1; −r is set to 2; andall other options are left at their default setting. For example, thefollowing command can be used to generate an output file containing acomparison between two sequences: C:\B12seq−i c:\seq1.txt−jc:\seq2.txt−p blastn−o c:\output.txt−q−1−r2.

To compare two amino acid sequences, the options of B12seq can be set asfollows: −i is set to a file containing the first amino acid sequence tobe compared (such as C:\seq1.txt); −j is set to a file containing thesecond amino acid sequence to be compared (such as C:\seq2.txt); −p isset to blastp; −o is set to any desired file name (such asC:\output.txt); and all other options are left at their default setting.

For example, the following command can be used to generate an outputfile containing a comparison between two amino acid sequences:C:\B12seq−i c:\seq1.txt−j c:\seq2.txt−p blastp−o c:\output.txt. If thetwo compared sequences share homology, then the designated output filewill present those regions of homology as aligned sequences. If the twocompared sequences do not share homology, then the designated outputfile will not present aligned sequences.

Once aligned, the number of matches is determined by counting the numberof positions where an identical nucleotide or amino acid residue ispresented in both sequences. The percent sequence identity is determinedby dividing the number of matches either by the length of the sequenceset forth in the identified sequence, or by an articulated length (suchas 100 consecutive nucleotides or amino acid residues from a sequenceset forth in an identified sequence), followed by multiplying theresulting value by 100. For example, a nucleic acid sequence that has1166 matches when aligned with a test sequence having 1154 nucleotidesis 75.0 percent identical to the test sequence (1166÷1554*100=75.0). Thepercent sequence identity value is rounded to the nearest tenth. Forexample, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, while75.15, 75.16, 75.17, 75.18, and 75.19 are rounded up to 75.2. The lengthvalue will always be an integer. In another example, a target sequencecontaining a 20-nucleotide region that aligns with 20 consecutivenucleotides from an identified sequence as follows contains a regionthat shares 75 percent sequence identity to that identified sequence(that is, 15≧20*100=75).

For comparisons of amino acid sequences of greater than about 30 aminoacids, the Blast 2 sequences function is employed using the defaultBLOSUM62 matrix set to default parameters, (gap existence cost of 11,and a per residue gap cost of 1). Homologs are typically characterizedby possession of at least 70% sequence identity counted over thefull-length alignment with an amino acid sequence using the NCBI BasicBlast 2.0, gapped blastp with databases such as the nr or swissprotdatabase. Queries searched with the blastn program are filtered withDUST (Hancock and Armstrong, 1994, Comput. Appl. Biosci. 10:67-70).Other programs use SEG. In addition, a manual alignment can beperformed. Proteins with even greater similarity will show increasingpercentage identities when assessed by this method, such as at leastabout 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity.

When aligning short peptides (fewer than around 30 amino acids), thealignment is be performed using the Blast 2 sequences function,employing the PAM30 matrix set to default parameters (open gap 9,extension gap 1 penalties). Proteins with even greater similarity to thereference sequence will show increasing percentage identities whenassessed by this method, such as at least about 60%, 70%, 75%, 80%, 85%,90%, 95%, 98%, 99% sequence identity. When less than the entire sequenceis being compared for sequence identity, homologs will typically possessat least 75% sequence identity over short windows of 10-20 amino acids,and can possess sequence identities of at least 85%, 90%, 95% or 98%depending on their identity to the reference sequence. Methods fordetermining sequence identity over such short windows are described atthe NCBI web site.

One indication that two nucleic acid molecules are closely related isthat the two molecules hybridize to each other under stringentconditions, as described above. Nucleic acid sequences that do not showa high degree of identity may nevertheless encode identical or similar(conserved) amino acid sequences, due to the degeneracy of the geneticcode. Changes in a nucleic acid sequence can be made using thisdegeneracy to produce multiple nucleic acid molecules that all encodesubstantially the same protein. Such homologous nucleic acid sequencescan, for example, possess at least about 60%, 70%, 80%, 90%, 95%, 98%,or 99% sequence identity determined by this method. An alternative (andnot necessarily cumulative) indication that two nucleic acid sequencesare substantially identical is that the polypeptide which the firstnucleic acid encodes is immunologically cross reactive with thepolypeptide encoded by the second nucleic acid.

One of skill in the art will appreciate that the particular sequenceidentity ranges are provided for guidance only; it is possible thatstrongly significant homologs could be obtained that fall outside theranges provided.

Sequences involved in (or related to) white blood cell activation anddifferentiation: Nucleic acid molecules (such as mRNA, cDNA, gene) andthe corresponding protein, whose expression is altered (such asupregulated or downregulated) in connection with the specialization,mobilization, or proliferation of white blood cells, or combinationsthereof, for example sequences that are differentially expressed tocause (or are differentially expressed as a result of) specialization,mobilization, and/or proliferation of white blood cells.

Exemplary sequences involved in white blood cell activation anddifferentiation include genes involved in cell adhesion, enzymesinvolved in the cell membrane remodeling allowing preparation for changeto a more differentiated state, and genes related to cell-cellinteractions. Particular examples include, but are not limited to,CD163; hypothetical protein FLJ22662 Laminin A motif; amyloid beta (A4)precursor-like protein 2; N-acetylneuraminate pyruvate lysase; v-fos FBJmurine osteosarcoma viral oncogene homolog; toll-like receptor 2;chondroitin sulfate proteoglycan 2 (versican); interleukin 13 receptor,alpha 1; CD14 antigen; bone marrow stromal cell antigen 1 (also known asCD157); complement component 1, q subcomponent, receptor 1; and pairedimmunoglobin-like type 2 receptor alpha; and Fc fragment of IgG, highaffinity Ia, receptor for (CD64).

Sequences involved in (or related to) hypoxia: Nucleic acid molecules(such as mRNA, cDNA, gene) and the corresponding protein, whoseexpression is altered (such as upregulated or downregulated) in responseto decreased available oxygen in the blood and tissues. For example, thebrain is hypoxic following an ischemic stroke. Particular examplesinclude, but are not limited to, adrenomedullin; dual specificityphosphatase 1; cytochrome b-245, beta polypeptide (chronic granulomatousdisease); ;eukotriene A4 hydrolase; erythroblastosis virus E26 oncogenehomolog 2 (avian); and neutrophil cytosolic factor 2 (65 kDa, chronicgranulomatous disease, autosomal 2).

Sequences involved in (or related to) vascular repair: Nucleic acidmolecules (such as mRNA, cDNA, gene) and the corresponding protein,whose expression is altered (such as upregulated or downregulated) inresponse to injury to a blood vessel. Particular examples include, butare not limited to, thrombomodulin; ectonucleoside triphosphatediphosphohydrolase 1; and CD36 antigen (collagen type I receptor,thrombospondin receptor).

Sequences involved in (or related to) a specific PBMC response to thealtered cerebral microenvironment: Nucleic acid molecules (such as mRNA,cDNA, gene) and the corresponding protein, whose expression is altered(such as upregulated or downregulated) in PBMCs in response to changesin the brain microenvironment.

Examples include those potentially associated with enhancedneurotransmitter degradation (such as catechol-o-methyl transferase andglutamine ligase), those that permit increased modulation of Ca²⁺homeostasis in the cerebral environment, genes involved in theinhibition of neuronal apoptosis (such as the neuronal apoptosisinhibitory protein and Ets2), genes involved in proNGF-induced neuronalcell death (such as sortilin), genes involved in apoptotic cell death inthe hippocampus after global cerebral ischemic injury (such asphospholipid scramblase 1), and genes involved in neurite growth inneuronal development (such as growth arrest-specific 7).

Particular examples include, but are not limited to,catechol-O-methyltransferase; glutamate-ammonia ligase (glutamineligase); 5100 calcium binding protein A8 (calgranulin A); neuronalapoptosis inhibitory protein: Homo sapiens transcribed sequence withstrong similarity to protein sp:Q13075 (H. sapiens) BIR1_HUMANBaculoviral IAP repeat-containing protein 1; sortilin; phospholipidscramblase 1; growth-arrest-specific 7; and GLI pathogenesis-related 1(glioma).

Subject: Living multi-cellular vertebrate organisms, a category thatincludes human and non-human mammals.

Target sequence: A sequence of nucleotides located in a particularregion in the human genome that corresponds to a desired sequence, suchas ischemic stroke related sequence. The target can be for instance acoding sequence; it can also be the non-coding strand that correspondsto a coding sequence. Examples of target sequences include thosesequences associated with ischemic stroke, such as any of those listedin Tables 2-5.

Test agent: Any substance, including, but not limited to, a protein(such as an antibody), nucleic acid molecule, organic compound,inorganic compound, or other molecule of interest. In particularexamples, a test agent can permeate a cell membrane (alone or in thepresence of a carrier).

Therapeutically effective amount: An amount of a pharmaceuticalpreparation that alone, or together with a pharmaceutically acceptablecarrier or one or more additional therapeutic agents, induces thedesired response. A therapeutic agent, such as an anticoagulant or athrombolytic agent, is administered in therapeutically effectiveamounts.

Effective amounts a therapeutic agent can be determined in manydifferent ways, such as assaying for a reduction in atheroscleroticdisease or improvement of physiological condition of a subject havingvascular disease. Effective amounts also can be determined throughvarious in vitro, in vivo or in situ assays.

Therapeutic agents can be administered in a single dose, or in severaldoses, for example daily, during a course of treatment. However, theeffective amount of can be dependent on the source applied, the subjectbeing treated, the severity and type of the condition being treated, andthe manner of administration.

In one example, it is an amount sufficient to partially or completelyalleviate symptoms of ischemic stroke within a subject. Treatment caninvolve only slowing the progression of the ischemic stroke temporarily,but can also include halting or reversing the progression of theischemic stroke permanently. For example, a pharmaceutical preparationcan decrease one or more symptoms of ischemic stroke, for exampledecrease a symptom by at least 20%, at least 50%, at least 70%, at least90%, at least 98%, or even at least 100%, as compared to an amount inthe absence of the pharmaceutical preparation.

Thrombolytics: Agents that promote lysis of thrombi that occlude acerebral vessel. Examples include, but are not limited to, tissueplasminogen activator (tPA), urokinase, and pro-urokinase.Administration of antithrombotics is one treatment for ischemic stroke,and is often a first line treatment for ischemic stroke. For example,intravenous t-PA can be administered within 3 hours of ischemic strokeonset. Intra-arterial thrombolytic therapy and mechanical clot-retrievaldevices can be used to promote rapid lysis of thrombi.

Treating a disease: “Treatment” refers to a therapeutic intervetnionthat ameliorates a sign or symptom of a disease or pathologicalcondition, such a sign or symptom of vascular disease. Treatment canalso induce remission or cure of a condition, such as an ischemicstroke. In particular examples, treatment includes preventing a disease,for example by inhibiting the full development of a disease, such aspreventing development of a disease or disorder that results from anischemic stroke. Prevention of a disease does not require a totalabsence of disease. For example, a decrease of at least 50% can besufficient.

Under conditions sufficient for: A phrase that is used to describe anyenvironment that permits the desired activity.

In one example, includes culturing cells (such as PBMCs) underconditions sufficient to mimic an ischemic stroke, such as culturing thecells under hypoxic conditions, hypoglycemic conditions, or both.

In another example, includes administering a test agent to a cellculture or a subject sufficient to allow the desired activity. Inparticular examples, the desired activity is altering the activity (suchas the expression) of an ischemic stroke-related molecule.

Upregulated or activation: When used in reference to the expression of anucleic acid molecule, such as a gene, refers to any process whichresults in an increase in production of a gene product. A gene productcan be RNA (such as mRNA, rRNA, tRNA, and structural RNA) or protein.Therefore, gene upregulation or activation includes processes thatincrease transcription of a gene or translation of mRNA.

Examples of processes that increase transcription include those thatfacilitate formation of a transcription initiation complex, those thatincrease transcription initiation rate, those that increasetranscription elongation rate, those that increase processivity oftranscription and those that relieve transcriptional repression (forexample by blocking the binding of a transcriptional repressor). Geneupregulation can include inhibition of repression as well as stimulationof expression above an existing level. Examples of processes thatincrease translation include those that increase translationalinitiation, those that increase translational elongation and those thatincrease mRNA stability.

Gene upregulation includes any detectable increase in the production ofa gene product. In certain examples, production of a gene productincreases by at least 2-fold, for example at least 3-fold or at least4-fold, as compared to a control (such an amount of gene expression in anormal cell). In one example, a control is a relative amount of geneexpression in a PBMC in a subject who has not suffered an ischemicstroke.

Ischemic Stroke-Related Molecules

The inventors have identified 22-637 genes whose expression is altered(such as upregulated or downregulated) following an ischemic stroke. Thenumber of genes identified depended on the specificity and sensitivityof the algorithm used. For example, using the PAM dataset 22 ischemicstroke related genes were identified (Table 5), using the Westfall andYoung dataset 82 ischemic stroke related genes were identified (Table4), using the Bonferroni correction set 190 ischemic stroke relatedgenes were identified (Table 3), and using the Benjamini & Yekutieli set637 ischemic stroke related genes were identified (Table 2). One skilledin the art will appreciate that changes in protein expression can bedetected as an alternative to detecting gene expression.

Several genes not previously associated with ischemic stroke wereidentified, such as at least CD163; hypothetical protein FLJ22662Laminin A motif; bone marrow stromal cell antigen 1 (BST-1, alsoreferred to in the literature as CD157); Fc fragment of IgG, highaffinity Ia, receptor for (FcγRI, also known as CD64); baculoviral IAPrepeat-containing protein 1; and KIAA0146. In particular examples, allof these genes were upregulated following an ischemic stroke. In oneexample, four classes of genes whose expression was upregulatedfollowing an ischemic stroke were identified: sequences involved inactivation and differentiation of white blood cells, sequences relatedto hypoxia, sequences involved in vascular repair, and sequences relatedto altered cerebral microenvironment. Particular examples of such genes(and their corresponding proteins) are provided in Table 5.

Based on the identification of these ischemic stroke-related molecules,methods were developed to evaluate a stroke. For example, the disclosedmethods can be used to diagnose an ischemic stroke, determine theseverity of an ischemic stroke, determine the likely neurologicalrecovery of a subject who had an ischemic stroke, or combinationsthereof. The method can further include determining an appropriatetherapy for a subject found to have experienced an ischemic stroke usingthe disclosed assays.

The disclosed methods provide a rapid, straightforward, and accurategenetic screening method performed in one assay for evaluating ischemicstroke. It allows identification of subjects who may requireanticoagulant therapy following an ischemic stroke. For example, byestablishing that an individual has had an ischemic stroke, effectivetherapeutic measures, such as the emergent administration of athrombolytic agent or of treatments to prevent stroke recurrence andextension, can be instituted.

Evaluation of an Ischemic Stroke

Provided herein are methods of evaluating a stroke. Particular examplesof evaluating a stroke include determining whether a subject, such as anotherwise healthy subject, or a subject suspected or at risk of havingan ischemic stroke, has had an ischemic stroke, assessing the severityof an ischemic stroke, predicting the likelihood of neurologicalrecovery of a subject who has had an ischemic stroke, or combinationsthereof. The identification of a subject who has had an ischemic strokecan help to evaluate other clinical data (such as neurologicalimpairment or brain imaging information) to determine whether anischemic stroke has occurred. In particular examples, the method candetermine with a reasonable amount of sensitivity and specificitywhether a subject has suffered an ischemic stroke within the previous 72hours, such as within the previous 48 hours, previous 24 hours, orprevious 12 hours. In some examples, isolated or purified PBMCs obtainedfrom the subject are used to determine whether a subject has had anischemic stroke.

In particular examples, the method also includes administering anappropriate treatment therapy for subjects who have had an ischemicstroke. For example, subjects identified or evaluated as having had anischemic stroke can then be provided with appropriate treatments, suchas anti-platelet agents (for example aspirin) that would be appropriatefor a subject identified as having had an ischemic stroke but not asappropriate for a subject who has had a hemorrhagic stroke. It ishelpful to be able to classify a subject as having had an ischemicstroke, because the treatments for ischemic stroke are often distinctfrom the treatments for hemorrhagic stroke. In fact, treating ahemorrhagic stroke with a therapy designed for an ischemic stroke (suchas a thrombolytic agent) can have devastating clinical consequences.Hence using the results of the disclosed assays to help distinguishischemic from hemorrhagic stroke offers a substantial clinical benefit,and allows subjects to be selected for treatments appropriate toischemic stroke but not hemorrhagic stroke.

In particular examples, methods of evaluating a stroke involve detectingdifferential expression (such as an increase or decrease in gene orprotein expression) in any combination of at least four ischemicstroke-related molecules of the subject, such as any combination of atleast four of the genes (or proteins) listed in any of Tables 2-5. Inone example, the method includes screening expression of one or more ofCD163; hypothetical protein FLJ22662 Laminin A motif; BST-1; FcγRI;baculoviral IAP repeat-containing protein 1; or KIAA0146, or acombination of ischemic stroke-related molecules that includes at least1, at least 2, at least 3, at least 4, at least 5 or at least 6 of thesemolecules. For example, the method can include screening expression ofCD163, along with other ischemic stroke-related molecules (such as anycombination that includes at least 3 additional molecules listed inTables 2-5).

Differential expression can be represented by increased or decreasedexpression in the at least one ischemic stroke-related molecule (forinstance, a nucleic acid or a protein). For example, differentialexpression includes, but is not limited to, an increase or decrease inan amount of a nucleic acid molecule or protein, the stability of anucleic acid molecule or protein, the localization of a nucleic acidmolecule or protein, or the biological activity of a nucleic acidmolecule or protein. Specific examples include evaulative methods inwhich changes in gene expression in at least four ischemicstroke-related nucleic acid molecules (or corresponding protein) aredetected (for example nucleic acids or proteins obtained from a subjectthought to have had or known to have had an ischemic stroke), such aschanges in gene (or protein) expression in any combination of at least5, at least 10, at least 15, at least 20, at least 25, at least 50, atleast 100, at least 150, at least 160, at least 170, at least 175, atleast 180, at least 185, at least 200, at least 250, at least 300, atleast 400, at least 500, at least 510, at least 550, at least 575, atleast 600, at least 620, at least 630, or at least 637 ischemicstroke-related molecules. Exemplary ischemic stroke-related moleculesare provided in Tables 2-5.

In particular examples a change in expression is detected in a subset ofischemic stroke-related molecules (such as nucleic acid sequences orprotein sequences) that selectively evaluate a stroke, for example todetermine if a subject has had an ischemic stroke. In a particularexample, the subset of molecules can include a set of any combination offour ischemic stroke-related genes listed in Table 5, or a set of anycombination of 22 ischemic stroke-related genes listed in Table 5. In aparticular example, the subset of molecules includes any combination ofat least one gene (or protein) from each class of the four classeslisted in Table 5, such as at least 2, at least 3, at least 5, or atleast 10 genes from each class listed in Table 5.

In a particular example, differential expression is detected in ischemicstroke-related molecules that are both upregulated and down regulated.For example, increased expression of one or more of CD163; hypotheticalprotein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; or KIAA0146, and decreased gene (orprotein) expression of one or more of intercellular adhesion molecule 2,protein kinase D2, GATA binding protein 3, hypothetical proteinFLJ20257, or protein kinase C, theta, indicates that the subject has hada stroke, has had a severe stroke, has a lower likelihood ofneurological recovery, or combinations thereof. For example,differential expression can be detected by determining if the subjecthas increased gene (or protein) expression of CD163; hypotheticalprotein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; and KIAA0146, and determining if thesubject has decreased gene (or protein) expression of intercellularadhesion molecule 2, protein kinase D2, GATA binding protein 3,hypothetical protein FLJ20257, and protein kinase C, theta.

In particular examples, the number of ischemic stroke-related genesscreened is at least 5, at least 10, at least 15, at least 20, at least25, at least 50, at least 100, at least 150, at least 160, at least 170,at least 175, at least 180, at least 185, at least 200, at least 250, atleast 300, at least 400, at least 500, at least 510, at least 550, atleast 575, at least 600, at least 620, at least 630, or at least 637ischemic stroke-related molecules. In other examples, the methods employscreening no more than 637, no more than 630, no more than 620, no morethan 600, no more than 575, no more than 550, no more than 510, no morethan 500, no more than 400, no more than 300, no more than 250, no morethan 200, no more than 185, no more than 180, no more than 175, no morethan 170, no more than 160, no more than 150, no more than 100, no morethan 50, no more than 25, no more than 20, no more than 15, no more than10, no more than 5, or no more than 4 ischemic stroke-related genes.Examples of particular ischemic stroke-related genes are shown in Tables2-5. In one example, the number of ischemic stroke-related genesscreened includes at least one gene from each class listed in Table 5,such as at least 2, at least 3, at least 5, or at least 10 genes fromeach class listed in Table 5.

In certain methods, differential expression includes over- orunder-expression of an ischemic stroke-related molecule. For instance,differential expression can include overexpression, for instanceoverexpression of any combination of at least 4 molecules (such at least10 or at least 20 molecules) shown in Table 5, or any combination of atleast 4 molecules in any of Tables 2-4 with a positive t-statisticvalue, such as a t-statistic value of at least 3, such as at least 3.5,at least 3.6 or even at least 3.7. In a particular example, differentialexpression includes overexpression of any combination of at least onegene from each class listed in Table 5, such as at least 2, at least 3,at least 5, or at least 10 genes from each of the classes listed inTable 5. In another example, differential expression includesunderexpression, for instance underexpression of any combination of atleast 5 molecules (such at least 50 or at least 150 molecules) shown inTables 2-4 with a negative t-statistic value, such as a t-statisticvalue of less than −3, such as less than −3.5, less than -3.6 or evenless than −3.7. In a specific example, differential expression includesany combination of underexpression or overexpression of at least 4ischemic stroke-related molecules shown in Tables 2-4, such asoverexpression of at least 3 ischemic stroke-related molecules shown inTables 2-5 with a positive t-statistic value and underexpression of atleast one ischemic stroke related molecule shown in Tables 2-4 with anegative t-statistic value, or for example overexpression of at least 4ischemic stroke-related molecules shown in Tables 2-5 with a positivet-statistic value, or for example, overexpression of at least 2 ischemicstroke-related molecules shown in Tables 2-5 with a positive t-statisticvalue and underexpression of at least 2 ischemic stroke relatedmolecules shown in Tables 2-4 with a negative t-statistic value.

In some examples, differential expression of proteins that areassociated with ischemic stroke includes detecting patterns of suchexpression, such as detecting upregulation of CD163; hypotheticalprotein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; or KIAA0146, detecting downregulation ofintercellular adhesion molecule 2, protein kinase D2, GATA bindingprotein 3, hypothetical protein FLJ20257, or protein kinase C, theta, orcombinations thereof. For example, detecting upregulation ordownregulation can include a magnitude of change of at least 25%, atleast 50%, at least 100%, or even at least 200%, such as a magnitude ofchange of at least 25% for CD163; at least 25% for hypothetical proteinFLJ22662 Laminin A motif; at least 25% for BST-1; FcγRI; at least 25%for baculoviral IAP repeat-containing protein 1; at least 25% forKIAA0146; at least 25% for intercellular adhesion molecule 2; at least25% for protein kinase D2; at least 25% for GATA binding protein 3; atleast 25% for hypothetical protein FLJ20257; and at least 25% forprotein kinase C, theta. Alternatively, upregulation is detected by alevel having a t-value of at least 3 and downregulation is detected by alevel having a t-value value of no more than −3.

In particular examples, the disclosed method of evaluating a stroke isat least 78% sensitive (such as at least 80% sensitive, at least 85%sensitive, at least 90% sensitive, or at least 95% sensitive) and atleast 80% specific (such as at least 85% specific, at least 90%specific, at least 95% specific, or at least 98% specific) fordetermining whether a subject has had an ischemic stroke.

As used herein, the term “ischemic stroke-related molecule” includesischemic stroke-related nucleic acid molecules (such as DNA, RNA, forexample cDNA or mRNA) and ischemic stroke-related proteins. The term isnot limited to those molecules listed in Tables 2-5 (and molecules thatcorrespond to those listed), but also includes other nucleic acidmolecules and proteins that are influenced (such as to level, activity,localization) by or during an ischemic stroke, including all of suchmolecules listed herein. Examples of particular ischemic stroke-relatedgenes are listed in Tables 2-5, such as CD163; hypothetical proteinFLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; or KIAA0146. In examples where theischemia-related molecule is an ischemia -related nucleic acid sequence,methods of detecting differential expression can include in vitronucleic acid amplification, nucleic acid hybridization (which caninclude quantified hybridization), RT-PCR, real time PCR, orcombinations thereof. In examples where the ischemia-related molecule isan ischemia -related protein sequence, methods of detecting differentialexpression can include in vitro hybridization (which can includequantified hybridization) such as hybridization to a protein-specificbinding agent for example an antibody, quantitative spectroscopicmethods (for example mass spectrometry, such as surface-enhanced laserdesorption/ionization (SELDI)-based mass spectrometry) or combinationsthereof.

In particular examples, methods of evaluating a subject who has had oris thought to have had an ischemic stroke includes determining a levelof expression (for example in a PBMC) of any combination of at least 4of the genes (or proteins) listed in Tables 2-5, such as at least 10, atleast 15, at least 20, or at least 22 of the genes listed in Table 5,such as at least 150, at least 180, or at least 185 of the gene listedin Table 3, or any combination of at least 500, at least 600, or atleast 630 of the genes listed in Table 2. In one example, the methodincludes determining a level of expression of at least CD163;hypothetical protein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviralIAP repeat-containing protein 1; or KIAA0146, or any combination ofischemic stroke related molecules that includes 1, 2, 3, 4, 5, or 6 ofthese molecules. In one example, the method includes determining a levelof expression of at least one gene from each class listed in Table 5,such as at least 2, at least 3, at least 5, or at least 10 genes fromeach class.

Methods of evaluating a stroke can include diagnosing a stroke,stratifying the seriousness of a cerebral ischemic event, and predictingneurological recovery. Similarly, methods of evaluating a stroke caninclude determining the severity of a stroke, predicting neurologicalrecovery, or combinations thereof. For example, a change in expressionin any combination of at least 4 of the genes listed in Tables 2-5indicates that the subject has had an ischemic stroke. For example, anincrease in expression in one or more of CD163; hypothetical proteinFLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; or KIAA0146 in particular examplesindicates that the subject has had an ischemic stroke.

Determining the level of expression can involve measuring an amount ofthe ischemia-related molecules in a sample derived from the subject,such as a purified PBMC sample. Such an amount can be compared to thatpresent in a control sample (such as a sample derived from a subject whohas not had an ischemic stroke or a standard ischemic stroke-relatedmolecule level in analogous samples from a subject not having ischemiaor not having a predisposition developing ischemia), wherein adifference (such as an increase or a decrease reflecting an upregulationor downregulation, respectively) in the level of any combination of atleast 4 ischemia-related molecules listed in Tables 2-5, such as anycombination of at least 4 ischemia-related molecules listed in Table 5,in the subject relative to the control sample is diagnostic for ischemicstroke.

In other examples, the method includes determining a level of expressionof any combination of at least four sequences listed in Table 5, such asat least 10, or at least 22 of the sequences listed in Table 5, forexample at least 150 of the genes listed in Table 3, such as at least160, at least 170, at least 175, at least 180, or at least 185 of thegenes listed in Table 3, or at least 500 of the ischemic stroke-relatedmolecules listed in Table 2, such as at least 600 of the ischemicstroke-related molecules listed in Table 2. A change in expression in atleast four genes listed in Table 5 (or the corresponding proteins), suchas at least 22 of the genes (or the corresponding proteins) listed inTable 5, such as 150 or more of the genes listed in Table 3 (or thecorresponding proteins), such as 500 or more of the genes listed inTable 2 (or the corresponding proteins, indicates that the subject hashad a more severe stroke, has a higher risk of long term adverseneurological sequelae, or combinations thereof, than a subject having achange in expression in less than 500 of the molecules listed in Table3, less than 150 of the molecules listed in Table 3 or less than 22 (orless than four) of the molecules listed in Table 5. Determining thelevel of expression can involve measuring an amount of theischemia-related molecules in a sample derived from the subject. Such anamount can be compared to that present in a control sample (such as asample derived from a subject who has not had an ischemic stroke or asample derived from the subject at an earlier time), wherein adifference (such as an increase or a decrease reflecting an upregulationor downregulation, respectively) in the level of at least 4 or at least22 of the ischemia-related molecules listed in Table 5 (such as at least150 of the ischemia-related molecules listed in Table 3 or such as atleast 500 of the ischemia-related molecules listed in Table 2) in thesubject relative to the control sample indicates that the subject hashad a more severe stroke, has a higher risk of long term adverseneurological sequelae, or both.

The disclosed methods can further include administering to the subjectan appropriate treatment to avoid or reduce ischemic injury, if thepresence of differential expression indicates that the subject has hadan ischemic stroke. Since the results of the disclosed assays arereliable predictors of the ischemic nature of the stroke, the results ofthe assay can be used (alone or in combination with other clinicalevidence and brain scans) to determine whether thrombolytic therapydesigned to lyse a neurovascular occlusion such as a thrombus (forexample by using tissue plasminogen activator or streptokinase) shouldbe administered to the subject. In certain example, thrombolytic therapyis given to the subject once the results of the differential gene assayare known if the assay provides an indication that the stroke isischemic in nature. Such methods can reduce brain damage following anischemic stroke.

In particular examples, the method includes determining if there is analteration in the expression of at least four sequences listed in Table5, such as at least 10, or at least 22 of the sequences listed in Table5, for example at least 150 of the genes listed in Table 3, such as atleast 160, at least 170, at least 175, at least 180, or at least 185 ofthe genes listed in Table 3, or at least 500 of the ischemicstroke-related molecules listed in Table 2, such as at least 600 of theischemic stroke-related molecules listed in Table 2. In some examples,detecting differential expression of at least 4 ischemic stroke-relatedmolecules involves quantitatively or qualitatively analyzing a DNA,mRNA, cDNA, protein, or combinations thereof.

If differenential expression is detected in at least four, at least 22,at least 150, or at least 500 ischemic stroke-related molecules isidentified, this indicates that the subject has experienced an ischemicstroke (and not a hemorrhagic stroke), and a treatment is selected toprevent or reduce brain damage or to provide protection from the onsetof brain damage. Examples of such treatment include administration of ananticoagulant, an antithrombotic, or combinations thereof. A particularexample includes administration of a thrombolytic agent such as t-PA tolyse the blood clot, alone or in combination with one or more agentsthat prevent further strokes, such as anticoagulants (such asantiplatelet agents), antihypertensive agents, or lipid lowering agents.In particular examples, the level of expression of a protein in asubject can be appropriately increased or decreased by expressing in thesubject a recombinant genetic construct that includes a promoteroperably linked to a nucleic acid molecule, wherein the nucleic acidmolecule includes at least 10 consecutive nucleotides of an ischemicstroke-related nucleic acid sequence (such as any of the sequenceslisted in Tables 2-5). Expression of the nucleic acid molecule willchange expression of the ischemic stroke-related protein. The nucleicacid molecule can be in an antisense orientation relative to thepromoter or in sense orientation relative to the promoter. In someexamples, the recombinant genetic construct expresses an ssRNAcorresponding to an ischemic stroke-related nucleic acid sequence.

In examples of the methods described herein, detecting differentialexpression of at least four ischemic stroke-related molecules involvesdetermining whether a gene expression profile from the subject indicatesdevelopment or progression of brain injury.

In particular examples, the disclosed methods are performed followingthe onset of signs and symptoms associated with ischemic stroke.Examples of such symptoms include, but are not limited to headache,sensory loss (such as numbness, particularly confined to one side of thebody or face), paralysis (such as hemiparesis), pupillary changes,blindness (including bilateral blindness), ataxia, memory impairment,dysarthria, somnolence, and other effects on the central nervous systemrecognized by those of skill in the art. In particular examples, themethod of evaluating a stroke is performed after a sufficient period oftime for the differential regulation of the genes (or proteins) tooccur, for example at least 24 hours after onset of the symptom orconstellation of symptoms that have indicated a potential cerebralischemic event. In other examples, the method is performed prior toperforming any diagnostics imaging tests (such as those that can findanatomic evidence of ischemic stroke). For example, it can be difficultfor imaging modalities (such as CT and MRI) to detect acute ischemicstrokes, at least until brain changes (such as edema) have taken placein response to the ischemia. Hence the assay described herein is able todetect the stroke even before definitive brain imaging evidence of thestroke is known.

The neurological sequelae of an ischemic event in the central nervoussystem can have consequences that range from the insignificant todevastating, and the disclosed assays permit early and accuratestratification of risk of long-lasting neurological impairment. Forexample, a test performed as early as within the first 24 hours of onsetof signs and symptoms of a stroke, and even as late as 7-14 days or evenas late as 90 days or more after the event can provide clinical datathat is highly predictive of the eventual care needs of the subject.

The disclosed assay is also able to identify subjects who have had anischemic stroke in the past, for example more than 2 weeks ago, or evenmore than 90 days ago. The identification of such subjects helpsevaluate other clinical data (such as neurological impairment or brainimaging information) to determine whether an ischemic stroke hasoccurred.

In particular examples, the disclosed methods provide a lower costalternative to expensive imaging modalities (such as MRI and CT scans),can be used in instances where those imaging modalities are notavailable (such as in field hospitals), can be more convenient thanplacing people in scanners (especially considering that some people arenot able to fit in the scanner, or can not be subjected to MRI if theyhave certain types of metallic implants in their bodies), orcombinations thereof.

Clinical Specimens

Appropriate specimens for use with the current disclosure in diagnosingand prognosing ischemic stroke include any conventional clinicalsamples, for instance blood or blood-fractions (such as serum).Techniques for acquisition of such samples are well known in the art(for example see Schluger et al. J. Exp. Med. 176:1327-33, 1992, for thecollection of serum samples). Serum or other blood fractions can beprepared in the conventional manner. For example, about 200 μL of serumcan be used for the extraction of DNA for use in amplificationreactions. However, if DNA is not amplified, larger amounts of blood canbe collected. For example, if at least 5 μg of mRNA is desired, about20-30 mls of blood can be collected.

In one example, PBMCs are used as a source of isolated nucleic acidmolecules or proteins. The inflammatory response from peripheral bloodborne white blood cells, in particular monocytes, are also a componentof the evolving ischemic lesion (Kochanek et al., Stroke 23:1367-79,1992). One advantage of using blood (for example instead of braintissue) is that it is easily available can be drawn serially.

Once a sample has been obtained, the sample can be used directly,concentrated (for example by centrifugation or filtration), purified,amplified, or combinations thereof. For example, rapid DNA preparationcan be performed using a commercially available kit (such as theInstaGene Matrix, BioRad, Hercules, Calif.; the NucliSens isolation kit,Organon Teknika, Netherlands. In one example, the DNA preparation methodyields a nucleotide preparation that is accessible to, and amenable to,nucleic acid amplification. Similarly, RNA can be prepared using acommercially available kit (such as the RNeasy Mini Kit, Qiagen,Valencia, Calif.).

Arrays for Detecting Nucleic Acid and Protein Sequences

In particular examples, methods for detecting a change in expression inthe disclosed ischemic stroke-related genes listed in Tables 2-5 use thearrays disclosed herein. Arrays can be used to detect the presence ofsequences whose expression is upregulated or downregulated in responseto an ischemic stroke, such as sequences listed in Tables 2-5, forexample using specific oligonucleotide probes or antibody probes. Thearrays herein termed “ischemic stroke detection arrays,” are used toevaluate a stroke, for example to determine whether a subject has had anischemic stroke, determine the severity of the stroke, predict thelikelihood of neurological recovery of a subject who has had an ischemicstroke, to identify an appropriate therapy for a subject who has had anischemic stroke, or combinations thereof. In particular examples, thedisclosed arrays can include nucleic acid molecules, such as DNA or RNAmolecules, or antibodies.

Nucleic Acid Arrays

In one example, the array includes nucleic acid oligonucleotide probesthat can hybridize to any combination of at least four of the ischemicstroke-related gene sequences listed in Table 5, at least 150 of theischemic stroke-related gene sequences listed in Table 3, or at least500 of the ischemic stroke-related gene sequences listed in Table 2. Inparticular examples, an array includes oligonucleotides that canrecognize all 22 ischemic stroke-associated genes listed in Table 5, all82 of the ischemic stroke-related gene sequences listed in Table 4, all190 of the ischemic stroke-related gene sequences listed in Table 3, orall 637 of the ischemic stroke-related gene sequences listed in Table 2.Certain of such arrays (as well as the methods described herein) caninclude ischemic stroke-related molecules that are not listed in Tables2-5.

In a specific example, an array includes oligonucleotide probes that canrecognize at least CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; and KIAA0146,or a probe that can recognize any one of these molecules. For example,the array can include oligonucleotide probes that can recognize at least1, at least 2, at least 3, at least 4, at least 5 or at least 6 of thefollowing, CD163; hypothetical protein FLJ22662 Laminin A motif; BST-1;FcγRI; baculoviral IAP repeat-containing protein 1; and KIAA0146. Inanother example, the array includes an oligonucleotide probe that canrecognize at least CD163, for example in combination with otheroligonucleotide probes that recognize other ischemic stroke relatedmolecules (such as any combination of at least 3 of those listed inTables 2-5).

In another specific example, an array includes oligonucleotide probesthat can recognize at least one white blood cell activation anddifferentiation gene, at least one gene related to hypoxia, at least onegene involved in vascular repair, and at least one gene related to aspecific PBMC response to the altered cerebral microenvironment, or atleast 2, at least 3, at least 5, or at least 10 genes from each of thesefamilies.

In one example, a set of oligonucleotide probes is attached to thesurface of a solid support for use in detection of ischemicstroke-associated sequences, such as those nucleic acid sequences (suchas cDNA or mRNA) obtained from the subject. Additionally, if an internalcontrol nucleic acid sequence is used (such as a nucleic acid sequenceobtained from a PBMC from a subject who has not had an ischemic stroke)an oligonucleotide probe can be included to detect the presence of thiscontrol nucleic acid molecule.

The oligonucleotide probes bound to the array can specifically bindsequences obtained from the subject, or amplified from the subject (suchas under high stringency conditions). Thus, sequences of use with themethod are oligonucleotide probes that recognize ischemic stroke-relatedsequences, such as gene sequences (or corresponding proteins) listed inTables 2-5. Such sequences can be determined by examining the sequencesof the different species, and choosing oligonucleotide sequences thatspecifically anneal to a particular ischemic stroke-related sequence(such as those listed in Tables 2-5 or represented by those listed inTables 2-5), but not others. One of skill in the art can identify otherischemic stroke-associated oligonucleotide molecules that can beattached to the surface of a solid support for the detection of otherischemic stroke-associated nucleic acid sequences.

The methods and apparatus in accordance with the present disclosuretakes advantage of the fact that under appropriate conditionsoligonucleotides form base-paired duplexes with nucleic acid moleculesthat have a complementary base sequence. The stability of the duplex isdependent on a number of factors, including the length of theoligonucleotides, the base composition, and the composition of thesolution in which hybridization is effected. The effects of basecomposition on duplex stability can be reduced by carrying out thehybridization in particular solutions, for example in the presence ofhigh concentrations of tertiary or quaternary amines.

The thermal stability of the duplex is also dependent on the degree ofsequence similarity between the sequences. By carrying out thehybridization at temperatures close to the anticipated T_(m)'s of thetype of duplexes expected to be formed between the target sequences andthe oligonucleotides bound to the array, the rate of formation ofmis-matched duplexes may be substantially reduced.

The length of each oligonucleotide sequence employed in the array can beselected to optimize binding of target ischemic stroke-associatednucleic acid sequences. An optimum length for use with a particularischemic stroke-associated nucleic acid sequence under specificscreening conditions can be determined empirically. Thus, the length foreach individual element of the set of oligonucleotide sequencesincluding in the array can be optimized for screening. In one example,oligonucleotide probes are from about 20 to about 35 nucleotides inlength or about 25 to about 40 nucleotides in length.

The oligonucleotide probe sequences forming the array can be directlylinked to the support. Alternatively, the oligonucleotide probes can beattached to the support by non-ischemic stroke-associated sequences suchas oligonucleotides or other molecules that serve as spacers or linkersto the solid support.

Protein Arrays

In another example, an array includes protein sequences (or a fragmentof such proteins, or antibodies specific to such proteins or proteinfragments), which include at least four of the ischemic stroke-relatedprotein sequences listed in Table 5, at least 150 of the ischemicstroke-related protein sequences listed in Table 3, or at least 500 ofthe ischemic stroke-related protein sequences listed in Table 2. Inparticular examples, an array includes proteins that can recognize all22 ischemic stroke-associated proteins listed in Table 5, all 82 of theischemic stroke-related protein sequences listed in Table 4, all 190 ofthe ischemic stroke-related proteins listed in Table 3, or all 637 ofthe ischemic stroke-related proteins listed in Table 2. Such arrays canalso contain any particular subset of the sequences listed in Tables2-5. For example, an array can include probes that can recognize atleast one white blood cell activation and differentiation protein, atleast one protein related to hypoxia, at least one protein involved invascular repair, and at least one protein related to a specific PBMCresponse to the altered cerebral microenvironment, or at least 2, atleast 3, at least 5, or at least 10 proteins from each of thesefamilies. In another specific example, the array includes probes thatrecognize one or more of CD163; hypothetical protein FLJ22662 Laminin Amotif; BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; orKIAA0146. For example, the array can include a probe that recognizesCD163 and additional probes that recognize other ischemic stroke relatedproteins (such as any combination of at least 3 or at least 22 of thoselisted in Tables 2-5).

The proteins or antibodies forming the array can be directly linked tothe support. Alternatively, the proteins or antibodies can be attachedto the support by spacers or linkers to the solid support.

Changes in expression of ischemic stroke-related proteins can bedetected using, for instance, an ischemic stroke protein-specificbinding agent, which in some instances is labeled with an agent that canbe detected. In certain examples, detecting a change in proteinexpression includes contacting a protein sample obtained from the PBMCsof a subject with an ischemic stroke protein-specific binding agent(which can be for example present on an array); and detecting whetherthe binding agent is bound by the sample and thereby measuring thelevels of the ischemic stroke-related protein present in the sample. Adifference in the level of an ischemic stroke-related protein in thesample, relative to the level of an ischemic stroke-related proteinfound an analogous sample from a subject who has not had an ischemicstroke, in particular examples indicates that the subject has sufferedan ischemic stroke.

Array Substrate

The solid support can be formed from an organic polymer. Suitablematerials for the solid support include, but are not limited to:polypropylene, polyethylene, polybutylene, polyisobutylene,polybutadiene, polyisoprene, polyvinylpyrrolidine,polytetrafluroethylene, polyvinylidene difluroide,polyfluoroethylene-propylene, polyethylenevinyl alcohol,polymethylpentene, polycholorotrifluoroethylene, polysulfornes,hydroxylated biaxially oriented polypropylene, aminated biaxiallyoriented polypropylene, thiolated biaxially oriented polypropylene,etyleneacrylic acid, thylene methacrylic acid, and blends of copolymersthereof (see U.S. Pat. No. 5,985,567, herein incorporated by reference).

In general, suitable characteristics of the material that can be used toform the solid support surface include: being amenable to surfaceactivation such that upon activation, the surface of the support iscapable of covalently attaching a biomolecule such as an oligonucleotidethereto; amenability to “in situ” synthesis of biomolecules; beingchemically inert such that at the areas on the support not occupied bythe oligonucleotides are not amenable to non-specific binding, or whennon-specific binding occurs, such materials can be readily removed fromthe surface without removing the oligonucleotides.

In one example, the solid support surface is polypropylene.Polypropylene is chemically inert and hydrophobic. Non-specific bindingis generally avoidable, and detection sensitivity is improved.Polypropylene has good chemical resistance to a variety of organic acids(such as formic acid), organic agents (such as acetone or ethanol),bases (such as sodium hydroxide), salts (such as sodium chloride),oxidizing agents (such as peracetic acid), and mineral acids (such ashydrochloric acid). Polypropylene also provides a low fluorescencebackground, which minimizes background interference and increases thesensitivity of the signal of interest.

In another example, a surface activated organic polymer is used as thesolid support surface. One example of a surface activated organicpolymer is a polypropylene material aminated via radio frequency plasmadischarge. Such materials are easily utilized for the attachment ofnucleotide molecules. The amine groups on the activated organic polymersare reactive with nucleotide molecules such that the nucleotidemolecules can be bound to the polymers. Other reactive groups can alsobe used, such as carboxylated, hydroxylated, thiolated, or active estergroups.

Array Formats

A wide variety of array formats can be employed in accordance with thepresent disclosure. One example includes a linear array ofoligonucleotide bands, generally referred to in the art as a dipstick.Another suitable format includes a two-dimensional pattern of discretecells (such as 4096 squares in a 64 by 64 array). As is appreciated bythose skilled in the art, other array formats including, but not limitedto slot (rectangular) and circular arrays are equally suitable for use(see U.S. Pat. No. 5,981,185, herein incorporated by reference). In oneexample, the array is formed on a polymer medium, which is a thread,membrane or film. An example of an organic polymer medium is apolypropylene sheet having a thickness on the order of about 1 mil.(0.001 inch) to about 20 mil., although the thickness of the film is notcritical and can be varied over a fairly broad range. Particularlydisclosed for preparation of arrays at this time are biaxially orientedpolypropylene (BOPP) films; in addition to their durability, BOPP filmsexhibit a low background fluorescence.

The array formats of the present disclosure can be included in a varietyof different types of formats. A “format” includes any format to whichthe solid support can be affixed, such as microtiter plates, test tubes,inorganic sheets, dipsticks, and the like. For example, when the solidsupport is a polypropylene thread, one or more polypropylene threads canbe affixed to a plastic dipstick-type device; polypropylene membranescan be affixed to glass slides. The particular format is, in and ofitself, unimportant. All that is necessary is that the solid support canbe affixed thereto without affecting the functional behavior of thesolid support or any biopolymer absorbed thereon, and that the format(such as the dipstick or slide) is stable to any materials into whichthe device is introduced (such as clinical samples and hybridizationsolutions).

The arrays of the present disclosure can be prepared by a variety ofapproaches. In one example, oligonucleotide or protein sequences aresynthesized separately and then attached to a solid support (see U.S.Pat. No. 6,013,789, herein incorporated by reference). In anotherexample, sequences are synthesized directly onto the support to providethe desired array (see U.S. Pat. No. 5,554,501, herein incorporated byreference). Suitable methods for covalently coupling oligonucleotidesand proteins to a solid support and for directly synthesizing theoligonucleotides or proteins onto the support are known to those workingin the field; a summary of suitable methods can be found in Matson etal., Anal. Biochem. 217:306-10, 1994. In one example, theoligonucleotides are synthesized onto the support using conventionalchemical techniques for preparing oligonucleotides on solid supports(such as see PCT applications WO 85/01051 and WO 89/10977, or U.S. Pat.No. 5,554,501, herein incorporated by reference).

A suitable array can be produced using automated means to synthesizeoligonucleotides in the cells of the array by laying down the precursorsfor the four bases in a predetermined pattern. Briefly, amultiple-channel automated chemical delivery system is employed tocreate oligonucleotide probe populations in parallel rows (correspondingin number to the number of channels in the delivery system) across thesubstrate. Following completion of oligonucleotide synthesis in a firstdirection, the substrate can then be rotated by 90° to permit synthesisto proceed within a second)(2° set of rows that are now perpendicular tothe first set. This process creates a multiple-channel array whoseintersection generates a plurality of discrete cells.

The oligonucleotides can be bound to the polypropylene support by eitherthe 3′ end of the oligonucleotide or by the 5′ end of theoligonucleotide. In one example, the oligonucleotides are bound to thesolid support by the 3′ end. However, one of skill in the art candetermine whether the use of the 3′ end or the 5′ end of theoligonucleotide is suitable for bonding to the solid support. Ingeneral, the internal complementarity of an oligonucleotide probe in theregion of the 3′ end and the 5′ end determines binding to the support.

In particular examples, the oligonucleotide probes on the array includeone or more labels, that permit detection of oligonucleotideprobe:target sequence hybridization complexes.

Detection of Nucleic Acid and Protein Molecules

The nucleic acid molecules and proteins obtained from the subject (forexample from a PBMC) can contain altered levels of one or more genesassociated with ischemic stroke, such as those listed in Tables 2-5.Changes in expression can be detected to evaluate a stroke, or exampleto determine if the subject has had an ischemic stroke, to determine theseverity of the stroke, to determine the likelihood of neurologicalrecovery of a subject who has had an ischemic stroke, to determine theappropriate therapy for a subject who has had an ischemic stroke, orcombinations thereof. The present disclosure is not limited toparticular methods of detection. Any method of detecting a nucleic acidmolecule or protein can be used, such as physical or functional assays.For example, the level of gene activation can be quantitated utilizingmethods well known in the art and those disclosed herein, such asNorthern-Blots, RNase protection assays, nucleic acid or antibody probearrays, quantitative PCR (such as TaqMan assays), dot blot assays,in-situ hybridization, or combinations thereof. In addition, proteinscan be quantitated using antibody probe arrays, quantitativespectroscopic methods (for example mass spectrometry, such assurface-enhanced laser desorption/ionization (SELDI)-based massspectrometry), or combinations thereof.

Methods for labeling nucleic acid molecules and proteins so that theycan be detected are well known. Examples of such labels includenon-radiolabels and radiolabels. Non-radiolabels include, but are notlimited to enzymes, chemiluminescent compounds, fluorophores, metalcomplexes, haptens, colorimetric agents, dyes, or combinations thereof.Radiolabels include, but are not limited to, ¹²⁵I and ³⁵S. Radioactiveand fluorescent labeling methods, as well as other methods known in theart, are suitable for use with the present disclosure. In one example,the primers used to amplify the subject's nucleic acids are labeled(such as with biotin, a radiolabel, or a fluorophore). In anotherexample, the amplified nucleic acid samples are end-labeled to formlabeled amplified material. For example, amplified nucleic acidmolecules can be labeled by including labeled nucleotides in theamplification reactions. In another example, nucleic acid moleculesobtained from a subject are labeled, and applied to an array containingoligonucleotides. In a particular example, proteins obtained from asubject are labeled and subsequently analyzed, for example by applyingthem to an array.

The nucleic acid molecules obtained from the subject that are associatedwith ischemic stroke are applied to an ischemic stroke detection arrayunder suitable hybridization conditions to form a hybridization complex.In particular examples, the nucleic acid molecules include a label. Inone example, a pre-treatment solution of organic compounds, solutionsthat include organic compounds, or hot water, can be applied beforehybridization (see U.S. Pat. No. 5,985,567, herein incorporated byreference).

Hybridization conditions for a given combination of array and targetmaterial can be optimized routinely in an empirical manner close to theT_(m) of the expected duplexes, thereby maximizing the discriminatingpower of the method. Identification of the location in the array, suchas a cell, in which binding occurs, permits a rapid and accurateidentification of sequences associated with ischemic stroke present inthe amplified material (see below).

The hybridization conditions are selected to permit discriminationbetween matched and mismatched oligonucleotides. Hybridizationconditions can be chosen to correspond to those known to be suitable instandard procedures for hybridization to filters and then optimized foruse with the arrays of the disclosure. For example, conditions suitablefor hybridization of one type of target would be adjusted for the use ofother targets for the array. In particular, temperature is controlled tosubstantially eliminate formation of duplexes between sequences otherthan exactly complementary ischemic stroke-associated wild-type ofmutant sequences. A variety of known hybridization solvents can beemployed, the choice being dependent on considerations known to one ofskill in the art (see U.S. Pat. No. 5,981,185, herein incorporated byreference).

Once the nucleic acid molecules associated with ischemic stroke from thesubject have been hybridized with the oligonucleotides present in theischemic stroke detection array, the presence of the hybridizationcomplex can be analyzed, for example by detecting the complexes.

Detecting a hybridized complex in an array of oligonucleotide probes hasbeen previously described (see U.S. Pat. No. 5,985,567, hereinincorporated by reference). In one example, detection includes detectingone or more labels present on the oligonucleotides, the sequencesobtained from the subject, or both. In particular examples, developingincludes applying a buffer. In one example, the buffer is sodium salinecitrate, sodium saline phosphate, tetramethylammonium chloride, sodiumsaline citrate in ethylenediaminetetra-acetic, sodium saline citrate insodium dodecyl sulfate, sodium saline phosphate inethylenediaminetetra-acetic, sodium saline phosphate in sodium dodecylsulfate, tetramethylammonium chloride in ethylenediaminetetra-acetic,tetramethylammonium chloride in sodium dodecyl sulfate, or combinationsthereof. However, other suitable buffer solutions can also be used.

Detection can further include treating the hybridized complex with aconjugating solution to effect conjugation or coupling of the hybridizedcomplex with the detection label, and treating the conjugated,hybridized complex with a detection reagent. In one example, theconjugating solution includes streptavidin alkaline phosphatase, avidinalkaline phosphatase, or horseradish peroxidase. Specific, non-limitingexamples of conjugating solutions include streptavidin alkalinephosphatase, avidin alkaline phosphatase, or horseradish peroxidase. Theconjugated, hybridized complex can be treated with a detection reagent.In one example, the detection reagent includes enzyme-labeledfluorescence reagents or calorimetric reagents. In one specificnon-limiting example, the detection reagent is enzyme-labeledfluorescence reagent (ELF) from Molecular Probes, Inc. (Eugene, Oreg.).The hybridized complex can then be placed on a detection device, such asan ultraviolet (UV) transilluminator (manufactured by UVP, Inc. ofUpland, Calif.). The signal is developed and the increased signalintensity can be recorded with a recording device, such as a chargecoupled device (CCD) camera (manufactured by Photometrics, Inc. ofTucson, Ariz.). In particular examples, these steps are not performedwhen fluorophores or radiolabels are used.

In particular examples, the method further includes quantification, forinstance by determining the amount of hybridization.

Kits

The present disclosure provides for kits that can be used to evaluate astroke, for example to determine if a subject has had an ischemicstroke, to determine the severity of the stroke, to determine thelikelihood of neurological recovery of a subject who has had an ischemicstroke, to determine the appropriate therapy for a subject who has hadan ischemic stroke, or combinations thereof. Such kits allow one todetermine if a subject has a differential expression in ischemicstroke-related genes, such as any combination of four or more of thoselisted in Table 5, any combination of 150 or more of those listed inTable 3, or any combination of 500 or more of those listed in Table 2,for example any combination of at least one gene from each class ofgenes listed in Table 5 (such as at least 2 or at least 3 genes fromeach of the four classes of genes listed in Table 5).

The disclosed kits include a binding molecule, such as anoligonucleotide probe that selectively hybridizes to an ischemicstroke-related molecule that is the target of the kit. In particularexamples, the oligonucleotides probes are attached to an array. In oneexample, the kit includes oligonucleotide probes or primers (orantibodies) that recognize any combination of at least four of themolecules in Table 5, such as at least 5, at least 10, at least 15, atleast 20, or at least 22 of the ischemic stroke-related molecules listedin Table 5, such as any combination of at least 150 of the molecules inTable 3, such as at least 160, at least 170, at least 175, at least 180,at least 185, or at least 190 of the sequences listed in Table 3, suchas any combination of at least 500 of the molecules in Table 2, such asat least 525, at least 550, at least 575, at least 600, at least 610, orat least 637 of the sequences listed in Table 2. In particular examples,the kit includes oligonucleotide probes or primers (or antibodies) thatrecognize at least one gene (or protein) from each class listed in Table5, such as at least 2, at least 3, at least 5, or at least 10 genes fromeach class.

In one particular example, the kit includes oligonucleotide probes orprimers (or antibodies) that recognize at least CD163; hypotheticalprotein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; and KIAA0146. In one particular example,the kit includes oligonucleotide probes or primers (or antibodies) thatrecognize at least 1, at least 2, at least 3, at least 4, at least 5 orat least 6 of CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; or KIAA0146.In another particular example, the kit includes oligonucleotide probesor primers (or antibodies) that recognize CD163, for example incombination with oligonucleotide probes or primers (or antibodies) thatrecognize any combination of at least three ischemic stroke relatedmolecules listed in Tables 2-5.

In a particular example, kits include antibodies capable of binding toischemic stroke-related proteins. Such antibodies can be present on anarray.

The kit can further include one or more of a buffer solution, aconjugating solution for developing the signal of interest, or adetection reagent for detecting the signal of interest, each in separatepackaging, such as a container. In another example, the kit includes aplurality of ischemic stroke-related target nucleic acid sequences forhybridization with an ischemic stroke detection array to serve aspositive control. The target nucleic acid sequences can includeoligonucleotides such as DNA, RNA, and peptide-nucleic acid, or caninclude PCR fragments.

Ischemic Stroke Therapy

The present disclosure also provides methods of reducing brain injury ina subject determined to have suffered an ischemic stroke. For example,if using the assays described above a change in expression in at least 4of the ischemic stroke-related molecules listed in Table 5 is detectedin the subject, for example at least 22 of the ischemic stroke-relatedmolecules listed in Table 5 is detected in the subject, a treatment isselected to avoid or reduce brain injury or to delay the onset of braininjury. In another example, if using the screening methods describedabove a change in expression in at least 500 of the ischemicstroke-related molecules listed in Table 2 is detected in the subject, atreatment is selected to avoid or reduce brain injury or to delay theonset of brain injury. The subject then can be treated in accordancewith this selection, for example by administration of one or moreanticoagulant agents. In some examples, the treatment selected isspecific and tailored for the subject, based on the analysis of thatsubject's profile for one or more ischemic stroke-related molecules.

Screening Test Agents

Based on the identification of multiple ischemic stroke-relatedmolecules whose expression is altered following an ischemic stroke (suchas those listed in Tables 2-5), the disclosure provides methods foridentifying agents that can enhance, normalize, or reverse theseeffects. For example, the method permits identification of agents thatnormalize activity of an ischemic stroke-related molecule, such as agene (or its corresponding protein) involved in vascular repair,response to hypoxia, response to altered cerebral microenvironment, orcombinations thereof (see Table 5). Normalizing activity (such as theexpression) of an ischemic stroke-related molecule can includedecreasing activity of an ischemic stroke-related molecule whoseactivity is increased following an ischemic stroke, or increasingactivity of an ischemic stroke-related molecule whose activity isdecreased following an ischemic stroke. In another example, the methodpermits identification of agents that enhance the activity of anischemic stroke-related molecule, such as an ischemic stroke-relatedmolecule whose activity provides a protective effect to the subjectfollowing an ischemic stroke. For example, the method permitsidentification of agonists. In yet another example, the method permitsidentification of agents that decrease the activity of an ischemicstroke-related molecule, such as an ischemic stroke-related moleculewhose activity results in one or more negative symptoms of ischemicstroke. For example, the method permits identification of antagonists.

In particular examples the identified agents can be used to treat asubject who has had an ischemic stroke, for example to alleviate orprevent one or more symptoms of an ischemic stroke, such as paralysis ormemory loss.

The disclosed methods can be performed in vitro, for example by addingthe test agent to cells in culture, or in vivo, for example byadministering the test agent to a mammal (such as a human or alaboratory animal, for example a mouse, rat, dog, or rabbit). Inparticular examples, the method includes exposing the cell or mammal toconditions sufficient for mimicking an ischemic stroke. The one or moretest agents are added to the cell culture or administered to the mammalunder conditions sufficient to alter the activity of an ischemicstroke-related molecule, such as at least one of the molecules listed inTables 2-5. Subsequently, the activity of the ischemic stroke-relatedmolecule is determined, for example by measuring expression of one ormore ischemic stroke-related molecules or by measuring an amount ofbiological activity of one or more ischemic stroke-related proteins. Achange in the activity one or more ischemic stroke-related moleculeindicates that the test agent alters the activity of an ischemicstroke-related molecule listed in Tables 2-5. In particular examples,the change in activity is determined by a comparison to a standard, suchas an amount of activity present when no ischemic stroke has occurred,or an amount of activity present when an ischemic stroke has occurred,or to a control.

Any suitable compound or composition can be used as a test agent, suchas organic or inorganic chemicals, including aromatics, fatty acids, andcarbohydrates; peptides, including monoclonal antibodies, polyclonalantibodies, and other specific binding agents; phosphopeptides; ornucleic acid molecules. In a particular example, the test agent includesa random peptide library (for example see Lam et al., Nature 354:82-4,1991), random or partially degenerate, directed phosphopeptide libraries(for example see Songyang et al., Cell 72:767-78, 1993). A test agentcan also include a complex mixture or “cocktail” of molecules.

Therapeutic agents identified with the disclosed approaches can be usedas lead compounds to identify other agents having even greater desiredactivity. In addition, chemical analogs of identified chemical entities,or variants, fragments, or fusions of peptide test agents, can be testedfor their ability to alter activity of an ischemic stroke-relatedmolecule using the disclosed assays. Candidate agents can be tested forsafety in animals and then used for clinical trials in animals orhumans.

In one example, the method is an in vitro assay. For example, cells,such as cells that can provide a model of what happens in vivo followingan ischemic stroke, are cultured under conditions sufficient formimicking an ischemic stroke, such as hypoxia, hypoglycemia, orcombinations thereof. Simultaneously or at a time thereafter, one ormore test agents are incubated with the cells under conditionssufficient for the test agent to have the desired effect on the cell,for example to alter (such as normalize) the activity of a ischemicstroke-related molecule. In particular examples, the test agent has thedesired effect on more than one ischemic stroke-related molecule.

Examples of cells that can be used include, but are not limited to:PBMCs, endothelial cells, neuronal cells, or combinations thereof.Methods of isolating PBMCs from a subject are disclosed herein. Neuronalcells and endothelial cells can also be obtained from a subject, such asa mammal, and grown as a primary culture using standard methods. Forexample, endothelial cells can be obtained from umbilical cord tissue(for example see Ulrich-Merzenich et al., In Vitro Cellular &Developmental Biology-Animal, 38: 265-72, 2002); coronary arteries (Dameet al., In Vitro Cellular & Developmental Biology-Animal, 39:402-6,2003); or lung tissue (for example see Dong et al., Arteriosclerosis,Thrombosis, and Vascular Biology, 17:1599-604, 1997). For example,neuronal cells can be obtained from mammalian brain tissue (for examplesee Shevtsova et al., Exp. Physiol. 90:53-9, 2005 and Buse et al., BrainRes. 283:221-34, 1983). In one example, established neuronal orendothelial tissue culture cell lines are used, such as those availablefrom American Type Culture Collection (ATCC) and other commercialsources. For example, rat PC12 pheochromocytoma neurosecretory cell line(ATCC No. CRL-1721), human neuronal HCN-2 cells (ATCC No. CRL-10742),the rat neuronal RSC96 cell line (CRL-2765), human HAAE-2 endothelialcells (ATCC No. CRL-2473), human HPAE-26 endothelial cells (ATCC No.CRL-2598), human aortic endothelial cells (Clonetics), and bovine FBHEendothelial cells (ATCC No. CRL-1395) are particular examples of celllines that can be used. However one skilled in the art will appreciatethat other cell lines can be used.

Methods of providing conditions sufficient for mimicking an ischemicstroke in vitro are known in the art. For example, cells can be exposedto hypoxic conditions (low oxygen) by culturing the cells in anatmosphere controlled-culture chamber (for example a chamber from BellcoGlass [Vineland, N.J.]; a modular hypoxia chamber [Billups-Rothenberg];an Espec [Grand Rapids, Mich.]; or BIO-LABO [Juji Field, Tokyo, Japan].A particular example of hypoxic conditions is a chamber containing a gasmixture of 94% N₂, 5% CO₂, and 1% O₂. Cells are generally grown at 37°C. The amount of time the cells are exposed to hypoxic conditions canvary. In particular examples, cells are exposed to hypoxic conditionsfor at least 10 minutes, such as at least 30 minutes, at least 1 hour,at least 6 hours, at least 12 hours, or even at least 24 hours. In oneexample, hypoxic conditions are used to identify free radical scavengeragents.

Another method that can be used to mimic an ischemic stroke is to exposethe cells to hypoglycemic conditions (low glucose). Hypoglycemia (suchas <30 mg glucose/dl) can result from ischemia (for example using theconditions described above), or can be induced by culturing cells ingrowth medium that does not contain added glucose. Cells are generallygrown at 37° C. The amount of time the cells are exposed to hypoglycemicconditions (deprived of glucose) can vary. In particular examples, cellsare exposed to hypoglycemic conditions for at least 1 hour, such as atleast 4 hours, at least 6 hours, at least 12 hours, at least 24 hours,at least 48 hours, or even at least 72 hours. In some examples, thehypoglycemic conditions are combined with hypoxic conditions.

One or more test agents are incubated with the cells under conditionssufficient for the test agent to have the desired effect on the cell.The agent can be added at a time subsequent to mimicking an ischemicstroke, or at substantially the same time as mimicking an ischemicstroke. In one example, the agent is added at least 30 minutes aftermimicking an ischemic stroke, such as at least 1 hour, at least 2 hours,at least 6 hours, at least 24 hours, at least 72 hours, at least 7 days,at least 14 days, at least 30, days, at least 60 days or even at least90 days after mimicking an ischemic stroke.

In another example, the method is an in vivo assay. For example, agentsidentified as candidates in the in vitro assay can be tested in vivo fortheir ability to alter (such as normalize) the activity of a ischemicstroke-related molecule (such as one or more of those listed in Tables2-5). In particular examples, the mammal has had an ischemic stroke orhas been exposed to conditions that induce an ischemic stroke.Simultaneously or at a time thereafter, one or more test agents areadministered to the subject under conditions sufficient for the testagent to have the desired effect on the subject, for example to alter(such as normalize) the activity of an ischemic stroke-related moleculeor a pattern of ischemic stroke-related molecules. In particularexamples, the test agent has the desired effect on more than oneischemic stroke-related molecule.

Methods of providing conditions sufficient for inducing an ischemicstroke in vivo are known in the art. For example, ischemic stroke can beinduced in a mammal by occlusion of the middle cerebral artery (MCA)under anesthesia. Ischemic stroke can also be induced in a mammal (suchas a rat), for example by three-vessel (bilateral vertebral andunilateral common carotid artery) occlusion (3-VO) to induceunilaterally accentuated brain hypoperfusion under anesthesia (forexample using the method described in Busch et al., J. Cereb. Blood FlowMetab. 23:621-8, 2003) or by the four-vessel occlusion (4-VO) method toinduce transient forebrain ischemia. In another example, the subject isexposed hypoxic conditions. For example, a mammal can be exposed tosublethal hypoxia conditions, such as 11% oxygen for 2 hours. In anotherexample, the right carotid artery is ligated and mammal exposed to 8%oxygen for 2 hours.

One or more test agents are administered to the subject under conditionssufficient for the test agent to have the desired effect on the subject.Any appropriate method of administration can be used, such asintravenous, intramuscular, or transdermal. The agent can beadministered at a time subsequent to the ischemic stroke, or atsubstantially the same time as the ischemic stroke. In one example, theagent is added at least 30 minutes after the ischemic stroke, such as atleast 1 hour, at least 2 hours, at least 6 hours, at least 24 hours, atleast 72 hours, at least 7 days, at least 14 days, at least 30 days, atleast 60 days or even at least 90 days after the ischemic stroke.

The effect on the one or more test agents on the activity of one or moreischemic stroke-related molecules can be determined using methods knownin the art. For example, the effect on expression of one or moreischemic stroke-related genes can be determined using the arrays andmethods disclosed herein. For example, RNA can be isolated from thecultured cells exposed to the test agent, or from cells obtained from asubject (such as PBMCs) administered the test agent. The isolated RNAcan be labeled and exposed to an array containing one or more nucleicacid molecules (such as a primer or probe) that can specificallyhybridize to one or more pre-selected ischemic stroke-related genes,such at least 1, at least 2, or at least 3 of those listed in Tables2-5, or to a pre-selected pattern of such genes that is associated withischemic stroke. In a particular example, the one or more pre-selectedischemic stroke-related genes include at least one gene involved invascular repair, at least one response to hypoxia gene, at least oneresponse to altered cerebral microenvironment gene, or combinationsthereof (for example see Table 5). In another example, proteins areisolated from the cultured cells exposed to the test agent, or fromcells obtained from a subject (such as PBMCs) administered the testagent. The isolated proteins can be analyzed to determine amounts ofexpression or biological activity of one or more ischemic stroke-relatedproteins, such at least 1, at least 2, or at least 3 of those listed inTables 2-5, or a pattern of upregulation or downregulation ofpre-identified or pre-selected proteins. In a particular example, theone or more pre-selected ischemic stroke-related proteins include atleast one protein involved in vascular repair, at least one response tohypoxia protein, at least one response to altered cerebralmicroenvironment protein, or combinations thereof (for example see Table5). In a particular example, mass spectrometry is used to analyze theproteins.

In particular examples, differential expression of an ischemicstroke-related molecule is compared to a standard or a control. Oneexample of a control includes the amount of activity of an ischemicstroke-related molecule present or expected in a subject who has not hadan ischemic stroke, wherein an increase or decrease in activity in atest sample of an ischemic stroke-related molecule (such as those listedin Tables 2-5) compared to the control indicates that the test agentalters the activity of at least one ischemic stroke-related molecule.Another example of a control includes the amount of activity of anischemic stroke-related molecule present or expected in a subject whohas had an ischemic stroke, wherein an increase or decrease in activityin a test sample (such as gene expression, amount of protein, orbiological activity of a protein) of an ischemic stroke-related molecule(such as those listed in Tables 2-5) compared to the control indicatesthat the test agent alters the activity of at least one ischemicstroke-related molecule. Detecting differential expression can includemeasuring a change in gene expression, measuring an amount of protein,or determining an amount of the biological activity of a proteinpresent.

In particular examples, test agents that altered the activity of anischemic stroke-related molecule are selected.

The disclosure is further illustrated by the following non-limitingExamples.

Example 1 Isolation of Samples

This example describes methods used to obtain RNA from control subjects(subjects who had not previously had a stroke) and subjects who sufferedan ischemic stroke within the previous 72 hours.

A cohort of elderly volunteers was obtained and their stroke riskfactors recorded, including a history of hypertension, smoking, diabetesmellitus and heart disease. Approximately 30 milliliters of blood wasdrawn into four yellow top ACD A tubes (ACD Acid Citrate Dextrose A,22.0 g/L Trisodium Citrate, 8.0 g/L Citric Acid, 24.5 g/L Dextrose, BDFranklin Lakes, N.J.) by aseptic antecubital fossa venipuncture. PBMCisolation was completed within two hours.

Acute stroke patients admitted to the National Institutes of HealthStroke Program at Suburban Hospital in Bethesda, Md. underwent asepticantebrachial venipuncture followed by withdrawal of 30 ml of blood asdescribed above. Blood samples were drawn within 72 hours of strokeonset. The blood samples were processed for RNA within two hours ofcollection.

Table 1 lists the demographic features of the patients and controls inthe index cohort (n=38) and the patients and controls in the validation(test) cohort (n=19). The two index groups are reasonably comparable interms of age sex and pre-morbid risk factors consistent with a communitybased stroke population.

TABLE 1 Demographics of Patients and Controls Index Cohort Test CohortFactor Patients Controls Patients Controls Number 19 19 9 10 Age (years)75.7 ± 15.1 66.0 ± 11.5 79.6 ± 8.1 67.6 ± 16.1 Sex Female  7 (37) 13(68) 4 (44) 6 (60) Race Caucasian 18 (95) 13 (68) 8 (89) 7 (70) AfricanAmerican 1 (5)  5 (26) 1 (11) 2 (20) Asian 0 (0) 1 (5) 0 (0)  1 (10)Risk Factors Hypertension 12 (63)  5 (26) 5 (56) 4 (40) Diabetes 1 (5) 0(0) 1 (11) 1 (10) Smoking  7 (37)  7 (37) 5 (56) 2 (20) Coronary arterydisease  4 (21) 1 (5) 3 (33) 1 (10) Framingham risk score 16.2 ± 7.4 9.8 ± 5.6 18.6 ± 2.5 12.2 ± 8.4  Stroke-Related NIHSS score* 3.7 ± 5.1 5.9 ± 6.2 Time to blood draw (hours) 32.4 ± 17.8  53.3 ± 39.7 Figuresare numbers (%) for groups and mean ± SD for continuous factors.*NIHSS—National Institutes of Health Stroke Scale.

Acute stroke was confirmed by magnetic resonance imaging studiesincluding diffusion weighted imaging (DWI) and perfusion imaging. Strokerisk factors were recorded on each patient and volunteer according tothe Framingham risk profile (see Wolf et al., Stroke 22:312-8, 1991).Stroke severity was determined by serial neurological examination and bythe National Institutes of Health Stroke Scale (NIHSS) score (see Brottet al., Stroke 20:871-5, 1989).

RNA was isolated from PBMCs as follows. Total RNA (5-15 μg) wasextracted from PBMCs separated from whole blood using a Density Gradienttube (Uni-Sep, Novamed, Jerusalem, Israel) as follows: 20-30 ml ACDanti-coagulated blood was diluted with an equal volume of phosphatebuffered saline (PBS) and added to the density gradient tube, followedby centrifugation at 1000 g for 30 minutes. After centrifugation, thePBMC layer was removed.

RNA was extracted using RNeasy Mini Kit (Qiagen Cat. #75162, Valencia,Calif.), as per the manufacturer's protocol. Briefly, harvested PBMCsare diluted 1:1 with PBS and centrifuged for 10 minutes at 4000 rpm. Theresulting supernatant was discarded and the pellet resuspended in 600 μlRLT buffer (1 ml buffer+10 μl 2-β-mercaptoethanol). The sample washomogenized by passing the lysate 5-10 times through 20-G (French)needle fitted to a syringe. Cells were resuspended in 600 μl of DEPC-H₂Odiluted in 70% EtOH and was loaded onto an RNeasy mini spin columnfitted with a 2-ml collection tube. The sample was twice centrifuged at14,000 rpm for 15 seconds. The RNeasy column was transferred to a new 2ml collection tube and 500 μl of RPE buffer added followed bycentrifugation at 14,000 rpm for 15 seconds. RPE buffer (5000 was addedand the sample centrifuged at 10,000 rpm for 2 minutes. The RNeasycolumn was then transferred into a new 1.5 ml collection tube and RNAfree water (30 μl) directly added to the RNase membrane followed byfurther centrifugation at 10,000 rpm for 1 minute. This was repeated andthe extracted RNA stored at −80° C.

Example 2 RNA Labeling

This example describes methods used to label the RNA obtained inExample 1. However, one skilled in the art will appreciate that otherlabels and methods can be used.

RNA obtained from PBMCs was biotin-labeled and cleaned according toAffymetrix guidelines for Human Genome 133A arrays. Briefly, the EnzoBioArray HighYield RNA Transcript Labeling Kit3 (Affymetrix, P/N 900182)was used for generating labeled cRNA target. Template cDNA and the otherreaction components were added to RNase-free microfuge tubes. To avoidprecipitation of DTT, reactions were at room temperature while additionswere made. After adding all reagents, the tube was incubated are a 37°C. for 4 to 5 hours, gently mixing the contents of the tube every 30-45minutes during the incubation.

To ensure the quality of the initial isolated total RNA, DNase was usedto remove contaminant DNA from the sample. In addition, Northern blotfollowed by optical density analysis was used to determine theconcentration of the RNA band.

If the total RNA concentration was >5 μg, the RNA was used forsubsequent gene chip hybridization as per the manufacturer's protocol.

Example 3 Microarray Hybridization and Statistical Analysis

Coded mRNA samples were analyzed using the Affymetrix GeneChipR HumanGenome U133A chips that include 22,283 gene probes (around 19,000 genes)of the best characterized human genes. Microarrays were scanned (Axonscanner, Axon Instruments Inc, CA), and images were analyzed usingGenePix image analysis software (Axon Instruments Inc, CA) allowing forgene spot fluorescent quantification following subtraction of thesurrounding background fluorescent signal within the

Affymetrix MASS gene chip analysis suite with production of .CEL, and.DAT output files. The .CDF file or annotation file for the AffymetrixHU133A chip and the .CEL files, containing the scanned gene expressioninformation, were the only data files used in all subsequent analyses.

For the data analysis, .CEL files of 19 patients and 19 controls wereused following exclusion from analysis of one chip in each of the indexpatient and control groups due to unsatisfactory hybridization (seeIrizarry et al., The Analysis of Gene Expression Data. New York:Springer, 2003). The analysis was completed using the Bioconductorapplications of the R programming language and implemented on a 64-bitoperating system (SGI Octane 14000 MIPS 600 MHz CPU running Irix 6.5.15)due to the large dataset for analysis (Moore et al., 32 bitarchitecture—a severe bio-informatics limitation. NHLBI Symposium FromGenome to Disease. 2003, Bethesda, Md.: 64). Sample RNA degradationduring processing was tightly distributed and uniform across all chips.

Quantile normalization was performed simultaneously on the .CEL dataset(stroke patients, n=19, controls, n=19).

Following normalization, expression levels for each gene were calculatedusing the perfect match array probes and a robust median polishtechnique after background correction and log₂ transformation (Irizarryet al., The Analysis of Gene Expression Data. New York: Springer, 2003).The resulting expression set was compared in a univariate manner betweenthe stroke patients and control group using parametric testing (t-test).The uncorrected p-value were assigned a cutoff threshold value ofsignificance of <0.05. Subsequent multiple comparison correction wasperformed using Bonferroni and false discovery techniques (Benjamini andYekutieli, The Annals of Statistics 29:1165-88, 2001). The effects ofvarious multiple comparison correction techniques are shown in FIG. 1.

The uncorrected significant gene expression set was further analyzedusing permutation analysis of Westfall and Young (Resampling-basedmultiple testing: Examples and methods for p-value adjustment. New York:John Wiley & Sons, 1993). Hierarchical cluster analysis was performed onthe gene subset found to be significantly different between strokepatients and controls using the method of Eisen et al. where each genewas pair-wise correlated by calculation of a distance matrix using aEuclidean metric (Proc. Natl. Acad. Sci. 95:14863-8, 1998). The distancematrix then formed the basis for hierarchical clustering. Geneannotation and ontology were determined using the Affymetrix on-lineNetAffix suite together with subsequent literature searches, allowingcategorization of a gene listing into molecular function, cellularfunction and biological function.

Using the PAM algorithm (Prediction Analysis for Microarrays) theability of the index set to separate prospectively obtained samples fromten stroke patients and ten controls was examined (Tibshirani et al.,Proc. Natl. Acad. Sci. 90:6567-72, 2002). The arrays of 9 patients and10 controls were used. In one stroke case, the hybridization was not ofsufficient quality to be included.

Without multiple comparison correction, 5060 genes were significantlydifferent in the dataset. The Benjamini and Yekutieli correctionresulted in 771 significant gene probes (Table 2), which represent 637genes. This approach seeks to limit the false discovery rate (theproportion of non-differentiated genes among all those genes declaredsignificantly different) to 5%. As shown in Table 2, several genes wereupregulated (positive T-statistic, such as a value that is at least3.77) or downregulated (negative t-statistic, such as a value that isless than −3.76, such as less than −3.77) following an ischemic stroke.In addition, several genes not previously associated with ischemicstroke, such as CD163; hypothetical protein FLJ22662 Laminin A motif;bone marrow stromal cell antigen 1/CD157; Fc fragment of IgG, highaffinity Ia, receptor for (CD64); baculoviral IAP repeat-containingprotein 1; and KIAA0146, were identified.

TABLE 2 Ischemic stroke related-genes using Benjamini and Yekutielicorrection. UniGene Affy ID No. t-statistic* Gene Name ID No.{circumflexover ( )} 218454_at 7.89390463 hypothetical protein FLJ22662 178470215049_x_at 7.86959913 CD163 antigen 74076 203645_s_at 7.79274287 CD163antigen 74076 211404_s_at 7.61929825 amyloid beta (A4) precursor-likeprotein 2 279518 206120_at 7.61303715 CD33 antigen (gp67) 83731208771_s_at 7.4480951 leukotriene A4 hydrolase 81118 210872_x_at7.29576739 growth arrest-specific 7 226133 201328_at 7.19607698 v-etserythroblastosis virus E26 oncogene homolog 292477 2 (avian) 222173_s_at7.01811369 TBC1 domain family, member 2 371016 211612_s_at 6.71007614interleukin 13 receptor, alpha 1 285115 211067_s_at 6.66328089 growtharrest-specific 7 226133 211368_s_at 6.65646046 caspase 1,apoptosis-related cysteine protease 2490 (interleukin 1, beta,convertase) 219788_at 6.6357632 paired immunoglobin-like type 2 receptoralpha 122591 202896_s_at 6.63433745 protein tyrosine phosphatase,non-receptor type 156114 substrate 1 221210_s_at 6.63079363N-acetylneuraminate pyruvate lyase 64896 (dihydrodipicolinate synthase)204924_at 6.60026287 toll-like receptor 2 439608 206488_s_at 6.54747468CD36 antigen (collagen type I receptor, 443120 thrombospondin receptor)208146_s_at 6.53595206 carboxypeptidase, vitellogenic-like 95594213006_at 6.50588342 KIAA0146 protein 381058 208923_at 6.46904449cytoplasmic FMR1 interacting protein 1 26704 208702_x_at 6.46198549amyloid beta (A4) precursor-like protein 2 279518 204452_s_at 6.45273495frizzled homolog 1 (Drosophila) 94234 205715_at 6.43160146 bone marrowstromal cell antigen 1 169998 216942_s_at 6.42353873 CD58 antigen,(lymphocyte function-associated 75626 antigen 3) 218217_at 6.41930598likely homolog of rat and mouse retinoid-inducible 431107 serinecarboxypeptidase 212192_at 6.41402934 hypothetical protein BC013764109438 200868_s_at 6.39211608 zinc finger protein 313 144949 202912_at6.38896329 adrenomedullin 441047 207691_x_at 6.37169995 ectonucleosidetriphosphate diphosphohydrolase 1 444105 209124_at 6.322399 myeloiddifferentiation primary response gene (88) 82116 204620_s_at 6.31071007chondroitin sulfate proteoglycan 2 (versican) 434488 203535_at6.29981025 S100 calcium binding protein A9 (calgranulin B) 112405202878_s_at 6.29001183 complement component 1, q subcomponent, 97199receptor 1 204249_s_at 6.28630536 LIM domain only 2 (rhombotin-like 1)283063 208872_s_at 6.26653125 polyposis locus protein 1 173119205603_s_at 6.25337908 diaphanous homolog 2 (Drosophila) 226483208818_s_at 6.20310945 catechol-O-methyltransferase 240013 205158_at6.20094021 ribonuclease, RNase A family, 4 283749 200765_x_at 6.19288966catenin (cadherin-associated protein), alpha 1, 254321 102 kDa220615_s_at 6.13260793 hypothetical protein FLJ10462 134497 202897_at6.1313157 protein tyrosine phosphatase, non-receptor type 156114substrate 1 204222_s_at 6.12453094 GLI pathogenesis-related 1 (glioma)511765 201743_at 6.11554977 CD14 antigen 75627 211744_s_at 6.05217577CD58 antigen, (lymphocyte function-associated 75626 antigen 3)207168_s_at 6.04197964 H2A histone family, member Y 75258 220034_at6.04155844 interleukin-1 receptor-associated kinase 3 268552 204099_at6.02751709 SWI/SNF related, matrix associated, actin 444445 dependentregulator of chromatin, subfamily d, member 3 212335_at 6.01677891glucosamine (N-acetyl)-6-sulfatase (Sanfilippo 334534 disease IIID)211135_x_at 6.01231784 leukocyte immunoglobulin-like receptor, subfamily511766 B (with TM and ITIM domains), member 3 203127_s_at 5.98628713serine palmitoyltransferase, long chain base subunit 2 59403 201041_s_at5.97525939 dual specificity phosphatase 1 171695 209949_at 5.97496326neutrophil cytosolic factor 2 (65 kDa, chronic 949 granulomatousdisease, autosomal 2) 203922_s_at 5.95791758 cytochrome b-245, betapolypeptide (chronic 88974 granulomatous disease) 200838_at 5.95626946cathepsin B 135226 210844_x_at 5.93419339 catenin (cadherin-associatedprotein), alpha 1, 254321 102 kDa 200886_s_at 5.905732 phosphoglyceratemutase 1 (brain) 447492 208949_s_at 5.88800393 lectin,galactoside-binding, soluble, 3 (galectin 3) 411701 211284_s_at5.87237505 granulin 180577 210992_x_at 5.78142217 Fc fragment of IgG,low affinity IIa, receptor for 352642 (CD32) 204860_s_at 5.76755994 Homosapiens transcribed sequence with strong 508565 similarity to proteinsp: Q13075 (H. sapiens) BIR1_HUMAN Baculoviral IAP repeat-containingprotein 1 (Neuronal apoptosis inhibitory protein) 212788_x_at 5.75081118ferritin, light polypeptide 433670 211776_s_at 5.7448982 erythrocytemembrane protein band 4.1-like 3 103839 221731_x_at 5.74075036chondroitin sulfate proteoglycan 2 (versican) 434488 210225_x_at5.74059556 leukocyte immunoglobulin-like receptor, subfamily 511766 B(with TM and ITIM domains), member 3 218404_at 5.73126746 sorting nexin10 418132 214511_x_at 5.7139856 Fc fragment of IgG, high affinity Ia,receptor for 77424 (CD64) 200764_s_at 5.67242227 catenin(cadherin-associated protein), alpha 1, 254321 102 kDa 210904_s_at5.66794891 interleukin 13 receptor, alpha 1 285115 201200_at 5.64946077cellular repressor of E1A-stimulated genes 5710 209189_at 5.64912247v-fos FBJ murine osteosarcoma viral oncogene 25647 homolog 202943_s_at5.6217726 N-acetylgalactosaminidase, alpha- 75372 201329_s_at 5.60980712v-ets erythroblastosis virus E26 oncogene homolog 292477 2 (avian)200678_x_at 5.59206951 granulin 180577 200839_s_at 5.59110282 cathepsinB 135226 204053_x_at 5.58890981 phosphatase and tensin homolog (mutatedin 253309 multiple advanced cancers 1) 204759_at 5.57510891 chromosomecondensation 1-like 27007 217897_at 5.56972714 FXYD domain containingion transport regulator 6 410748 203973_s_at 5.56911715 KIAA0146 protein381058 210951_x_at 5.54846557 RAB27A, member RAS oncogene family 298530216041_x_at 5.5475628 granulin 180577 208454_s_at 5.54191982 plasmaglutamate carboxypeptidase 197335 209970_x_at 5.52920792 caspase 1,apoptosis-related cysteine protease 2490 (interleukin 1, beta,convertase) 204646_at 5.50217863 dihydropyrimidine dehydrogenase 1602202990_at 5.49766192 phosphorylase, glycogen; liver (Hers disease,282417 glycogen storage disease type VI) 218606_at 5.4924926 zincfinger, DHHC domain containing 7 9725 219316_s_at 5.47793995 chromosome14 open reading frame 58 267566 207574_s_at 5.47094508 growth arrest andDNA-damage-inducible, beta 110571 212807_s_at 5.46295198 sortilin 1394609 214875_x_at 5.46291913 amyloid beta (A4) precursor-like protein 2279518 202446_s_at 5.45795408 phospholipid scramblase 1 348478210784_x_at 5.416225 leukocyte immunoglobulin-like receptor, subfamily511766 B (with TM and ITIM domains), member 3 203561_at 5.4154987 Fcfragment of IgG, low affinity IIa, receptor for 352642 (CD32) 210152_at5.40888799 leukocyte immunoglobulin-like receptor, subfamily 67846 B(with TM and ITIM domains), member 4 210427_x_at 5.374221 annexin A2462864 212830_at 5.37395389 EGF-like-domain, multiple 5 236216 204169_at5.36588724 IMP (inosine monophosphate) dehydrogenase 1 317095209500_x_at 5.34575265 tumor necrosis factor (ligand) superfamily,member 54673 13 201432_at 5.33693741 catalase 395771 215646_s_at5.33373927 chondroitin sulfate proteoglycan 2 (versican) 434488201422_at 5.33217618 interferon, gamma-inducible protein 30 14623204112_s_at 5.33018103 histamine N-methyltransferase 42151 214318_s_at5.32431367 hypothetical protein CG003 390874 204588_s_at 5.32319243solute carrier family 7 (cationic amino acid 194693 transporter, y+system), member 7 211366_x_at 5.32286549 caspase 1, apoptosis-relatedcysteine protease 2490 (interleukin 1, beta, convertase) 217865_at5.27748545 ring finger protein 130 155718 211133_x_at 5.26677423leukocyte immunoglobulin-like receptor, subfamily 511766 B (with TM andITIM domains), member 3 209091_s_at 5.26607942 SH3-domain GRB2-likeendophilin B1 136309 209474_s_at 5.2656896 ectonucleoside triphosphatediphosphohydrolase 1 444105 209514_s_at 5.25717561 RAB27A, member RASoncogene family 298530 211571_s_at 5.25409403 chondroitin sulfateproteoglycan 2 (versican) 434488 201426_s_at 5.25332759 vimentin 435800209069_s_at 5.23594128 H3 histone, family 3B (H3.3B) 180877 208130_s_at5.23289975 thromboxane A synthase 1 (platelet, cytochrome 444510 P450,family 5, subfamily A) 220990_s_at 5.22930546 likely ortholog of ratvacuole membrane protein 1 166254 210314_x_at 5.22262249 tumor necrosisfactor (ligand) superfamily, member 54673 13 203140_at 5.21224928 B-cellCLL/lymphoma 6 (zinc finger protein 51) 155024 205147_x_at 5.20456789neutrophil cytosolic factor 4, 40 kDa 196352 210101_x_at 5.19857938SH3-domain GRB2-like endophilin B1 136309 205896_at 5.19850838 solutecarrier family 22 (organic cation transporter), 441130 member 4206130_s_at 5.19713599 asialoglycoprotein receptor 2 1259 211367_s_at5.18249106 caspase 1, apoptosis-related cysteine protease 2490(interleukin 1, beta, convertase) 217521_at 5.1760536 histidineammonia-lyase 190783 212501_at 5.16612621 CCAAT/enhancer binding protein(C/EBP), beta 99029 218013_x_at 5.16025276 dynactin 4 (p62) 328865209188_x_at 5.1523164 down-regulator of transcription 1, TBP-binding348418 (negative cofactor 2) 202670_at 5.15097523 mitogen-activatedprotein kinase kinase 1 132311 217492_s_at 5.14879874 phosphatase andtensin homolog (mutated in 493716 multiple advanced cancers 1),pseudogene 1 206600_s_at 5.14522932 solute carrier family 16(monocarboxylic acid 90911 transporters), member 5 208959_s_at5.13849248 thioredoxin domain containing 4 (endoplasmic 154023reticulum) 209073_s_at 5.1251219 numb homolog (Drosophila) 445301206237_s_at 5.11823604 neuregulin 1 172816 209185_s_at 5.11676697insulin receptor substrate 2 143648 211702_s_at 5.09810016 ubiquitinspecific protease 32 436133 200742_s_at 5.09255723ceroid-lipofuscinosis, neuronal 2, late infantile 429658(Jansky-Bielschowsky disease) 214449_s_at 5.08839258 ras homolog genefamily, member Q 442989 204834_at 5.07009362 fibrinogen-like 2 351808204619_s_at 5.06774454 chondroitin sulfate proteoglycan 2 (versican)434488 208926_at 5.06247837 sialidase 1 (lysosomal sialidase) 118721201944_at 5.0610548 hexosaminidase B (beta polypeptide) 69293202727_s_at 5.05203162 interferon gamma receptor 1 180866 211676_s_at5.0386297 interferon gamma receptor 1 180866 204493_at 5.03178215 BH3interacting domain death agonist 300825 219015_s_at 5.03010765uncharacterized hematopoietic stem/progenitor cells 110853 proteinMDS031 209397_at 5.03002491 malic enzyme 2, NAD(+)-dependent,mitochondrial 75342 217741_s_at 5.02535951 zinc finger protein 216406096 201044_x_at 5.01624832 dual specificity phosphatase 1 171695219694_at 5.013375 hypothetical protein FLJ11127 155085 201127_s_at5.00643448 ATP citrate lyase 387567 209304_x_at 5.00154395 growth arrestand DNA-damage-inducible, beta 110571 211395_x_at 4.99850312 Fc fragmentof IgG, low affinity IIb, receptor for 126384 (CD32) 205786_s_at4.99689814 integrin, alpha M (complement component receptor 172631 3,alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide)212268_at 4.99395229 serine (or cysteine) proteinase inhibitor, clade B381167 (ovalbumin), member 1 202787_s_at 4.99061446 mitogen-activatedprotein kinase-activated protein 234521 kinase 3 203888_at 4.98963325thrombomodulin 2030 221841_s_at 4.98297365 Kruppel-like factor 4 (gut)376206 201888_s_at 4.97738085 interleukin 13 receptor, alpha 1 285115200785_s_at 4.95578962 low density lipoprotein-related protein 1(alpha-2- 162757 macroglobulin receptor) 203167_at 4.9520306 tissueinhibitor of metalloproteinase 2 6441 201193_at 4.94983228 isocitratedehydrogenase 1 (NADP+), soluble 11223 208018_s_at 4.94368736hemopoietic cell kinase 89555 216202_s_at 4.91295079 serinepalmitoyltransferase, long chain base subunit 2 59403 212820_at4.91065301 rabconnectin-3 200828 218092_s_at 4.91053386 HIV-1 Revbinding protein 352962 207654_x_at 4.89959607 down-regulator oftranscription 1, TBP-binding 348418 (negative cofactor 2) 203746_s_at4.89297035 holocytochrome c synthase (cytochrome c heme- 211571 lyase)207704_s_at 4.89274931 growth arrest-specific 7 226133 222218_s_at4.89264688 paired immunoglobin-like type 2 receptor alpha 122591207980_s_at 4.88126247 Cbp/p300-interacting transactivator, withGlu/Asp- 82071 rich carboxy-terminal domain, 2 202917_s_at 4.87438447S100 calcium binding protein A8 (calgranulin A) 416073 207791_s_at4.86793585 RAB1A, member RAS oncogene family 227327 222148_s_at4.85805606 ras homolog gene family, member T1 14202 207275_s_at4.85293013 fatty-acid-Coenzyme A ligase, long-chain 2 511920 202803_s_at4.84922223 integrin, beta 2 (antigen CD18 (p95), lymphocyte 375957function-associated antigen 1; macrophage antigen 1 (mac-1) betasubunit) 211100_x_at 4.84737438 leukocyte immunoglobulin-like receptor,subfamily 149924 B (with TM and ITIM domains), member 1 208817_at4.84504478 catechol-O-methyltransferase 240013 203767_s_at 4.83050164steroid sulfatase (microsomal), arylsulfatase C, 79876 isozyme S212606_at 4.82536301 WD repeat and FYVE domain containing 3 105340205174_s_at 4.82195934 glutaminyl-peptide cyclotransferase (glutaminyl79033 cyclase) 204714_s_at 4.81879712 coagulation factor V(proaccelerin, labile factor) 30054 221060_s_at 4.81814747 toll-likereceptor 4 174312 211999_at 4.81797645 H3 histone, family 3B (H3.3B)180877 211102_s_at 4.81093803 leukocyte immunoglobulin-like receptor,subfamily 149924 B (with TM and ITIM domains), member 1 216243_s_at4.80291726 interleukin 1 receptor antagonist 81134 203126_at 4.79908699inositol(myo)-1(or 4)-monophosphatase 2 5753 210785_s_at 4.79694283chromosome 1 open reading frame 38 10649 204232_at 4.78915713 Fcfragment of IgE, high affinity I, receptor for; 433300 gamma polypeptide200648_s_at 4.78637919 glutamate-ammonia ligase (glutamine synthase)442669 218627_at 4.77005668 hypothetical protein FLJ11259 416393209555_s_at 4.76938604 CD36 antigen (collagen type I receptor, 443120thrombospondin receptor) 206034_at 4.76674446 serine (or cysteine)proteinase inhibitor, clade B 368077 (ovalbumin), member 8 221581_s_at4.75435645 Williams-Beuren syndrome chromosome region 5 56607 203799_at4.73734337 type I transmembrane C-type lectin receptor DCL-1 2441203041_s_at 4.73458725 lysosomal-associated membrane protein 2 232432209004_s_at 4.73446496 F-box and leucine-rich repeat protein 5 5548217995_at 4.72584361 sulfide quinone reductase-like (yeast) 435468220326_s_at 4.72372372 hypothetical protein FLJ10357 22451 207104_x_at4.72227406 leukocyte immunoglobulin-like receptor, subfamily 149924 B(with TM and ITIM domains), member 1 217889_s_at 4.71506397 cytochrome breductase 1 31297 215001_s_at 4.71118486 glutamate-ammonia ligase(glutamine synthase) 442669 207761_s_at 4.71005806 DKFZP586A0522 protein288771 205726_at 4.70850268 diaphanous homolog 2 (Drosophila) 226483208704_x_at 4.70631847 amyloid beta (A4) precursor-like protein 2 279518206674_at 4.70459455 fms-related tyrosine kinase 3 385 219582_at4.70387413 hypothetical protein FLJ21079 16512 207872_s_at 4.70179932leukocyte immunoglobulin-like receptor, subfamily 149924 B (with TM andITIM domains), member 1 200782_at 4.69959007 annexin A5 145741201301_s_at 4.6939926 annexin A4 422986 202895_s_at 4.68690449 proteintyrosine phosphatase, non-receptor type 156114 substrate 1 209835_x_at4.67551042 CD44 antigen (homing function and Indian blood 306278 groupsystem) 201887_at 4.67403802 interleukin 13 receptor, alpha 1 285115205329_s_at 4.67285443 sorting nexin 4 267812 205863_at 4.64921037 S100calcium binding protein A12 (calgranulin C) 19413 202902_s_at 4.64873073cathepsin S 181301 205640_at 4.64661387 aldehyde dehydrogenase 3 family,member B1 274235 204900_x_at 4.64331607 sin3-associated polypeptide, 30kDa 512813 208908_s_at 4.63754102 calpastatin 440961 217868_s_at4.63345426 DORA reverse strand protein 1 279583 203360_s_at 4.62883239c-myc binding protein 78221 207677_s_at 4.62647264 neutrophil cytosolicfactor 4, 40 kDa 196352 206111_at 4.60837517 ribonuclease, RNase Afamily, 2 (liver, eosinophil- 728 derived neurotoxin) 210153_s_at4.59360403 malic enzyme 2, NAD(+)-dependent, mitochondrial 75342222231_s_at 4.58618625 hypothetical protein PRO1855 370927 201537_s_at4.57925877 dual specificity phosphatase 3 (vaccinia virus 181046phosphatase VH1-related) 202201_at 4.57781605 biliverdin reductase B(flavin reductase (NADPH)) 76289 203591_s_at 4.5770407 colonystimulating factor 3 receptor (granulocyte) 381027 214366_s_at 4.5700119arachidonate 5-lipoxygenase 89499 217977_at 4.56856597 selenoprotein X,1 279623 212527_at 4.55396497 DNA segment, Chr 15, Wayne StateUniversity 75, 511996 expressed 211286_x_at 4.54820757 colonystimulating factor 2 receptor, alpha, low- 520937 affinity(granulocyte-macrophage) 222303_at 4.54612275 v-ets erythroblastosisvirus E26 oncogene homolog 292477 2 (avian) 216652_s_at 4.54389883down-regulator of transcription 1, TBP-binding 348418 (negative cofactor2) 210660_at 4.53820668 leukocyte immunoglobulin-like receptor,subfamily 149924 B (with TM and ITIM domains), member 1 202867_s_at4.53800788 DnaJ (Hsp40) homolog, subfamily B, member 12 7960 218559_s_at4.53299564 v-maf musculoaponeurotic fibrosarcoma oncogene 169487 homologB (avian) 216950_s_at 4.53084661 Fc fragment of IgG, high affinity Ia,receptor for 77424 (CD64) 213503_x_at 4.52978946 annexin A2 462864214084_x_at 4.52713467 Homo sapiens similar to neutrophil cytosolicfactor 397369 1 (47 kD, chronic granulomatous disease, autosomal 1)(LOC220830), mRNA 201298_s_at 4.52689504 chromosome 2 open reading frame6 196437 201940_at 4.52465759 carboxypeptidase D 5057 220266_s_at4.51798181 Kruppel-like factor 4 (gut) 376206 58780_s_at 4.51518692hypothetical protein FLJ10357 22451 211791_s_at 4.51444942 potassiumvoltage-gated channel, shaker-related 440497 subfamily, beta member 231826_at 4.51322023 KIAA0674 protein 522351 206643_at 4.51089381histidine ammonia-lyase 190783 204227_s_at 4.50226383 thymidine kinase2, mitochondrial 274701 201590_x_at 4.50092732 annexin A2 462864207674_at 4.49675798 Fc fragment of IgA, receptor for 193122 210569_s_at4.49584084 sialic acid binding Ig-like lectin 9 245828 200889_s_at4.49074615 signal sequence receptor, alpha (translocon- 250773associated protein alpha) 207697_x_at 4.48374293 leukocyteimmunoglobulin-like receptor, subfamily 306230 B (with TM and ITIMdomains), member 2 212117_at 4.47875698 ras homolog gene family, memberQ 442989 213385_at 4.47853745 chimerin (chimaerin) 2 407520 212112_s_at4.46538788 syntaxin 12 433838 201943_s_at 4.46470107 carboxypeptidase D5057 210235_s_at 4.45960765 protein tyrosine phosphatase, receptor type,f 128312 polypeptide (PTPRF), interacting protein (liprin), alpha 1211336_x_at 4.4529126 leukocyte immunoglobulin-like receptor, subfamily149924 B (with TM and ITIM domains), member 1 211509_s_at 4.45275311reticulon 4 436349 202349_at 4.44313773 dystonia 1, torsion (autosomaldominant; torsin A) 19261 212625_at 4.4411393 syntaxin 10 43812211101_x_at 4.44083795 leukocyte immunoglobulin-like receptor, subfamily149924 B (with TM and ITIM domains), member 1 217764_s_at 4.43853195RAB31, member RAS oncogene family 223025 212602_at 4.43444968 WD repeatand FYVE domain containing 3 105340 220088_at 4.42977252 complementcomponent 5 receptor 1 (C5a ligand) 2161 204445_s_at 4.42874496arachidonate 5-lipoxygenase 89499 202593_s_at 4.4273484 membraneinteracting protein of RGS16 512607 201235_s_at 4.42419251 BTG family,member 2 75462 217473_x_at 4.42406639 — — 212271_at 4.42248213mitogen-activated protein kinase 1 324473 204861_s_at 4.42112414baculoviral IAP repeat-containing 1 79019 204502_at 4.41495415 SAMdomain and HD domain 1 371264 212663_at 4.41324534 KIAA0674 protein522351 202295_s_at 4.40282943 cathepsin H 114931 207571_x_at 4.40054035chromosome 1 open reading frame 38 10649 219974_x_at 4.39530706uncharacterized hypothalamus protein HCDASE 437091 201444_s_at4.38865234 ATPase, H+ transporting, lysosomal accessory 183434 protein 2204043_at 4.38432768 transcobalamin II; macrocytic anemia 417948201963_at 4.37921369 fatty-acid-Coenzyme A ligase, long-chain 2 511920205071_x_at 4.37300052 X-ray repair complementing defective repair in150930 Chinese hamster cells 4 205173_x_at 4.36642735 CD58 antigen,(lymphocyte function-associated 75626 antigen 3) 200615_s_at 4.36556565adaptor-related protein complex 2, beta 1 subunit 370123 211419_s_at4.36300495 chimerin (chimaerin) 2 407520 205789_at 4.36189551 CD1Dantigen, d polypeptide 1799 212124_at 4.35711838 retinoic acid induced17 438767 202436_s_at 4.35300568 cytochrome P450, family 1, subfamily B,154654 polypeptide 1 203971_at 4.34868301 solute carrier family 31(copper transporters), 414471 member 1 219892_at 4.34634755transmembrane 6 superfamily member 1 151155 208594_x_at 4.34443555leukocyte immunoglobulin-like receptor, subfamily 511766 B (with TM andITIM domains), member 3 202877_s_at 4.33642974 complement component 1, qsubcomponent, 97199 receptor 1 214501_s_at 4.33619357 H2A histonefamily, member Y 75258 201425_at 4.33199642 aldehyde dehydrogenase 2family (mitochondrial) 331141 203066_at 4.32776894 B cell RAG associatedprotein 523379 202484_s_at 4.32503279 methyl-CpG binding domain protein2 25674 211296_x_at 4.31941158 ubiquitin C 183704 213590_at 4.31821109solute carrier family 16 (monocarboxylic acid 90911 transporters),member 5 215990_s_at 4.31739177 B-cell CLL/lymphoma 6 (zinc fingerprotein 51) 155024 208653_s_at 4.30983843 CD164 antigen, sialomucin43910 208734_x_at 4.30135956 RAB2, member RAS oncogene family 78305209005_at 4.29969708 F-box and leucine-rich repeat protein 5 5548218739_at 4.29917434 abhydrolase domain containing 5 19385 208248_x_at4.29909709 amyloid beta (A4) precursor-like protein 2 279518 208934_s_at4.29599303 lectin, galactoside-binding, soluble, 8 (galectin 8) 4082202820_at 4.28937583 aryl hydrocarbon receptor 170087 210154_at4.28524889 malic enzyme 2, NAD(+)-dependent, mitochondrial 75342201311_s_at 4.28104152 SH3 domain binding glutamic acid-rich proteinlike 14368 210732_s_at 4.27689192 lectin, galactoside-binding, soluble,8 (galectin 8) 4082 200942_s_at 4.27633661 heat shock factor bindingprotein 1 250899 201538_s_at 4.27183553 dual specificity phosphatase 3(vaccinia virus 181046 phosphatase VH1-related) 201179_s_at 4.27082196guanine nucleotide binding protein (G protein), 73799 alpha inhibitingactivity polypeptide 3 205418_at 4.2619161 feline sarcoma oncogene 7636209297_at 4.25619908 intersectin 1 (SH3 domain protein) 66392 206934_at4.25371303 signal-regulatory protein beta 1 194784 219889_at 4.24708622frequently rearranged in advanced T-cell 126057 lymphomas 212657_s_at4.24239023 interleukin 1 receptor antagonist 81134 209305_s_at4.24071078 growth arrest and DNA-damage-inducible, beta 110571201720_s_at 4.23720249 Lysosomal-associated multispanning membrane436200 protein-5 202100_at 4.23631606 v-ral simian leukemia viraloncogene homolog B 348024 (ras related; GTP binding protein) 210422_x_at4.23603224 solute carrier family 11 (proton-coupled divalent 135163metal ion transporters), member 1 203574_at 4.2315199 nuclear factor,interleukin 3 regulated 79334 209616_s_at 4.22891755 carboxylesterase 1(monocyte/macrophage serine 278997 esterase 1) 203185_at 4.2285949 Rasassociation (RalGDS/AF-6) domain family 2 80905 212681_at 4.22845394erythrocyte membrane protein band 4.1-like 3 103839 221675_s_at4.22714814 choline phosphotransferase 1 225567 209499_x_at 4.22636014tumor necrosis factor (ligand) superfamily, member 54673 13 204959_at4.22614064 myeloid cell nuclear differentiation antigen 153837204277_s_at 4.22513355 thymidine kinase 2, mitochondrial 274701204393_s_at 4.22305118 acid phosphatase, prostate 388677 216899_s_at4.22228511 src family associated phosphoprotein 2 410745 205627_at4.21755984 cytidine deaminase 72924 220001_at 4.21439779 peptidylarginine deiminase, type IV 397050 211864_s_at 4.21257919 fer-1-like 3,myoferlin (C. elegans) 362731 213241_at 4.21206935 plexin C1 286229215708_s_at 4.21183314 Homo sapiens transcribed sequence with strong356530 similarity to protein sp: P49643 (H. sapiens) PRI2_HUMAN DNAprimase large subunit (DNA primase 58 kDa subunit) (P58) 205568_at4.2078814 aquaporin 9 104624 201900_s_at 4.20012284 aldo-keto reductasefamily 1, member A1 (aldehyde 372170 reductase) 216015_s_at 4.19778183cold autoinflammatory syndrome 1 159483 204908_s_at 4.19238275 B-cellCLL/lymphoma 3 31210 206420_at 4.19184626 immunoglobulin superfamily,member 6 135194 206359_at 4.18559959 suppressor of cytokine signaling 3436943 216905_s_at 4.18538303 suppression of tumorigenicity 14 (coloncarcinoma, 56937 matriptase, epithin) 218439_s_at 4.18516434 PTD002protein 151458 211816_x_at 4.18499309 Fc fragment of IgA, receptor for193122 204336_s_at 4.18093971 regulator of G-protein signalling 19422336 201647_s_at 4.17905107 scavenger receptor class B, member 2323567 219872_at 4.17884427 hypothetical protein DKFZp434L142 323583211527_x_at 4.17650619 vascular endothelial growth factor 73793211749_s_at 4.17531793 vesicle-associated membrane protein 3(cellubrevin) 66708 219666_at 4.17515543 membrane-spanning 4-domains,subfamily A, 371612 member 6A 221858_at 4.17028941 KIAA0608 protein100960 208351_s_at 4.16464496 mitogen-activated protein kinase 1 324473218035_s_at 4.1625156 RNA-binding protein 95549 209276_s_at 4.16115658glutaredoxin (thioltransferase) 28988 202497_x_at 4.16041756 solutecarrier family 2 (facilitated glucose 419240 transporter), member 3213988_s_at 4.15957906 spermidine/spermine N1-acetyltransferase 28491202381_at 4.14084013 a disintegrin and metalloproteinase domain 9 2442(meltrin gamma) 205936_s_at 4.13559524 hexokinase 3 (white cell) 411695209287_s_at 4.13557674 CDC42 effector protein (Rho GTPase binding) 3352554 221194_s_at 4.13485757 PTD016 protein 30154 210648_x_at4.13480197 sorting nexin 3 12102 205237_at 4.1324867 ficolin(collagen/fibrinogen domain containing) 1 440898 204899_s_at 4.12933139sin3-associated polypeptide, 30 kDa 512813 207085_x_at 4.12207721 colonystimulating factor 2 receptor, alpha, low- 520937 affinity(granulocyte-macrophage) 207266_x_at 4.12058364 RNA binding motif,single stranded interacting 241567 protein 1 221492_s_at 4.12038439autophagy Apg3p/Aut1p-like 26367 207387_s_at 4.11738071 glycerol kinase1466 204122_at 4.11663505 TYRO protein tyrosine kinase binding protein9963 207671_s_at 4.11610597 vitelliform macular dystrophy (Best disease,167344 bestrophin) 207857_at 4.10927392 leukocyte immunoglobulin-likereceptor, subfamily 149924 B (with TM and ITIM domains), member 1201850_at 4.10860435 capping protein (actin filament), gelsolin-like82422 202934_at 4.10351746 hexokinase 2 406266 206335_at 4.10242677galactosamine (N-acetyl)-6-sulfate sulfatase 159479 (Morquio syndrome,mucopolysaccharidosis type IVA) 221078_s_at 4.09863405 hypotheticalprotein FLJ10392 292925 201337_s_at 4.09676745 vesicle-associatedmembrane protein 3 (cellubrevin) 66708 203005_at 4.0932063 lymphotoxinbeta receptor (TNFR superfamily, 1116 member 3) 203676_at 4.09251365glucosamine (N-acetyl)-6-sulfatase (Sanfilippo 334534 disease IIID)205401_at 4.09190279 alkylglycerone phosphate synthase 407933 218865_at4.08907346 hypothetical protein FLJ22390 195345 201473_at 4.08893087 junB proto-oncogene 400124 220000_at 4.08612321 sialic acid binding Ig-likelectin 5 117005 208983_s_at 4.0855044 platelet/endothelial cell adhesionmolecule (CD31 78146 antigen) 218424_s_at 4.08296857 dudulin 2 57655201186_at 4.08234245 low density lipoprotein receptor-related protein75140 associated protein 1 210959_s_at 4.08090496steroid-5-alpha-reductase, alpha polypeptide 1 (3- 552 oxo-5alpha-steroid delta 4-dehydrogenase alpha 1) 213160_at 4.07719887dedicator of cyto-kinesis 2 17211 201463_s_at 4.07608806 transaldolase 1438678 200078_s_at 4.07300443 ATPase, H+ transporting, lysosomal 21 kDa,V0 7476 subunit c″ 201506_at 4.07150831 transforming growth factor,beta-induced, 68 kDa 421496 217826_s_at 4.07137819 ubiquitin-conjugatingenzyme E2, J1 (UBC6 184325 homolog, yeast) 38487_at 4.06946114 stabilin1 301989 217827_s_at 4.06896229 acid cluster protein 33 242458 201642_at4.06630731 interferon gamma receptor 2 (interferon gamma 409200transducer 1) 211997_x_at 4.06180968 H3 histone, family 3B (H3.3B)180877 211540_s_at 4.06076677 retinoblastoma 1 (including osteosarcoma)408528 221036_s_at 4.05925589 anterior pharynx defective 1B-like 42954208097_s_at 4.049855 thioredoxin domain containing 125221 201828_x_at4.04673957 CAAX box 1 250708 217853_at 4.04364724 tensin-like SH2domain-containing 1 12210 207270_x_at 4.04254236 CMRF35 leukocyteimmunoglobulin-like receptor 2605 217159_x_at 4.04053417 sialic acidbinding Ig-like lectin 7 274470 209901_x_at 4.03786304 allograftinflammatory factor 1 76364 216236_s_at 4.03358432 solute carrier family2 (facilitated glucose 401274 transporter), member 14 204961_s_at4.03301863 neutrophil cytosolic factor 1 (47 kDa, chronic 458275granulomatous disease, autosomal 1) 202101_s_at 4.03192448 v-ral simianleukemia viral oncogene homolog B 348024 (ras related; GTP bindingprotein) 208189_s_at 4.03164659 myosin VIIA (Usher syndrome 1B(autosomal 370421 recessive, severe)) 201554_x_at 4.03078928 glycogenin174071 219505_at 4.03062109 cat eye syndrome chromosome region,candidate 1 170310 202445_s_at 4.02993448 Notch homolog 2 (Drosophila)8121 208071_s_at 4.02784691 leukocyte-associated Ig-like receptor 1407964 220832_at 4.02284364 toll-like receptor 8 272410 212419_at4.02284151 hypothetical protein FLJ90798 28264 203857_s_at 4.02278318for protein disulfide isomerase-related 76901 202122_s_at 4.02240203cargo selection protein (mannose 6 phosphate 140452 receptor bindingprotein) 208936_x_at 4.02052401 lectin, galactoside-binding, soluble, 8(galectin 8) 4082 219806_s_at 4.01642219 FN5 protein 416456 205922_at4.01615381 vanin 2 293130 209311_at 4.01610957 BCL2-like 2 410026210340_s_at 4.01506832 colony stimulating factor 2 receptor, alpha, low-520937 affinity (granulocyte-macrophage) 216346_at 4.01350716 SEC14-like3 (S. cerevisiae) 434140 202944_at 4.00826135 N-acetylgalactosaminidase,alpha- 75372 206877_at 4.00750632 MAX dimerization protein 1 379930209473_at 4.00302974 ectonucleoside triphosphate diphosphohydrolase 1444105 208785_s_at 3.99946577 Homo sapiens transcribed sequence withstrong 419777 similarity to protein ref: NP_073729.1 (H. sapiens)microtubule-associated proteins 1A/1B light chain 3 [Homo sapiens]202108_at 3.99887308 peptidase D 444207 201926_s_at 3.99380381 decayaccelerating factor for complement (CD55, 408864 Cromer blood groupsystem) 201413_at 3.990689 hydroxysteroid (17-beta) dehydrogenase 4356894 210190_at 3.99016278 syntaxin 11 118958 215842_s_at 3.98910601ATPase, Class VI, type 11A 29189 204361_s_at 3.98317434 src familyassociated phosphoprotein 2 410745 202826_at 3.97921395 serine proteaseinhibitor, Kunitz type 1 233950 200798_x_at 3.97812485 myeloid cellleukemia sequence 1 (BCL2-related) 86386 203471_s_at 3.97445343pleckstrin 77436 213532_at 3.97420929 hypothetical protein LOC285148509314 206710_s_at 3.97151204 erythrocyte membrane protein band 4.1-like3 103839 221879_at 3.97046064 ceroid-lipofuscinosis, neuronal 6, lateinfantile, 43654 variant 204446_s_at 3.97025459 arachidonate5-lipoxygenase 89499 200677_at 3.96789671 pituitary tumor-transforming 1interacting protein 369026 201118_at 3.96505944 phosphogluconatedehydrogenase 392837 205868_s_at 3.96375543 protein tyrosinephosphatase, non-receptor type 11 83572 (Noonan syndrome 1) 212252_at3.96319972 calcium/calmodulin-dependent protein kinase 297343 kinase 2,beta 203887_s_at 3.96298525 thrombomodulin 2030 202192_s_at 3.96240466growth arrest-specific 7 226133 201096_s_at 3.95648407 ADP-ribosylationfactor 4 435639 219911_s_at 3.94841313 solute carrier family 21 (organicanion transporter), 235782 member 12 200796_s_at 3.94807209 myeloid cellleukemia sequence 1 (BCL2-related) 86386 219890_at 3.94731168 C-type(calcium dependent, carbohydrate- 126355 recognition domain) lectin,superfamily member 5 208724_s_at 3.94528806 RAB1A, member RAS oncogenefamily 227327 212374_at 3.94463692 fem-1 homolog b (C. elegans) 362733219104_at 3.94384785 ring finger protein 141 44685 203748_x_at3.94217815 RNA binding motif, single stranded interacting 241567 protein1 210773_s_at 3.94043935 formyl peptide receptor-like 1 99855219607_s_at 3.93984379 membrane-spanning 4-domains, subfamily A, 325960member 4 206348_s_at 3.9380531 pyruvate dehydrogenase kinase, isoenzyme3 193124 215856_at 3.93781449 hypothetical protein LOC284266 287692200737_at 3.93283779 phosphoglycerate kinase 1 78771 218831_s_at3.93205147 Fc fragment of IgG, receptor, transporter, alpha 111903202437_s_at 3.92627151 cytochrome P450, family 1, subfamily B, 154654polypeptide 1 201942_s_at 3.92566977 carboxypeptidase D 5057 219859_at3.92247489 C-type (calcium dependent, carbohydrate- 236516 recognitiondomain) lectin, superfamily member 9 212054_x_at 3.91644887 KIAA0676protein 155829 208540_x_at 3.91561327 — 506947 213119_at 3.91488544solute carrier family 36 (proton/amino acid 409314 symporter), member 1205119_s_at 3.91440214 formyl peptide receptor 1 753 201576_s_at3.91382693 galactosidase, beta 1 445183 212014_x_at 3.9085234 CD44antigen (homing function and Indian blood 306278 group system)210156_s_at 3.90785487 protein-L-isoaspartate (D-aspartate) O- 79137methyltransferase 205540_s_at 3.90407281 Ras-related GTP binding B 50282212598_at 3.90198488 WD repeat and FYVE domain containing 3 105340221724_s_at 3.89891636 C-type (calcium dependent, carbohydrate- 115515recognition domain) lectin, superfamily member 6 208952_s_at 3.89761036KIAA0217 protein 192881 200738_s_at 3.89752042 phosphoglycerate kinase 178771 206380_s_at 3.89281079 properdin P factor, complement 53155211287_x_at 3.89139509 colony stimulating factor 2 receptor, alpha, low-520937 affinity (granulocyte-macrophage) 210953_at 3.89109344 KIAA0669gene product 52526 201798_s_at 3.88996697 fer-1-like 3, myoferlin (C.elegans) 362731 208885_at 3.88981825 lymphocyte cytosolic protein 1(L-plastin) 381099 202671_s_at 3.88812247 pyridoxal (pyridoxine, vitaminB6) kinase 284491 202433_at 3.88667317 solute carrier family 35, memberB1 154073 220775_s_at 3.88608806 ubiquitin-conjugating enzyme E2-like407991 202030_at 3.88474448 branched chain alpha-ketoacid dehydrogenase20644 kinase 205639_at 3.88308443 acyloxyacyl hydrolase (neutrophil)82542 202096_s_at 3.88275079 benzodiazapine receptor (peripheral) 202202241_at 3.87918071 phosphoprotein regulated by mitogenic pathways444947 200958_s_at 3.8722837 syndecan binding protein (syntenin) 164067211689_s_at 3.87053754 transmembrane protease, serine 2 439309207157_s_at 3.86989748 guanine nucleotide binding protein (G protein),436765 gamma 5 210186_s_at 3.86911308 FK506 binding protein 1A, 12 kDa374638 200987_x_at 3.86682174 proteasome (prosome, macropain) activatorsubunit 152978 3 (PA28 gamma; Ki) 208853_s_at 3.8665582 calnexin 155560212026_s_at 3.86220136 likely ortholog of mouse exocyst componentprotein 511946 70 kDa homolog (S. cerevisiae) Exo70: exocyst componentprotein 70 kDa homolog (S. cerevisiae) 201898_s_at 3.861804ubiquitin-conjugating enzyme E2A (RAD6 379466 homolog) 209615_s_at3.85852692 p21/Cdc42/Rac1-activated kinase 1 (STE20 64056 homolog,yeast) 208488_s_at 3.85497758 complement component (3b/4b) receptor 1,334019 including Knops blood group system 203853_s_at 3.85414745GRB2-associated binding protein 2 30687 209131_s_at 3.85261742synaptosomal-associated protein, 23 kDa 202308 204150_at 3.85178342stabilin 1 301989 212188_at 3.85075667 hypothetical protein BC013764109438 211087_x_at 3.85069595 mitogen-activated protein kinase 14 79107205920_at 3.8477849 solute carrier family 6 (neurotransmittertransporter, 1194 taurine), member 6 219079_at 3.84686335 NADPHcytochrome B5 oxidoreductase 5741 201619_at 3.84148866 peroxiredoxin 3397062 214438_at 3.84078431 H2.0-like homeo box 1 (Drosophila) 74870211507_s_at 3.83656731 myotubularin related protein 3 412833 217835_x_at3.83446552 chromosome 20 open reading frame 24 184062 217825_s_at3.82162344 ubiquitin-conjugating enzyme E2, J1 (UBC6 184325 homolog,yeast) 205681_at 3.81769723 BCL2-related protein A1 227817 200827_at3.81766405 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 75093(lysine hydroxylase, Ehlers-Danlos syndrome type VI) 211797_s_at3.8151505 nuclear transcription factor Y, gamma 285133 204194_at3.81135547 BTB and CNC homology 1, basic leucine zipper 154276transcription factor 1 201078_at 3.81097664 transmembrane 9 superfamilymember 2 298272 206343_s_at 3.81055509 neuregulin 1 172816 218091_at3.80590961 HIV-1 Rev binding protein 352962 205468_s_at 3.80336547interferon regulatory factor 5 334450 200929_at 3.79657368 transmembranetrafficking protein 74137 206881_s_at 3.79242916 leukocyteimmunoglobulin-like receptor, subfamily 113277 A (without TM domain),member 3 209404_s_at 3.79062874 CGI-109 protein 278391 207549_x_at3.79036164 membrane cofactor protein (CD46, trophoblast- 83532lymphocyte cross-reactive antigen) 219646_at 3.78787522 hypotheticalprotein FLJ20186 62771 219991_at 3.78398642 solute carrier family 2(facilitated glucose 95497 transporter), member 9 211922_s_at 3.78374234catalase 395771 210275_s_at 3.78115446 zinc finger protein 216 406096216883_x_at 3.77914282 phosphodiesterase 6D, cGMP-specific, rod, delta48291 202833_s_at 3.77713205 serine (or cysteine) proteinase inhibitor,clade A 297681 (alpha-1 antiproteinase, antitrypsin), member 1 217124_at3.77620277 KIAA1023 protein 446063 209062_x_at 3.77508965 nuclearreceptor coactivator 3 382168 208310_s_at 3.77468002 follistatin-like 1433622 212041_at 3.77461664 ATPase, H+ transporting, lysosomal 38 kDa,V0 106876 subunit d isoform 1 214500_at 3.77290459 H2A histone family,member Y 75258 217746_s_at 3.77075614 programmed cell death 6interacting protein 9663 218754_at −3.7702453 hypothetical proteinFLJ23323 59425 214749_s_at −3.7716173 hypothetical protein FLJ2081183530 203094_at −3.7722118 MAD2L1 binding protein 122346 221230_s_at−3.7758096 retinoblastoma binding protein 1-like 1 17428 212912_at−3.7760375 ribosomal protein S6 kinase, 90 kDa, polypeptide 2 301664205004_at −3.7765763 NF-kappa B-repressing factor 437084 205775_at−3.7769304 DNA segment on chromosome 6(unique) 2654 140944 expressedsequence 219007_at −3.7819237 nucleoporin 43 kDa 53263 206082_at−3.7826255 HLA complex P5 511759 214022_s_at −3.7838188 interferoninduced transmembrane protein 1 (9-27) 458414 210243_s_at −3.7882423UDP-Gal: betaGlcNAc beta 1,4- 321231 galactosyltransferase, polypeptide3 204228_at −3.7929943 peptidyl prolyl isomerase H (cyclophilin H) 9880204411_at −3.793944 KIAA0449 protein 511940 213388_at −3.7946632 Homosapiens mRNA; cDNA DKFZp586I1823 448231 (from clone DKFZp586I1823)205963_s_at −3.7953901 DnaJ (Hsp40) homolog, subfamily A, member 3 6216221535_at −3.8112387 hypothetical protein FLJ11301 436471 209302_at−3.811649 polymerase (RNA) II (DNA directed) polypeptide H 432574221867_at −3.8131693 hypothetical protein FLJ31821 511839 213028_at−3.8138531 Homo sapiens cDNA FLJ44314 fis, clone 419777 TRACH2025932209870_s_at −3.8147819 amyloid beta (A4) precursor protein-binding,family 26468 A, member 2 (X11-like) 210847_x_at −3.8164631 tumornecrosis factor receptor superfamily, member 299558 25 218955_at−3.8194881 BRF2, subunit of RNA polymerase III transcription 274136initiation factor, BRF1-like 64418_at −3.8220874 AP1 gamma subunitbinding protein 1 404215 36888_at −3.8320679 KIAA0841 protein 7426219971_at −3.8331453 interleukin 21 receptor 210546 221963_x_at−3.836647 Homo sapiens transcribed sequence with strong — similarity toprotein pir: TSHUP1 (H. sapiens) TSHUP1 thrombospondin 1 precursor -human 200045_at −3.8367612 ATP-binding cassette, sub-family F (GCN20),9573 member 1 221135_s_at −3.8379739 HT001 protein 254124 221940_at−3.8380758 C18B11 homolog (44.9 kD) 173311 203386_at −3.8411936 TBC1domain family, member 4 173802 212660_at −3.8431641 PHD finger protein15 397990 206240_s_at −3.8440853 zinc finger protein 136 (clone pHZ-20)479874 204461_x_at −3.8452 RAD1 homolog (S. pombe) 7179 49329_at−3.8471735 hypothetical protein FLJ14360 351563 201763_s_at −3.8485837death-associated protein 6 336916 218601_at −3.8507869 up-regulated gene4 5131 216309_x_at −3.8522271 jerky homolog (mouse) 142296 213742_at−3.8525732 splicing factor, arginine/serine-rich 11 443458 205255_x_at−3.8532902 transcription factor 7 (T-cell specific, HMG-box) 169294219123_at −3.8535773 zinc finger protein 232 279914 39248_at −3.8602222aquaporin 3 234642 214351_x_at −3.8603602 ribosomal protein L13 410817213360_s_at −3.8667261 similar to Nuclear envelope pore membrane protein450237 POM 121 (Pore membrane protein of 121 kDa) (P145) 210031_at−3.8668203 CD3Z antigen, zeta polypeptide (TiT3 complex) 97087 204484_at−3.8676808 phosphoinositide-3-kinase, class 2, beta polypeptide 343329217798_at −3.8703856 CCR4-NOT transcription complex, subunit 2 165725200957_s_at −3.8715464 structure specific recognition protein 1 79162206188_at −3.8905582 KIAA0628 gene product 43133 221518_s_at −3.8970401ubiquitin specific protease 47 441028 221978_at −3.8977136 majorhistocompatibility complex, class I, F 411958 218500_at −3.9056647mesenchymal stem cell protein DSCD75 25237 219765_at −3.9104452hypothetical protein FLJ12586 458377 207339_s_at −3.9120005 lymphotoxinbeta (TNF superfamily, member 3) 376208 218496_at −3.9220606ribonuclease H1 511960 204891_s_at −3.9250376 lymphocyte-specificprotein tyrosine kinase 1765 203611_at −3.9251415 telomeric repeatbinding factor 2 63335 213689_x_at −3.9253484 ribosomal protein L5469653 38398_at −3.9258197 MAP-kinase activating death domain 8254846256_at −3.9261723 SPRY domain-containing SOCS box protein SSB-3 7247214692_s_at −3.9264268 jerky homolog (mouse) 142296 40446_at −3.9318725PHD finger protein 1 166204 217802_s_at −3.9322297 nuclear ubiquitouscasein kinase and cyclin- 510265 dependent kinase substrate 218573_at−3.9379843 APR-1 protein 279819 221277_s_at −3.9418985 hypotheticalprotein FKSG32 98682 204182_s_at −3.9459862 zinc finger protein 297B355581 212653_s_at −3.94854 KIAA0903 protein 16218 201717_at −3.9504943mitochondrial ribosomal protein L49 75859 218700_s_at −3.9516027 RAB7,member RAS oncogene family-like 1 115325 217950_at −3.9535594 nitricoxide synthase interacting protein 7236 208758_at −3.95486315-aminoimidazole-4-carboxamide ribonucleotide 90280formyltransferase/IMP cyclohydrolase 202617_s_at −3.9570199 methyl CpGbinding protein 2 (Rett syndrome) 3239 212935_at −3.9602659 MCF.2 cellline derived transforming sequence-like 436905 222077_s_at −3.9734422Rac GTPase activating protein 1 23900 221087_s_at −3.9735482apolipoprotein L, 3 241535 202330_s_at −3.9749735 uracil-DNA glycosylase78853 206545_at −3.9833463 CD28 antigen (Tp44) 1987 218414_s_at−3.9863793 nudE nuclear distribution gene E homolog 1 (A. nidulans)263925 209440_at −3.9905647 phosphoribosyl pyrophosphate synthetase 1 56219966_x_at −3.9987967 BTG3 associated nuclear protein 448828215359_x_at −4.0024233 zinc finger protein 44 (KOX 7) 501604 215012_at−4.0067262 zinc finger protein 451 188662 205192_at −4.0075631mitogen-activated protein kinase kinase kinase 14 440315 206118_at−4.0108593 signal transducer and activator of transcription 4 80642213574_s_at −4.011904 karyopherin (importin) beta 1 439683 200644_at−4.015547 MARCKS-like protein 75061 218274_s_at −4.0156737 hypotheticalprotein FLJ10415 437647 212037_at −4.0191262 pinin, desmosome associatedprotein 409965 203723_at −4.0201929 inositol 1,4,5-trisphosphate3-kinase B 78877 202970_at −4.03346 dual-specificitytyrosine-(Y)-phosphorylation 173135 regulated kinase 2 219169_s_at−4.0376252 transcription factor B1, mitochondrial 279908 202562_s_at−4.0376994 chromosome 14 open reading frame 1 15106 213648_at −4.0401386KIAA0116 protein 254717 205442_at −4.0500447 KIAA0626 gene product178121 219658_at −4.0522935 hypothetical protein FLJ12598 126906217627_at −4.0526775 hypothetical protein FLJ30921 290703 202968_s_at−4.0534127 dual-specificity tyrosine-(Y)-phosphorylation 173135regulated kinase 2 204008_at −4.0615836 dynein, axonemal, lightpolypeptide 4 258203 203450_at −4.065337 chromosome 22 open readingframe 2 334911 219812_at −4.0673436 stromal antigen 3 323634 219109_at−4.0689872 PF20 6783 213473_at −4.0764661 ankyrin repeat domain 13122764 40016_g_at −4.0768183 KIAA0303 protein 212787 203556_at −4.079399transcription factor ZHX2 30209 209798_at −4.0837583 nuclear protein,ataxia-telangiectasia locus 89385 219635_at −4.0865204 hypotheticalprotein FLJ14260 287629 212589_at −4.0884147 related RAS viral (r-ras)oncogene homolog 2 206097 204327_s_at −4.0891305 zinc finger protein 202112556 216262_s_at −4.0902501 TGFB-induced factor 2 (TALE familyhomeobox) 94785 222348_at −4.0911661 KIAA0303 protein 212787 220035_at−4.101629 nucleoporin 210 292119 213039_at −4.1044199 Rho-specificguanine nucleotide exchange factor 6150 p114 208858_s_at −4.1054066likely ortholog of mouse membrane bound C2 8309 domain containingprotein 218805_at −4.1065589 immune associated nucleotide 4 like 1(mouse) 412331 209558_s_at −4.108666 huntingtin interactingprotein-1-related 96731 207394_at −4.1102265 zinc finger protein 137(clone pHZ-30) 373648 220418_at −4.1185695 ubiquitin associated and SH3domain containing, A 183924 219155_at −4.1208338 phosphatidylinositoltransfer protein, cytoplasmic 1 405933 222266_at −4.121441 chromosome 19open reading frame 2 7943 214739_at −4.1236762 hypothetical proteinMGC4126 334483 219006_at −4.1353669 chromosome 6 open reading frame 66512144 209657_s_at −4.14338 heat shock transcription factor 2 15819564064_at −4.1445869 immune associated nucleotide 4 like 1 (mouse) 412331205964_at −4.147438 zinc finger protein 426 324978 204635_at −4.1496187ribosomal protein S6 kinase, 90 kDa, polypeptide 5 109058 212320_at−4.151357 beta 5-tubulin 356729 208094_s_at −4.1580744 hypotheticalprotein MGC10471 24998 48117_at −4.1689003 hypothetical protein BC011981110407 218492_s_at −4.1719389 THAP domain containing 7 512756 219045_at−4.1781811 ras homolog gene family, member F (in filopodia) 512618217152_at −4.1800035 nuclear receptor co-repressor 1 144904 203159_at−4.1901598 glutaminase 128410 219700_at −4.1962225 plexin domaincontaining 1 125036 213958_at −4.2016236 CD6 antigen 436949 210763_x_at−4.2056306 natural cytotoxicity triggering receptor 3 509513 209586_s_at−4.2061369 TcD37 homolog 78524 202931_x_at −4.2107515 bridgingintegrator 1 193163 202741_at −4.2145218 protein kinase, cAMP-dependent,catalytic, beta 156324 218259_at −4.2150435 myocardin-relatedtranscription factor B 151076 202724_s_at −4.2194658 forkhead box O1A(rhabdomyosarcoma) 170133 217912_at −4.2238457 PP3111 protein 351484220969_s_at −4.2271761 — — 220367_s_at −4.2316067 mSin3A-associatedprotein 130 133523 219315_s_at −4.2333807 hypothetical protein FLJ2089825549 218510_x_at −4.237976 hypothetical protein FLJ20152 82273216983_s_at −4.2380619 zinc finger protein 224 279855 218735_s_at−4.2447866 zinc finger protein 438994 213179_at −4.2560283 RCD1 requiredfor cell differentiation1 homolog (S. pombe) 148767 204020_at −4.2566815purine-rich element binding protein A 29117 204630_s_at −4.2576483 golgiSNAP receptor complex member 1 124436 201853_s_at −4.2599718 celldivision cycle 25B 153752 214771_x_at −4.2674176 Rho interacting protein3 430725 213539_at −4.281273 CD3D antigen, delta polypeptide (TiT3complex) 95327 202693_s_at −4.2866716 serine/threonine kinase 17a(apoptosis-inducing) 9075 200953_s_at −4.2970373 cyclin D2 376071205590_at −4.3097591 RAS guanyl releasing protein 1 (calcium and DAG-189527 regulated) 213193_x_at −4.3143922 Homo sapiens T cell receptorbeta chain BV20S1 487862 BJ1-5 BC1 mRNA, complete cds 210915_x_at−4.342139 Homo sapiens T cell receptor beta chain BV20S1 349283 BJ1-5BC1 mRNA, complete cds 220176_at −4.3595778 chromosome 14 open readingframe 127 288981 38340_at −4.3617132 huntingtin interactingprotein-1-related 96731 209246_at −4.3621957 ATP-binding cassette,sub-family F (GCN20), 438823 member 2 204633_s_at −4.3717038 ribosomalprotein S6 kinase, 90 kDa, polypeptide 5 109058 202250_s_at −4.3738264H326 120904 210538_s_at −4.3739708 baculoviral IAP repeat-containing 3127799 219350_s_at −4.3780164 second mitochondria-derived activator ofcaspase 169611 209014_at −4.3855467 melanoma antigen, family D, 1 5258204642_at −4.4025727 endothelial differentiation, sphingolipidG-protein- 154210 coupled receptor, 1 207892_at −4.4032046 tumornecrosis factor (ligand) superfamily, member 652 5 (hyper-IgM syndrome)217957_at −4.4033051 likely ortholog of mouse gene trap locus 3 279818212333_at −4.4079871 DKFZP564F0522 protein 23060 202178_at −4.4303479protein kinase C, zeta 407181 210279_at −4.431287 G protein-coupledreceptor 18 88269 202726_at −4.4373616 ligase I, DNA, ATP-dependent 1770214298_x_at −4.4417332 septin 6 207426_s_at −4.4487533 tumor necrosisfactor (ligand) superfamily, member 181097 4 (tax-transcriptionallyactivated glycoprotein 1, 34 kDa) 212126_at −4.4504669 Homo sapiens,clone IMAGE: 5288883, mRNA 149466 206150_at −4.4509904 tumor necrosisfactor receptor superfamily, member 7 355307 209282_at −4.4662679protein kinase D2 205431 212313_at −4.4669031 hypothetical proteinMGC29816 5019 205379_at −4.4687636 carbonyl reductase 3 154510 217961_at−4.4688902 hypothetical protein FLJ20551 7994 219843_at −4.4747042intracisternal A particle-promoted polypeptide 157180 219826_at−4.4750415 hypothetical protein FLJ23233 98593 209682_at −4.4805853Cas-Br-M (murine) ecotropic retroviral 436986 transforming sequence b221790_s_at −4.4853949 LDL receptor adaptor protein 184482 203408_s_at−4.4896587 special AT-rich sequence binding protein 1 (binds 416026 tonuclear matrix/scaffold-associating DNA's) 210389_x_at −4.4925237 likelyortholog of mouse tubulin, delta 1 270847 221601_s_at −4.5045431regulator of Fas-induced apoptosis 58831 202478_at −4.5256195 tribbleshomolog 2 155418 214439_x_at −4.5286267 bridging integrator 1 19316336545_s_at −4.5486784 KIAA0542 gene product 62209 211596_s_at −4.571525leucine-rich repeats and immunoglobulin-like 166697 domains 1213587_s_at −4.5921811 chromosome 7 open reading frame 32 351612203717_at −4.6064222 dipeptidylpeptidase 4 (CD26, adenosine deaminase44926 complexing protein 2) 203648_at −4.6075718 KIAA0218 gene product75863 218723_s_at −4.6189582 RGC32 protein 76640 201528_at −4.6259618replication protein A1, 70 kDa 84318 202107_s_at −4.6331766 MCM2minichromosome maintenance deficient 2, 57101 mitotin (S. cerevisiae)32259_at −4.665109 enhancer of zeste homolog 1 (Drosophila) 194669221211_s_at −4.6673208 chromosome 21 open reading frame 7 41267201313_at −4.6724774 enolase 2, (gamma, neuronal) 511915 221234_s_at−4.6843954 BTB and CNC homology 1, basic leucine zipper 88414transcription factor 2 46665_at −4.6856302 sema domain, immunoglobulindomain (Ig), 7188 transmembrane domain (TM) and short cytoplasmicdomain, (semaphorin) 4C 219590_x_at −4.6895774 CGI-30 protein 406051203965_at −4.6942774 ubiquitin specific protease 20 5452 205042_at−4.7104355 UDP-N-acetylglucosamine-2-epimerase/N- 5920 acetylmannosaminekinase 205233_s_at −4.7127287 platelet-activating factor acetylhydrolase2, 40 kDa 477083 209881_s_at −4.723093 linker for activation of T cells498997 210201_x_at −4.7310315 bridging integrator 1 193163 208795_s_at−4.7315545 MCM7 minichromosome maintenance deficient 7 438720 (S.cerevisiae) 206829_x_at −4.7446912 zinc finger protein 430 309348215785_s_at −4.7595567 cytoplasmic FMR1 interacting protein 2 211201206337_at −4.7716012 chemokine (C-C motif) receptor 7 1652 214177_s_at−4.7755992 pre-B-cell leukemia transcription factor interacting 505806protein 1 204828_at −4.7856359 RAD9 homolog A (S. pombe) 240457205013_s_at −4.8029535 adenosine A2a receptor 197029 203564_at−4.8064489 Fanconi anemia, complementation group G 434873 202481_at−4.811268 short-chain dehydrogenase/reductase 1 17144 205310_at−4.8291386 hypothetical protein 20D7-FC4 128702 215235_at −4.830164spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 387905 203956_at−4.8519414 KIAA0852 protein 143840 214833_at −4.8566377 KIAA0792 geneproduct 119387 204957_at −4.8590232 origin recognition complex, subunit5-like (yeast) 153138 212414_s_at −4.8647531 septin 6 90998 213164_at−4.8698375 mitochondrial ribosomal protein S6 268016 211005_at−4.9017443 linker for activation of T cells 498997 209670_at −4.9218273T cell receptor alpha locus 74647 57082_at −4.9228846 LDL receptoradaptor protein 184482 203846_at −4.9250454 tripartite motif-containing32 236218 200965_s_at −5.0317556 actin binding LIM protein 1 442540214808_at −5.0730906 Homo sapiens cDNA FLJ11958 fis, clone 519791HEMBB1000996. 35147_at −5.0896447 MCF.2 cell line derived transformingsequence-like 436905 206039_at −5.1020197 RAB33A, member RAS oncogenefamily 56294 201677_at −5.1309712 DC12 protein 458320 221011_s_at−5.1441771 likely ortholog of mouse limb-bud and heart gene 57209203062_s_at −5.1456619 mediator of DNA damage checkpoint 1 433653207231_at −5.167881 zinc finger DAZ interacting protein 3 409210207734_at −5.2935692 hypothetical protein FLJ20340 272794 202423_at−5.3252148 MYST histone acetyltransferase (monocytic 93231 leukemia) 3201930_at −5.3290801 MCM6 minichromosome maintenance deficient 6 444118(MIS5 homolog, S. pombe) (S. cerevisiae) 213620_s_at −5.4358397intercellular adhesion molecule 2 433303 38269_at −5.5792458 proteinkinase D2 205431 209603_at −5.9506916 GATA binding protein 3 169946219798_s_at −5.9710113 hypothetical protein FLJ20257 178011 210038_at−6.1736133 protein kinase C, theta 408049 *Positive t-statisticindicates that the gene is upregulated following an ischemic stroke.Negative t-statistic indicates that the gene is downregulated followingan ischemic stroke. {circumflex over ( )}UniGene ID number is system forautomatically partitioning GenBank sequences into a non-redundant set ofgene-oriented clusters. Each UniGene cluster contains sequences thatrepresent a unique gene, as well as related information such as thetissue types in which the gene has been expressed and map location.UniGene numbers can be searched on the NCBI website.

Following Bonferroni correction, 231 gene probes, corresponding to 190genes, were found to be significant (Table 3). Clear separation of thestroke and control gene expression levels were observed. As shown inTable 3, several genes were upregulated (positive T-statistic, such as avalue that is at least 4.73) or downregulated (negative t-statistic,such as a value that is less than −4.73) following an ischemic stroke.

TABLE 3 Ischemic stroke related-genes using Bonferroni correction.UniGene ID Affy ID No. t-statistic* Gene Name No.{circumflex over ( )}218454_at 7.8939046 hypothetical protein FLJ22662 178470 215049_x_at7.8695991 CD163 antigen 74076 203645_s_at 7.7927429 CD163 antigen 74076211404_s_at 7.6192982 amyloid beta (A4) precursor-like protein 2 279518206120_at 7.6130371 CD33 antigen (gp67) 83731 208771_s_at 7.4480951leukotriene A4 hydrolase 81118 210872_x_at 7.2957674 growtharrest-specific 7 226133 201328_at 7.196077 v-ets erythroblastosis virusE26 oncogene homolog 292477 2 (avian) 222173_s_at 7.0181137 TBC1 domainfamily, member 2 371016 211612_s_at 6.7100761 interleukin 13 receptor,alpha 1 285115 211067_s_at 6.6632809 growth arrest-specific 7 226133211368_s_at 6.6564605 caspase 1, apoptosis-related cysteine protease2490 (interleukin 1, beta, convertase) 219788_at 6.6357632 pairedimmunoglobin-like type 2 receptor alpha 122591 202896_s_at 6.6343375protein tyrosine phosphatase, non-receptor type 156114 substrate 1221210_s_at 6.6307936 N-acetylneuraminate pyruvate lyase 64896(dihydrodipicolinate synthase) 204924_at 6.6002629 toll-like receptor 2439608 206488_s_at 6.5474747 CD36 antigen (collagen type I receptor,443120 thrombospondin receptor) 208146_s_at 6.5359521 carboxypeptidase,vitellogenic-like 95594 213006_at 6.5058834 KIAA0146 protein 381058208923_at 6.4690445 cytoplasmic FMR1 interacting protein 1 26704208702_x_at 6.4619855 amyloid beta (A4) precursor-like protein 2 279518204452_s_at 6.452735 frizzled homolog 1 (Drosophila) 94234 205715_at6.4316015 bone marrow stromal cell antigen 1 169998 216942_s_at6.4235387 CD58 antigen, (lymphocyte function-associated 75626 antigen 3)218217_at 6.419306 likely homolog of rat and mouse retinoid-inducible431107 serine carboxypeptidase 212192_at 6.4140293 hypothetical proteinBC013764 109438 200868_s_at 6.3921161 zinc finger protein 313 144949202912_at 6.3889633 adrenomedullin 441047 207691_x_at 6.3716999ectonucleoside triphosphate diphosphohydrolase 1 444105 209124_at6.322399 myeloid differentiation primary response gene (88) 82116204620_s_at 6.3107101 chondroitin sulfate proteoglycan 2 (versican)434488 203535_at 6.2998102 S100 calcium binding protein A9 (calgranulinB) 112405 202878_s_at 6.2900118 complement component 1, q subcomponent,97199 receptor 1 204249_s_at 6.2863054 LIM domain only 2(rhombotin-like 1) 283063 208872_s_at 6.2665313 polyposis locus protein1 173119 205603_s_at 6.2533791 diaphanous homolog 2 (Drosophila) 226483208818_s_at 6.2031095 catechol-O-methyltransferase 240013 205158_at6.2009402 ribonuclease, RNase A family, 4 283749 200765_x_at 6.1928897catenin (cadherin-associated protein), alpha 1, 254321 102 kDa220615_s_at 6.1326079 hypothetical protein FLJ10462 134497 202897_at6.1313157 protein tyrosine phosphatase, non-receptor type 156114substrate 1 204222_s_at 6.1245309 GLI pathogenesis-related 1 (glioma)511765 201743_at 6.1155498 CD14 antigen 75627 211744_s_at 6.0521758 CD58antigen, (lymphocyte function-associated 75626 antigen 3) 207168_s_at6.0419796 H2A histone family, member Y 75258 220034_at 6.0415584interleukin-1 receptor-associated kinase 3 268552 204099_at 6.0275171SWI/SNF related, matrix associated, actin 444445 dependent regulator ofchromatin, subfamily d, member 3 212335_at 6.0167789 glucosamine(N-acetyl)-6-sulfatase (Sanfilippo 334534 disease IIID) 211135_x_at6.0123178 leukocyte immunoglobulin-like receptor, subfamily 511766 B(with TM and ITIM domains), member 3 203127_s_at 5.9862871 serinepalmitoyltransferase, long chain base subunit 2 59403 201041_s_at5.9752594 dual specificity phosphatase 1 171695 209949_at 5.9749633neutrophil cytosolic factor 2 (65 kDa, chronic 949 granulomatousdisease, autosomal 2) 203922_s_at 5.9579176 cytochrome b-245, betapolypeptide (chronic 88974 granulomatous disease) 200838_at 5.9562695cathepsin B 135226 210844_x_at 5.9341934 catenin (cadherin-associatedprotein), alpha 1, 254321 102 kDa 200886_s_at 5.905732 phosphoglyceratemutase 1 (brain) 447492 208949_s_at 5.8880039 lectin,galactoside-binding, soluble, 3 (galectin 3) 411701 211284_s_at5.8723751 granulin 180577 210992_x_at 5.7814222 Fc fragment of IgG, lowaffinity IIa, receptor for 352642 (CD32) 204860_s_at 5.7675599 Homosapiens transcribed sequence with strong 508565 similarity to proteinsp: Q13075 (H. sapiens) BIR1_HUMAN Baculoviral LAP repeat-containingprotein 1 (Neuronal apoptosis inhibitory protein) 212788_x_at 5.7508112ferritin, light polypeptide 433670 211776_s_at 5.7448982 erythrocytemembrane protein band 4.1-like 3 103839 221731_x_at 5.7407504chondroitin sulfate proteoglycan 2 (versican) 434488 210225_x_at5.7405956 leukocyte immunoglobulin-like receptor, subfamily 511766 B(with TM and ITIM domains), member 3 218404_at 5.7312675 sorting nexin10 418132 214511_x_at 5.7139856 Fc fragment of IgG, high affinity Ia,receptor for 77424 (CD64) 200764_s_at 5.6724223 catenin(cadherin-associated protein), alpha 1, 254321 102 kDa 210904_s_at5.6679489 interleukin 13 receptor, alpha 1 285115 201200_at 5.6494608cellular repressor of E1A-stimulated genes 5710 209189_at 5.6491225v-fos FBJ murine osteosarcoma viral oncogene 25647 homolog 202943_s_at5.6217726 N-acetylgalactosaminidase, alpha- 75372 201329_s_at 5.6098071v-ets erythroblastosis virus E26 oncogene homolog 292477 2 (avian)200678_x_at 5.5920695 granulin 180577 200839_s_at 5.5911028 cathepsin B135226 204053_x_at 5.5889098 phosphatase and tensin homolog (mutated in253309 multiple advanced cancers 1) 204759_at 5.5751089 chromosomecondensation 1-like 27007 217897_at 5.5697271 FXYD domain containing iontransport regulator 6 410748 203973_s_at 5.5691171 KIAA0146 protein381058 210951_x_at 5.5484656 RAB27A, member RAS oncogene family 298530216041_x_at 5.5475628 granulin 180577 208454_s_at 5.5419198 plasmaglutamate carboxypeptidase 197335 209970_x_at 5.5292079 caspase 1,apoptosis-related cysteine protease 2490 (interleukin 1, beta,convertase) 204646_at 5.5021786 dihydropyrimidine dehydrogenase 1602202990_at 5.4976619 phosphorylase, glycogen; liver (Hers disease, 282417glycogen storage disease type VI) 218606_at 5.4924926 zinc finger, DHHCdomain containing 7 9725 219316_s_at 5.47794 chromosome 14 open readingframe 58 267566 207574_s_at 5.4709451 growth arrest andDNA-damage-inducible, beta 110571 212807_s_at 5.462952 sortilin 1 394609214875_x_at 5.4629191 amyloid beta (A4) precursor-like protein 2 279518202446_s_at 5.4579541 phospholipid scramblase 1 348478 210784_x_at5.416225 leukocyte immunoglobulin-like receptor, subfamily 511766 B(with TM and ITIM domains), member 3 203561_at 5.4154987 Fc fragment ofIgG, low affinity IIa, receptor for 352642 (CD32) 210152_at 5.408888leukocyte immunoglobulin-like receptor, subfamily 67846 B (with TM andITIM domains), member 4 210427_x_at 5.374221 annexin A2 462864 212830_at5.3739539 EGF-like-domain, multiple 5 236216 204169_at 5.3658872 IMP(inosine monophosphate) dehydrogenase 1 317095 209500_x_at 5.3457527tumor necrosis factor (ligand) superfamily, member 54673 13 201432_at5.3369374 catalase 395771 215646_s_at 5.3337393 chondroitin sulfateproteoglycan 2 (versican) 434488 201422_at 5.3321762 interferon,gamma-inducible protein 30 14623 204112_s_at 5.330181 histamineN-methyltransferase 42151 214318_s_at 5.3243137 hypothetical proteinCG003 390874 204588_s_at 5.3231924 solute carrier family 7 (cationicamino acid 194693 transporter, y+ system), member 7 211366_x_at5.3228655 caspase 1, apoptosis-related cysteine protease 2490(interleukin 1, beta, convertase) 217865_at 5.2774855 ring fingerprotein 130 155718 211133_x_at 5.2667742 leukocyte immunoglobulin-likereceptor, subfamily 511766 B (with TM and ITIM domains), member 3209091_s_at 5.2660794 SH3-domain GRB2-like endophilin B1 136309209474_s_at 5.2656896 ectonucleoside triphosphate diphosphohydrolase 1444105 209514_s_at 5.2571756 RAB27A, member RAS oncogene family 298530211571_s_at 5.254094 chondroitin sulfate proteoglycan 2 (versican)434488 201426_s_at 5.2533276 vimentin 435800 209069_s_at 5.2359413 H3histone, family 3B (H3.3B) 180877 208130_s_at 5.2328997 thromboxane Asynthase 1 (platelet, cytochrome 444510 P450, family 5, subfamily A)220990_s_at 5.2293055 likely ortholog of rat vacuole membrane protein 1166254 210314_x_at 5.2226225 tumor necrosis factor (ligand) superfamily,member 54673 13 203140_at 5.2122493 B-cell CLL/lymphoma 6 (zinc fingerprotein 51) 155024 205147_x_at 5.2045679 neutrophil cytosolic factor 4,40 kDa 196352 210101_x_at 5.1985794 SH3-domain GRB2-like endophilin B1136309 205896_at 5.1985084 solute carrier family 22 (organic cationtransporter), 441130 member 4 206130_s_at 5.197136 asialoglycoproteinreceptor 2 1259 211367_s_at 5.1824911 caspase 1, apoptosis-relatedcysteine protease 2490 (interleukin 1, beta, convertase) 217521_at5.1760536 histidine ammonia-lyase 190783 212501_at 5.1661262CCAAT/enhancer binding protein (C/EBP), beta 99029 218013_x_at 5.1602528dynactin 4 (p62) 328865 209188_x_at 5.1523164 down-regulator oftranscription 1, TBP-binding 348418 (negative cofactor 2) 202670_at5.1509752 mitogen-activated protein kinase kinase 1 132311 217492_s_at5.1487987 phosphatase and tensin homolog (mutated in 493716 multipleadvanced cancers 1), pseudogene 1 206600_s_at 5.1452293 solute carrierfamily 16 (monocarboxylic acid 90911 transporters), member 5 208959_s_at5.1384925 thioredoxin domain containing 4 (endoplasmic 154023 reticulum)209073_s_at 5.1251219 numb homolog (Drosophila) 445301 206237_s_at5.118236 neuregulin 1 172816 209185_s_at 5.116767 insulin receptorsubstrate 2 143648 211702_s_at 5.0981002 ubiquitin specific protease 32436133 200742_s_at 5.0925572 ceroid-lipofuscinosis, neuronal 2, lateinfantile 429658 (Jansky-Bielschowsky disease) 214449_s_at 5.0883926 rashomolog gene family, member Q 442989 204834_at 5.0700936 fibrinogen-like2 351808 204619_s_at 5.0677445 chondroitin sulfate proteoglycan 2(versican) 434488 208926_at 5.0624784 sialidase 1 (lysosomal sialidase)118721 201944_at 5.0610548 hexosaminidase B (beta polypeptide) 69293202727_s_at 5.0520316 interferon gamma receptor 1 180866 211676_s_at5.0386297 interferon gamma receptor 1 180866 204493_at 5.0317822 BH3interacting domain death agonist 300825 219015_s_at 5.0301077uncharacterized hematopoietic stem/progenitor cells 110853 proteinMDS031 209397_at 5.0300249 malic enzyme 2, NAD(+)-dependent,mitochondrial 75342 217741_s_at 5.0253595 zinc finger protein 216 406096201044_x_at 5.0162483 dual specificity phosphatase 1 171695 219694_at5.013375 hypothetical protein FLJ11127 155085 201127_s_at 5.0064345 ATPcitrate lyase 387567 209304_x_at 5.001544 growth arrest andDNA-damage-inducible, beta 110571 211395_x_at 4.9985031 Fc fragment ofIgG, low affinity IIb, receptor for 126384 (CD32) 205786_s_at 4.9968981integrin, alpha M (complement component receptor 172631 3, alpha; alsoknown as CD11b (p170), macrophage antigen alpha polypeptide) 212268_at4.9939523 serine (or cysteine) proteinase inhibitor, clade B 381167(ovalbumin), member 1 202787_s_at 4.9906145 mitogen-activated proteinkinase-activated protein 234521 kinase 3 203888_at 4.9896332thrombomodulin 2030 221841_s_at 4.9829736 Kruppel-like factor 4 (gut)376206 201888_s_at 4.9773809 interleukin 13 receptor, alpha 1 285115200785_s_at 4.9557896 low density lipoprotein-related protein 1(alpha-2- 162757 macroglobulin receptor) 203167_at 4.9520306 tissueinhibitor of metalloproteinase 2 6441 201193_at 4.9498323 isocitratedehydrogenase 1 (NADP+), soluble 11223 208018_s_at 4.9436874 hemopoieticcell kinase 89555 216202_s_at 4.9129508 serine palmitoyltransferase,long chain base subunit 2 59403 212820_at 4.910653 rabconnectin-3 200828218092_s_at 4.9105339 HIV-1 Rev binding protein 352962 207654_x_at4.8995961 down-regulator of transcription 1, TBP-binding 348418(negative cofactor 2) 203746_s_at 4.8929704 holocytochrome c synthase(cytochrome c heme- 211571 lyase) 207704_s_at 4.8927493 growtharrest-specific 7 226133 222218_s_at 4.8926469 paired immunoglobin-liketype 2 receptor alpha 122591 207980_s_at 4.8812625 Cbp/p300-interactingtransactivator, with Glu/Asprich 82071 carboxy-terminal domain, 2202917_s_at 4.8743845 S100 calcium binding protein A8 (calgranulin A)416073 207791_s_at 4.8679359 RAB1A, member RAS oncogene family 227327222148_s_at 4.8580561 ras homolog gene family, member T1 14202207275_s_at 4.8529301 fatty-acid-Coenzyme A ligase, long-chain 2 511920202803_s_at 4.8492222 integrin, beta 2 (antigen CD18 (p95), lymphocyte375957 function-associated antigen 1; macrophage antigen 1 (mac-1) betasubunit) 211100_x_at 4.8473744 leukocyte immunoglobulin-like receptor,subfamily 149924 B (with TM and ITIM domains), member 1 208817_at4.8450448 catechol-O-methyltransferase 240013 203767_s_at 4.8305016steroid sulfatase (microsomal), arylsulfatase C, 79876 isozyme S212606_at 4.825363 WD repeat and FYVE domain containing 3 105340205174_s_at 4.8219593 glutaminyl-peptide cyclotransferase (glutaminyl79033 cyclase) 204714_s_at 4.8187971 coagulation factor V (proaccelerin,labile factor) 30054 221060_s_at 4.8181475 toll-like receptor 4 174312211999_at 4.8179764 H3 histone, family 3B (H3.3B) 180877 211102_s_at4.810938 leukocyte immunoglobulin-like receptor, subfamily 149924 B(with TM and ITIM domains), member 1 216243_s_at 4.8029173 interleukin 1receptor antagonist 81134 203126_at 4.799087 inositol(myo)-1(or4)-monophosphatase 2 5753 210785_s_at 4.7969428 chromosome 1 openreading frame 38 10649 204232_at 4.7891571 Fc fragment of IgE, highaffinity I, receptor for; 433300 gamma polypeptide 200648_s_at 4.7863792glutamate-ammonia ligase (glutamine synthase) 442669 218627_at 4.7700567hypothetical protein FLJ11259 416393 209555_s_at 4.769386 CD36 antigen(collagen type I receptor, 443120 thrombospondin receptor) 206034_at4.7667445 serine (or cysteine) proteinase inhibitor, clade B 368077(ovalbumin), member 8 221581_s_at 4.7543565 Williams-Beuren syndromechromosome region 5 56607 203799_at 4.7373434 type I transmembraneC-type lectin receptor DCL-1 2441 203041_s_at 4.7345873lysosomal-associated membrane protein 2 232432 209004_s_at 4.734465F-box and leucine-rich repeat protein 5 5548 210201_x_at −4.731032bridging integrator 1 193163 208795_s_at −4.731554 MCM7 minichromosomemaintenance deficient 7 438720 (S. cerevisiae) 206829_x_at −4.744691zinc finger protein 430 309348 215785_s_at −4.759557 cytoplasmic FMR1interacting protein 2 211201 206337_at −4.771601 chemokine (C-C motif)receptor 7 1652 214177_s_at −4.775599 pre-B-cell leukemia transcriptionfactor interacting 505806 protein 1 204828_at −4.785636 RAD9 homolog A(S. pombe) 240457 205013_s_at −4.802954 adenosine A2a receptor 197029203564_at −4.806449 Fanconi anemia, complementation group G 434873202481_at −4.811268 short-chain dehydrogenase/reductase 1 17144205310_at −4.829139 hypothetical protein 20D7-FC4 128702 215235_at−4.830164 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 387905203956_at −4.851941 KIAA0852 protein 143840 214833_at −4.856638 KIAA0792gene product 119387 204957_at −4.859023 origin recognition complex,subunit 5-like (yeast) 153138 212414_s_at −4.864753 septin 6 90998213164_at −4.869838 mitochondrial ribosomal protein S6 268016 211005_at−4.901744 linker for activation of T cells 498997 209670_at −4.921827 Tcell receptor alpha locus 74647 57082_at −4.922885 LDL receptor adaptorprotein 184482 203846_at −4.925045 tripartite motif-containing 32 236218200965_s_at −5.031756 actin binding LIM protein 1 442540 214808_at−5.073091 Homo sapiens cDNA FLJ11958 fis, clone 397369 HEMBB1000996.35147_at −5.089645 MCF.2 cell line derived transforming sequence-like436905 206039_at −5.10202 RAB33A, member RAS oncogene family 56294201677_at −5.130971 DC12 protein 458320 221011_s_at −5.144177 likelyortholog of mouse limb-bud and heart gene 57209 203062_s_at −5.145662mediator of DNA damage checkpoint 1 433653 207231_at −5.167881 zincfinger DAZ interacting protein 3 409210 207734_at −5.293569 hypotheticalprotein FLJ20340 272794 202423_at −5.325215 MYST histoneacetyltransferase (monocytic 93231 leukemia) 3 201930_at −5.32908 MCM6minichromosome maintenance deficient 6 444118 (MIS5 homolog, S. pombe)(S. cerevisiae) 213620_s_at −5.43584 intercellular adhesion molecule 2433303 38269_at −5.579246 protein kinase D2 205431 209603_at −5.950692GATA binding protein 3 169946 219798_s_at −5.971011 hypothetical proteinFLJ20257 178011 210038_at −6.173613 protein kinase C, theta 408049*Positive t-statistic indicates that the gene is upregulated followingan ischemic stroke. Negative t-statistic indicates that the gene isdownregulated following an ischemic stroke. {circumflex over ( )}UniGeneID number is system for automatically partitioning GenBank sequencesinto a non-redundant set of gene-oriented clusters. Each UniGene clustercontains sequences that represent a unique gene, as well as relatedinformation such as the tissue types in which the gene has beenexpressed and map location. UniGene numbers can be searched on the NCBIwebsite.

After multiple comparison correction (MCC) using the Westfall and Youngpermutation approach, 91 gene probes, corresponding to 82 genes werefound to be significantly different (Table 4). As shown in Table 4,several genes were upregulated (positive T-statistic, such as a valuethat is at least 5.3) or downregulated (negative t-statistic, such as avalue that is less than −5.4) following an ischemic stroke.

TABLE 4 Ischemic stroke related-genes using Westfall and Youngcorrection. UniGene ID Affy ID # t-statistic* Gene Name No.{circumflexover ( )} 218454_at 7.893904631 hypothetical protein FLJ22662 178470215049_x_at 7.869599129 CD163 antigen 74076 203645_s_at 7.792742866CD163 antigen 74076 211404_s_at 7.61929825 amyloid beta (A4)precursor-like protein 2 279518 206120_at 7.613037145 CD33 antigen(gp67) 83731 208771_s_at 7.448095101 leukotriene A4 hydrolase 81118210872_x_at 7.295767389 growth arrest-specific 7 226133 201328_at7.196076979 v-ets erythroblastosis virus E26 oncogene 292477 homolog 2(avian) 222173_s_at 7.01811369 TBC1 domain family, member 2 371016211612_s_at 6.710076137 interleukin 13 receptor, alpha 1 285115211067_s_at 6.663280893 growth arrest-specific 7 226133 211368_s_at6.656460461 caspase 1, apoptosis-related cysteine protease 2490(interleukin 1, beta, convertase) 219788_at 6.635763202 pairedimmunoglobin-like type 2 receptor 122591 alpha 202896_s_at 6.634337453protein tyrosine phosphatase, non-receptor 156114 type substrate 1221210_s_at 6.630793631 N-acetylneuraminate pyruvate lyase 64896(dihydrodipicolinate synthase) 204924_at 6.60026287 toll-like receptor 2439608 206488_s_at 6.547474681 CD36 antigen (collagen type I receptor,443120 thrombospondin receptor) 208146_s_at 6.535952056carboxypeptidase, vitellogenic-like 95594 213006_at 6.505883417 KIAA0146protein 381058 208923_at 6.469044495 cytoplasmic FMR1 interactingprotein 1 26704 208702_x_at 6.461985493 amyloid beta (A4) precursor-likeprotein 2 279518 204452_s_at 6.452734953 frizzled homolog 1 (Drosophila)94234 205715_at 6.431601459 bone marrow stromal cell antigen 1 169998216942_s_at 6.423538729 CD58 antigen, (lymphocyte function- 75626associated antigen 3) 218217_at 6.419305978 likely homolog of rat andmouse retinoid- 431107 inducible serine carboxypeptidase 212192_at6.414029336 hypothetical protein BC013764 109438 200868_s_at 6.392116081zinc finger protein 313 144949 202912_at 6.388963292 adrenomedullin441047 207691_x_at 6.371699946 ectonucleoside triphosphate 444105diphosphohydrolase 1 209124_at 6.322399002 myeloid differentiationprimary response 82116 gene (88) 204620_s_at 6.310710071 chondroitinsulfate proteoglycan 2 (versican) 434488 203535_at 6.299810247 S100calcium binding protein A9 112405 (calgranulin B) 202878_s_at6.290011829 complement component 1, q subcomponent, 97199 receptor 1204249_s_at 6.286305359 LIM domain only 2 (rhombotin-like 1) 283063208872_s_at 6.266531252 polyposis locus protein 1 173119 205603_s_at6.253379078 diaphanous homolog 2 (Drosophila) 226483 208818_s_at6.203109452 catechol-O-methyltransferase 240013 205158_at 6.200940206ribonuclease, RNase A family, 4 283749 200765_x_at 6.192889656 catenin(cadherin-associated protein), alpha 254321 1, 102 kDa 220615_s_at6.13260793 hypothetical protein FLJ10462 134497 202897_at 6.131315699protein tyrosine phosphatase, non-receptor 156114 type substrate 1204222_s_at 6.124530943 GLI pathogenesis-related 1 (glioma) 511765201743_at 6.115549767 CD14 antigen 75627 211744_s_at 6.052175772 CD58antigen, (lymphocyte function- 75626 associated antigen 3) 207168_s_at6.04197964 H2A histone family, member Y 75258 220034_at 6.041558439interleukin-1 receptor-associated kinase 3 268552 204099_at 6.027517093SWI/SNF related, matrix associated, actin 444445 dependent regulator ofchromatin, subfamily d, member 3 212335_at 6.016778906 glucosamine(N-acetyl)-6-sulfatase 334534 (Sanfilippo disease IIID) 211135_x_at6.012317836 leukocyte immunoglobulin-like receptor, 511766 subfamily B(with TM and ITIM domains), member 3 203127_s_at 5.986287131 serinepalmitoyltransferase, long chain base 59403 subunit 2 201041_s_at5.975259394 dual specificity phosphatase 1 171695 209949_at 5.974963258neutrophil cytosolic factor 2 (65 kDa, chronic 949 granulomatousdisease, autosomal 2) 203922_s_at 5.957917579 cytochrome b-245, betapolypeptide (chronic 88974 granulomatous disease) 200838_at 5.956269465cathepsin B 135226 210844_x_at 5.934193387 catenin (cadherin-associatedprotein), alpha 254321 1, 102 kDa 200886_s_at 5.905731995phosphoglycerate mutase 1 (brain) 447492 208949_s_at 5.888003927 lectin,galactoside-binding, soluble, 3 411701 (galectin 3) 211284_s_at5.872375053 granulin 180577 210992_x_at 5.781422168 Fc fragment of IgG,low affinity IIa, receptor 352642 for (CD32) 204860_s_at 5.767559943Homo sapiens transcribed sequence with 508565 strong similarity toprotein sp: Q13075 (H. sapiens) BIR1_HUMAN Baculoviral IAPrepeat-containing protein 1 (Neuronal apoptosis inhibitory protein)212788_x_at 5.750811183 ferritin, light polypeptide 433670 211776_s_at5.744898203 erythrocyte membrane protein band 4.1-like 3 221731_x_at5.740750361 chondroitin sulfate proteoglycan 2 (versican) 434488210225_x_at 5.740595562 leukocyte immunoglobulin-like receptor, 511766subfamily B (with TM and ITIM domains), member 3 218404_at 5.731267464sorting nexin 10 418132 214511_x_at 5.713985599 Fc fragment of IgG, highaffinity Ia, receptor 77424 for (CD64) 200764_s_at 5.672422269 catenin(cadherin-associated protein), alpha 254321 1, 102 kDa 210904_s_at5.667948907 interleukin 13 receptor, alpha 1 285115 201200_at5.649460774 cellular repressor of E1A-stimulated genes 5710 209189_at5.649122471 v-fos FBJ murine osteosarcoma viral 25647 oncogene homolog202943_s_at 5.621772605 N-acetylgalactosaminidase, alpha- 75372201329_s_at 5.609807116 v-ets erythroblastosis virus E26 oncogene 292477homolog 2 (avian) 200678_x_at 5.592069508 granulin 180577 200839_s_at5.591102824 cathepsin B 135226 204053_x_at 5.588909808 phosphatase andtensin homolog (mutated in 253309 multiple advanced cancers 1) 204759_at5.575108906 chromosome condensation 1-like 27007 217897_at 5.56972714FXYD domain containing ion transport 410748 regulator 6 203973_s_at5.569117146 KIAA0146 protein 381058 210951_x_at 5.548465566 RAB27A,member RAS oncogene family 298530 216041_x_at 5.547562803 granulin180577 208454_s_at 5.541919824 plasma glutamate carboxypeptidase 197335209970_x_at 5.529207916 caspase 1, apoptosis-related cysteine protease2490 (interleukin 1, beta, convertase) 204646_at 5.502178632dihydropyrimidine dehydrogenase 1602 202990_at 5.497661918phosphorylase, glycogen; liver (Hers disease, 282417 glycogen storagedisease type VI) 218606_at 5.492492596 zinc finger, DHHC domaincontaining 7 9725 219316_s_at 5.477939952 chromosome 14 open readingframe 58 267566 207574_s_at 5.470945076 growth arrest andDNA-damage-inducible, 110571 beta 212807_s_at 5.462951979 sortilin 1394609 214875_x_at 5.462919125 amyloid beta (A4) precursor-like protein2 279518 202446_s_at 5.457954078 phospholipid scramblase 1 348478210784_x_at 5.416225005 leukocyte immunoglobulin-like receptor, 511766subfamily B (with TM and ITIM domains), member 3 203561_at 5.415498696Fc fragment of IgG, low affinity IIa, receptor 352642 for (CD32)210152_at 5.408887988 leukocyte immunoglobulin-like receptor, 67846subfamily B (with TM and ITIM domains), member 4 210427_x_at 5.374221003annexin A2 462864 212830_at 5.373953889 EGF-like-domain, multiple 5236216 204169_at 5.36588724 IMP (inosine monophosphate) 317095dehydrogenase 1 213620_s_at −5.435839683 intercellular adhesion molecule2 433303 38269_at −5.579245846 protein kinase D2 205431 209603_at−5.950691641 GATA binding protein 3 169946 219798_s_at −5.971011322hypothetical protein FLJ20257 178011 210038_at −6.173613284 proteinkinase C, theta 408049 *Positive t-statistic indicates that the gene isupregulated following an ischemic stroke. Negative t-statistic indicatesthat the gene is downregulated following an ischemic stroke. {circumflexover ( )}UniGene ID number is system for automatically partitioningGenBank sequences into a non-redundant set of gene-oriented clusters.Each UniGene cluster contains sequences that represent a unique gene, aswell as related information such as the tissue types in which the genehas been expressed and map location. UniGene numbers can be searched onthe NCBI website.

In contrast to the Benjamini and Yekutieli approach, the Westfall andYoung approach limits the probability of making even one false positivedeclaration at 5%. There was a predominant up-regulation pattern with77/82 genes up-regulated and 5 down-regulated (Table 4).

After PAM correction, 28 gene probes, corresponding to 22 genes werefound to be significantly different (Table 5). As shown in Table 5,several genes were upregulated following an ischemic stroke.

TABLE 5 Ischemic stroke related-genes using PAM correction. AffymetrixProbe ID Name and Function White Blood Cell Activation andDifferentiation 215049_x_at CD163 218454_at Hypothetical proteinFLJ22662 Laminin A motif 211404_s_at Amyloid beta (A4) precursor-likeprotein 2 221210_s_at N-acetylneuraminate pyruvate lysase 209189_atv-fos FBJ murine osteosarcoma viral oncogene homolog 204924_at Toll-likereceptor 2 211571_s_at Chondroitin sulfate proteoglycan 2 (versican)211612_s_at Interleukin 13 receptor, alpha 1 201743_at CD14 antigen205715_at Bone marrow stromal cell antigen 1/CD157 202878_s_atComplement component 1, q subcomponent, receptor 1 219788_at Pairedimmunoglobin-like type 2 receptor alpha 214511_x_at Fc fragment of IgG,high affinity Ia, receptor for (CD64) Vascular Repair 203888_atThrombomodulin 207691_x_at Ectonucleoside triphosphatediphosphohydrolase 1 206488_s_at CD36 antigen (collagen type I receptor,thrombospondin receptor) Response to Hypoxia 202912_at Adrenomedullin201041_s_at Dual specificity phosphatase 1 203922_s_at Cytochrome b-245,beta polypeptide (chronic granulomatous disease) 208771_s_at LeukotrieneA4 hydrolase 201328_at Erythroblastosis virus E26 oncogene homolog 2(avian) 209949_at Neutrophil cytosolic factor 2 (65 kDa, chronicgranulomatous disease, autosomal 2) Response to Altered CerebralMicroenvironment 208818_s_at Catechol-O-methyltransferase 200648_s_atGlutamate-ammonia ligase (glutamine ligase) 202917_s_at S100 calciumbinding protein A8 (calgranulin A) 204860_s_at Neuronal apoptosisinhibitory protein: Homo sapiens transcribed sequence with strongsimilarity to protein sp: Q13075 (H. sapiens) BIR1_HUMAN Baculoviral IAPrepeat-containing protein 1 212807_s_at Sortilin 202446_s_atPhospholipid scramblase 1 211067_s_at Growth-arrest-specific 7204222_s_at GLI pathogenesis-related 1 (glioma)

Table 6 provides a summary of the number of ischemic-stroke relatedgenes found using different correction methods.

TABLE 6 Number of genes different between stroke and control subjects bymultiple comparison correction filter.* Multiple comparison filter No.of genes PAM dataset 22 Westfall and Young dataset 82 Bonferronicorrection set 231 Benjamini & Yekutieli set 771 Raw p value list 5060*There were 22,283 gene probes on the microarray. The most conservativemultiple comparison correction is the PAM dataset, then the Westfall andYoung and Bonferroni dataset followed by the Benjamini & Yekutielidataset.

Example 4 Classes of Gene Expression Increased Following Ischemic Stroke

This example describes the four classes of genes whose expression wasincreased following ischemic stroke, based on the results obtained inExample 3.

A number of broad classes of gene expression were found (representativeexamples are shown in Table 5 above). The first were genes thatindicated differentiation of monocytes into macrophages and lymphocyteactivation (for example, CD14, toll-like receptor 2 and FcR2a).Concomitantly, a number of genes for cell cycle arrest wereup-regulated. Some other up-regulated genes were for cytoskeletalproteins (for example, alpha-catenin and galectin 3) involved inanchoring of white blood cells to tissue.

The second main grouping was related to hypoxia, many being inducible byhypoxia inducible factor-1 (for example, adrenomedullin, FcR2a andCD14). There may be a common promoter region for hypoxia induciblefactor-1.

A third class of genes is related to vascular repair. For example,up-regulation of ectonucleoside triphosphate diphosphohydrolase 1results in decreased platelet interaction and aggregation.

The fourth broad class of genes is related to a specific PBMC responseto the altered cerebral microenvironment.

Surprisingly, no specific steroid stress-related genes were identified.

In summary, the gene classes demonstrate both specific and non-specificgene expression in PBMCs during acute ischemic stroke. The finding ofgenes induced by hypoxic stress, vascular repair genes and neuronalspecific genes demonstrates a specific response to ischemic stroke.

Example 5 Predicting Severity and Neurological Recovery of IschemicStroke

This example describes methods used to analyze PBMCs isolated from 26subjects at three time-points following ischemic stroke, to demonstratethat there is a correlation between recovery and alterations in geneexpression.

Expression of the 22 genes listed in Table 5 was determined using themethods described in the above examples in a second and independentseries of 26 patients studied two years after the initial series. Thesepatients had blood samples drawn at day 1 (within 24 hours of onset ofsymptoms), day 7-14 and day 90 post stroke (26 subjects had blood drawsat day 1, 25 subjects had a blood draw at day 7-14 and 21 subjects had ablood draw at day 90 [some patients were deceased by this time]). At day1, detecting differential gene expression in the 22 genes accuratelyclassified 81% of subjects (21/26) as having had an ischemic stroke. The5 subjects classified as control (that is, subjects classified as nothaving had an ischemic stroke) using the method tended to be younger orto have mild stroke severity scores. These results confirm thediagnostic accuracy of the PAM list (Table 5) for acute stroke diagnosis(shown in Table 9), as this was the second independent series ofsubjects on which these results have been confirmed.

At days 7-14, detecting differential gene expression in the 22 genesaccurately classified 64% of subjects (16/25) as having had an ischemicstroke. At day 90, detecting differential gene expression in the 22genes accurately classified 62% of subjects (13/21) as having had anischemic stroke. Without wishing to be bound to a particular theory, itis proposed that the persistent gene changes of ischemic stroke at theday 7-14 and day 90 time points reflects ongoing inflammatory or otherprocesses related to the stroke or a lack of recovery of theseprocesses. Those who remained classified as a stroke at these timepoints were those with the more severe strokes and worse outcomes (seebelow).

The recovery of the subjects was compared to their classificationdetermined using the 22 genes listed in Table 5. An excellent recoverywas defined as a Barthel score of 100 at three months post stroke (forexample see Mahoney et al., Md. State Med. J. 14:61-5, 1965). TheBarthel score is a measure of 10 activities of daily living such asgetting dressed, walking, going to the toilet. The score ranges from 100(fully independent) to 0 (totally dependent and incapacitated ordeceased).

In terms of excellent stroke recovery, all 9/9 (100%) patients who wereclassified as a control at their last measurement (whether classified asa stroke or a control at the first time point) had excellent recovery.In contrast only 8/17 (47%) patients who remained classified as a strokeat their last follow-up measurement (at day 7-14 in 3 patients who diedand day 90 in the remaining) had excellent stroke recovery (p=0.008).This indicates persistence of the stroke state is related to changes ingene expression.

Therefore, it appears that the reason that some of the subjects wereindicated to not have had an ischemic stroke is that they recovered byday 90. Therefore, the disclosed ischemic stroke related molecules, suchas those listed in Tables 2-5, for example those listed in Table 5 canbe used to be determine the prognosis of a subject who has had anischemic stroke.

In view of these results, disclosed are methods of stratifying theseriousness of a stroke, and assessing the likely neurological recoveryof the subject. For example, stratification or assessing the likelyneurological recovery of the subject can be performed as early as oneday (or within 24 hours) after the ischemic stroke, 7-14 days after theischemic stroke, or 90 days after the ischemic stroke. In particularexamples, the method includes detecting differential expression in atleast four ischemic stroke-related molecules, such as at least the 22genes (or corresponding proteins) listed in Table 5. Detection ofincreased expression of at least four ischemic stroke-related molecules,such as at least the 22 genes (or corresponding proteins) listed inTable 5, indicates that the stroke was severe and the subject has alower probability of neurological recovery (for example as compared toan amount of expected neurological recovery in a subject who did nothave increased expression of the 22 genes/proteins listed in Table 5).In particular examples, the increased expression is determined bycalculating a t-statistic value, wherein a t-statistic value of at least3, at least 5.3, or at least 6 indicates that expression is increased.

In particular examples, the assay results can predict a Barthel score ofat least 45, for example at least 50, 90 or 100, as an indication ofneurological recovery.

Example 6 Temporal Relationship of Evaluating a Stroke

This example describes the temporal relationship of the disclosedmethods to the stroke or suspected stroke. The assay can be performedfollowing the onset of signs and symptoms associated with ischemicstroke. Particular examples of signs and symptoms associated withischemic stroke include but are not limited to: headache, sensory loss(such as numbness, particularly confined to one side of the body orface), paralysis (such as hemiparesis), pupillary changes, blindness(including bilateral blindness), ataxia, memory impairment, dysarthria,somnolence, and other effects on the central nervous system recognizedby those of skill in the art.

A sample can be obtained from the subject (such as a PBMC sample) andanalyzed using the disclosed methods, for example, within 1 hour, within6 hours, within 12 hours, or even within 24 hours of having signs orsymptoms associated with ischemic stroke, In another example, a sampleis obtained at least 7 days later following the onset of signs andsymptoms associated with ischemic stroke, such as within 7-14 days ofhaving signs or symptoms associated with ischemic stroke, or within 90days.

In particular examples, the assay can be performed after a sufficientperiod of time for the differential regulation of the genes (orproteins) to occur, for example at least 24 hours after onset of thesymptom or constellation of symptoms that have indicated a potentialcerebral ischemic event. In other examples it occurs prior to performingany imaging tests are performed to find anatomic evidence of ischemicstroke. Moreover, it is often difficult for imaging modalities (such asCT and MRI) to detect acute ischemic strokes, at least until brainchanges (such as edema) have taken place in response to the ischemia.Hence the assay described herein in particular examples is able todetect the ischemic stroke even before definitive brain imaging evidenceof the stroke is known.

Since the results of this assay are also highly reliable predictors ofthe ischemic nature of the stroke, the results of the assay can also beused (for example in combination with other clinical evidence and brainscans) to determine whether thrombolytic therapy designed to lyse aneurovascular occlusion such as a thrombus (for example by using tissueplasminogen activator or streptokinase) should be administered to thesubject. In certain example, thrombolytic therapy is given to thesubject once the results of the differential gene assay are known if theassay provides an indication that the stroke is ischemic in nature.

Moreover, the neurological sequelae of an ischemic event in the centralnervous system can have consequences that range from the insignificantto the devastating, and the disclosed assay permits early and accuratestratification of risk of long-lasting neurological impairment. Forexample, a test performed as early as within the first 24 hours of onsetof signs and symptoms of a stroke, and even as late as 7-14 days or evenas late as 90 days or more after the event can provide clinical datathat is highly predictive of the eventual care needs of the subject.

The disclosed assay is also able to identify subjects who have had anischemic stroke in the past, for example more than 2 weeks ago, or evenmore than 90 days ago. The identification of such subjects helpsevaluate other clinical data (such as neurological impairment or brainimaging information) to determine whether an ischemic stroke hasoccurred. Subjects identified or evaluated in this manner can then beprovided with appropriate treatments, such as anti-platelet agents (forexample aspirin) that would be appropriate for a subject identified ashaving had an ischemic stroke but not as appropriate for subject whohave had a hemorrhagic stroke. It is helpful to be able to classifysubject as having had an ischemic stroke, because the treatments forischemic stroke are often distinct from the treatments for hemorrhagicstroke. In fact, treating a hemorrhagic stroke with a therapy designedfor an ischemic stroke (such as a thrombolytic agent) can havedevastating clinical consequences. Hence using the results of thedisclosed assay to help distinguish ischemic from hemorrhagic strokeoffers substantial clinical benefit, and allows subjects to be selectedfor treatments appropriate to ischemic stroke but not hemorrhagicstroke.

Example 7 Quantitative Real Time Polymerase Chain Reaction

This example describes the use of quantitative real time polymerasechain reaction to confirm results obtained using the microarrays.

Quantitative real time polymerase chain reaction of gene expressionlevels were performed using RNA samples from 10 patients and 9 controls.Nine genes were selected for analysis on the basis of theirsignificantly high expression in the index set. One further gene, notup-regulated in the permutation dataset was selected as a negativecontrol. Primers were obtained from the published literature and orderedfrom Invitrogen (Carlsbad, Calif.) as listed in Table 7.

TABLE 7  Primers for real time-PCR Gene GenBank ID No Primer Forward*Primer reverse* Adreno- NM_001124 CGAAAGAAGTGGAATAAGTGGGCCCGCAGTTCCCTCTTCCC  medullin (1) (2) CD14 NM_000591CAAGGTACTGAGCATTGCCCA   TGTTCGCAGGAAAAGGCAG  (3) (4) CD36 M24795GATGCAGCCTCATTTCCACCT  AGGCCTTGGATGGAAGAACA  (5) (6) Caspase 1 NM_033292GACCCGAGCTTTGATTGACTCC TTGATCTGCTGAGAGTCCCAGC  (7) (8) a-CateninBC000385 GATGACCGTCGTGAGCGAATT  TTACGTCCAGCATTGCCCA  (9) (10) FcR2aNM_021642 GACTGTGCTTTCCGAATGGCT  TGACCTTGACCAGAGGCTTGTC  (11) (12)FcER1a NM_002001. AGATGGCGTGTTAGCAGTCCCT GCCATTGTGGAACCATTTGG  (13) (14)Cathepsin NM_147781 CTGGCTGGTTGCCAACTCC  AAAGAAGCCATTGTCACCCCA  B (15)(16) TRL2 BC033756. TCGGCGTTCTCTCAGGTGAC TGCAACACCAAACACTGGGAG  (17)(18) INFGR1 BC005333 AGAATTTGCTGTATGCCGAGATG TGATATCCAGTTTAGGTGGTCCAAT(19) (20) *SEQ ID NOS: shown in parenthesis.

Real time PCR was performed with an Opticon 2 (MJ research). Real timePCR results between patients and controls were compared usingnon-parametric statistics (Mann Whitney U tests).

As shown in Table 8, expression values derived from the microarrayscorrelated with RT-PCR for 9 up-regulated genes. Using RT-PCR, highervalues for 8/9 genes in the up-regulated list were found, with asignificant difference in 7/9 genes between 10 patients and 9 controls.A negative control was also included (gene not up-regulated in thepermutation dataset) with no significant difference observed betweenpatients who suffered a stroke and controls.

TABLE 8 Correlation of expression data with real time-PCR values MedianMedian Patients Controls Gene Name Genbank ID n = 10 n = 9 pUp-regulated in Westfall and Young Set Adrenomedullin NM_001124 1.2950.39 0.0015 CD14 NM_000591 2.207 1.094 0.0003 CD36 M24795 2.08 1.23 0.02Caspase 1 NM_033292 14.24 6.62 0.0041 a-Catenin BC000385 2.559 1.54870.0789 FcR2a NM_021642 0.58 0.26 0.003 FcER1a NM_002001 2.655 2.870.9048 Cathepsin B NM_147781 0.9 0.32 0.0041 Toll-like receptor 2BC033756 0.4939 0.1561 0.0021 Not Up-regulated in Westfall and Young SetINFGR1 BC005333 0.985 0.64 0.1128

Using data from 9 patients and 10 controls and the PAM, stroke wasprospectively classified with a sensitivity of 78% and a specificity of80% (Table 9).

TABLE 9 Accuracy of training dataset in the prediction of stroke.*Positive Predictive Negative Predictive Sensitivity Specificity ValueValue No. 7/9 8/10 7/9 8/10 % 78 80 78 80 *An independent cohort of 9stroke patients and 10 controls was used. Using a nearest shrunkencentroid algorithm, stroke was classified with a sensitivity of 78% anda specificity of 80%.

In summary, a distinct genomic profile of acute ischemic stroke in theperipheral blood mononuclear cells was identified. In addition, fourbroad classes of ischemic stroke related genes were identified that areupregulated following an ischemic stroke: white blood cell activationand differentiation genes, genes associated with hypoxia, vascularrepair genes and genes associated with an altered cerebralmicroenvironment, including neuronal apoptosis inhibitory protein.

Example 8 Array for Evaluating a Stroke

This example describes particular arrays that can be used to evaluate astroke, for example to diagnose an ischemic stroke.

In one example, the array includes probes (such as an oligonucleotide orantibody) that can recognize at least one gene (or protein) that isupregulated following an ischemic stroke, such as one or more of CD163;hypothetical protein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviralIAP repeat-containing protein 1; and KIAA0146, or any 1, 2, 3, 4, 5, or6 of these. For example, the array can include a probe (such as anoligonucleotide or antibody) recognizes CD163. In yet another example,the array includes probes (such as an oligonucleotide or antibody) thatcan recognize at least one gene (or protein) that is downregulatedfollowing an ischemic stroke, such as one or more of intercellularadhesion molecule 2; protein kinase D2; GATA binding protein 3;hypothetical protein FLJ20257; or protein kinase C, theta. In aparticular example, the array includes probes (such as anoligonucleotide or antibody) that can recognize at least one gene (orprotein) that is upregulated following an ischemic stroke (such as atleast one of CD163; hypothetical protein FLJ22662 Laminin A motif;BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; and KIAA0146)and at least one gene (or protein) that is downregulated following anischemic stroke (such as one or more of intercellular adhesion molecule2; protein kinase D2; GATA binding protein 3; hypothetical proteinFLJ20257; or protein kinase C, theta).

Other examplary probes that can be used are listed in Tables 2-5 and areidentified by their Affymetrix identification number. The disclosedoligonucleotide probes can further include one or more detectablelabels, to permit detection of hybridization signals between the probeand a target sequence.

In one example, the array includes probes (such as an oligonucleotide orantibody) that recognize any combination of at least four differentgenes (or proteins) listed in Tables 2-5. In particular examples, thearray includes probes recognize all 22 genes (or proteins) listed inTable 5. The accuracy of the PAM list (Table 5) to diagnose ischemicacute stroke has been confirmed in two independent series of subjects.The ability of the PAM list (Table 5) to provide an indication of theseverity of the stroke and to determine the likelihood of neurologicalrecovery has also been demonstrated. In some examples, the arrayincludes oligonucleotides, proteins, or antibodies that recognize anycombination of at least one gene from each of the four classes listed inTable 5 (such as at least 2 or at least 3 genes from each class).

In another example, the array includes probes (such as anoligonucleotide or antibody) that recognize any combination of at least150 different genes listed in Table 3 or all 190 genes listed in Table3. In yet another example, the array includes probes that recognize atleast 500 different genes listed in Table 2. In particular examples, theprobes recognize all 637 genes listed in Table 2.

Compilation of “loss” and “gain” of hybridization signals will revealthe genetic status of the individual with respect to the ischemicstroke-associated genes listed in Tables 2-5.

Example 9 Quantitative Spectroscopic Methods

This example describes quantitative spectroscopic approaches methods,such as SELDI, that can be used to detect differential proteinexpression of ischemic stroke related proteins.

In one example, surface-enhanced laser desorption-ionizationtime-of-flight (SELDI-TOF) mass spectrometry is used to detect changesin differential protein expression, for example by using theProteinChip™ (Ciphergen Biosystems, Palo Alto, Calif.). Such methods arewell known in the art (for example see U.S. Pat. No. 5,719,060; U.S.Pat. No. 6,897,072; and U.S. Pat. No. 6,881,586, all herein incorporatedby reference). SELDI is a solid phase method for desorption in which theanalyte is presented to the energy stream on a surface that enhancesanalyte capture or desorption.

Briefly, one version of SELDI uses a chromatographic surface with achemistry that selectively captures analytes of interest, such asischemic stroke related proteins. Chromatographic surfaces can becomposed of hydrophobic, hydrophilic, ion exchange, immobilized metal,or other chemistries. For example, the surface chemistry can includebinding functionalities based on oxygen-dependent, carbon-dependent,sulfur-dependent, and/or nitrogen-dependent means of covalent ornoncovalent immobilization of analytes. The activated surfaces are usedto covalently immobilize specific “bait” molecules such as antibodies,receptors, or oligonucleotides often used for biomolecular interactionstudies such as protein-protein and protein-DNA interactions.

The surface chemistry allows the bound analytes to be retained andunbound materials to be washed away. Subsequently, analytes bound to thesurface (such as ischemic stroke related proteins) can be desorbed andanalyzed by any of several means, for example using mass spectrometry.When the analyte is ionized in the process of desorption, such as inlaser desorption/ionization mass spectrometry, the detector can be anion detector. Mass spectrometers generally include means for determiningthe time-of-flight of desorbed ions. This information is converted tomass. However, one need not determine the mass of desorbed ions toresolve and detect them: the fact that ionized analytes strike thedetector at different times provides detection and resolution of them.Alternatively, the analyte can be detectably labeled (for example with afluorophore or radioactive isotope). In these cases, the detector can bea fluorescence or radioactivity detector. A plurality of detection meanscan be implemented in series to fully interrogate the analyte componentsand function associated with retained molecules at each location in thearray.

Therefore, in a particular example, the chromatographic surface includesantibodies that recognize ischemic stroke related proteins. In oneexample, antibodies are immobilized onto the surface using a bacterialFc binding support. The chromatographic surface is incubated with asample from the subject, such as a sample that includes PMBC proteins(such as a PBMC lysate). The antigens present in the sample canrecognize the antibodies on the chromatographic surface. The unboundproteins and mass spectrometric interfering compounds are washed awayand the proteins that are retained on the chromatographic surface areanalyzed and detected by SELDI-TOF. The MS profile from the sample canbe then compared using differential protein expression mapping, wherebyrelative expression levels of proteins at specific molecular weights arecompared by a variety of statistical techniques and bioinformaticsoftware systems.

Example 10 Nucleic Acid-Based Analysis

The ischemic stroke-related nucleic acid molecules provided herein (suchas those disclosed in Tables 2-5) can be used in evaluating a stroke,for example for determining whether a subject has had an ischemicstroke, determining the severity or likely neurological recovery of asubject who has had an ischemic stroke, and determining a treatmentregimen for a subject who has had an ischemic stroke. For suchprocedures, a biological sample of the subject is assayed for anincrease or decrease in expression of ischemic stroke-related nucleicacid molecules, such as those listed in Tables 2-5. Suitable biologicalsamples include samples containing genomic DNA or RNA (including mRNA)obtained from cells of a subject, such as those present in peripheralblood, urine, saliva, tissue biopsy, surgical specimen, amniocentesissamples and autopsy material. In a particular example, the sampleincludes PBMCs (or components thereof, such as nucleic acids or proteinsisolated from PBMCs).

The detection in the biological sample of increased or decreasedexpression in four or more ischemic stroke-related nucleic acidmolecules, such any combination of four or more molecules listed inTable 5, 150 or more molecules listed in Table 3, or 500 or moremolecules listed in Table 2, can be achieved by methods known in theart. In some examples, expression is determined for any combination ofat least one gene from each class listed in Table 5 (such as at least 2or at least 3 genes from each class). In some examples, expression isdetermined for at least CD163; hypothetical protein FLJ22662 Laminin Amotif; BST-1; FcγRI; baculoviral IAP repeat-containing protein 1; andKIAA0146.

Increased or decreased expression of an ischemic stroke-related moleculealso can be detected by measuring the cellular level of ischemicstroke-related nucleic acid molecule-specific mRNA. mRNA can be measuredusing techniques well known in the art, including for instance Northernanalysis, RT-PCR and mRNA in situ hybridization. Details of mRNAanalysis procedures can be found, for instance, in provided examples andin Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2nded., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,N.Y., 1989.

Oligonucleotides specific to ischemic stroke-related sequences can bechemically synthesized using commercially available machines. Theseoligonucleotides can then be labeled, for example with radioactiveisotopes (such as ³²P) or with non-radioactive labels such as biotin(Ward and Langer et al., Proc. Natl. Acad. Sci. USA 78:6633-57, 1981) ora fluorophore, and hybridized to individual DNA samples immobilized onmembranes or other solid supports by dot-blot or transfer from gelsafter electrophoresis. These specific sequences are visualized, forexample by methods such as autoradiography or fluorometric (Landegren etal., Science 242:229-37, 1989) or colorimetric reactions (Gebeyehu etal., Nucleic Acids Res. 15:4513-34, 1987).

Nucleic acid molecules isolated from PBMCs can be amplified usingroutine methods to form nucleic acid amplification products. Thesenucleic acid amplification products can then be contacted with anoligonucleotide probe that will hybridize under stringent conditionswith an ischemic stroke-related nucleic acid. The nucleic acidamplification products which hybridize with the probe are then detectedand quantified. The sequence of the oligonucleotide probe can bindspecifically to a nucleic acid molecule represented by the sequenceslisted in Tables 2-5.

Example 11 Protein-Based Analysis

This example describes methods that can be used to detect changes inexpression of ischemic stroke-related proteins. Ischemic stroke-relatedprotein sequences can be used in methods of evaluating a stroke, forexample for determining whether a subject has had an ischemic stroke,determining the severity or likely neurological recovery of a subjectwho has had an ischemic stroke, and determining a treatment regimen fora subject who has had an ischemic stroke. For such procedures, abiological sample of the subject is assayed for a change in expression(such as an increase or decrease) of any combination of at least fourischemic stroke-related proteins, such as any combination of at leastfour of those listed in Table 5, at least 150 of those listed in Table3, or at least 500 of those listed in Table 2. In some examples, proteinexpression is determined for any combination of at least one gene fromeach of the four classes of genes listed in Table 5 (such as at least 2or at least 3 genes from each of the four classes of genes listed inTable 5). In some examples, protein expression is determined for atleast CD163; hypothetical protein FLJ22662 Laminin A motif; BST-1;FcγRI; baculoviral IAP repeat-containing protein 1; and KIAA0146.

Suitable biological samples include samples containing protein obtainedfrom cells of a subject, such as those present in peripheral blood. Achange in the amount of four or more ischemic stroke-related proteins ina subject, such as an increase in four or more ischemic stroke-relatedproteins listed in Table 5, can indicate that the subject has sufferedan ischemic stroke.

The determination of increased or decreased ischemic stroke-relatedprotein levels, in comparison to such expression in a normal subject(such as a subject who has not previously had an ischemic stroke), is analternative or supplemental approach to the direct determination of theexpression level of ischemic stroke-related nucleic acid sequences bythe methods outlined above. The availability of antibodies specific toischemic stroke-related protein(s) will facilitate the detection andquantitation of ischemic stroke-related protein(s) by one of a number ofimmunoassay methods that are well known in the art, such as thosepresented in Harlow and Lane (Antibodies, A Laboratory Manual, CSHL, NewYork, 1988). Methods of constructing such antibodies are known in theart. Any standard immunoassay format (such as ELISA, Western blot, orRIA assay) can be used to measure ischemic stroke-related proteinlevels. A comparison to wild-type (normal) ischemic stroke-relatedprotein levels and an increase or decrease in ischemic stroke-relatedpolypeptide levels (such as an increase in any combination of at least 4proteins listed in Table 5 or a decrease in any combination of at least4 proteins listed in Tables 2-4 with a negative t-statistic) isindicative of ischemic stroke. Immunohistochemical techniques can alsobe utilized for ischemic stroke-related protein detection andquantification. For example, a tissue sample can be obtained from asubject, and a section stained for the presence of an ischemicstroke-related protein using the appropriate ischemic stroke-relatedprotein specific binding agents and any standard detection system (suchas one that includes a secondary antibody conjugated to horseradishperoxidase). General guidance regarding such techniques can be found inBancroft and Stevens (Theory and Practice of Histological Techniques,Churchill Livingstone, 1982) and Ausubel et al. (Current Protocols inMolecular Biology, John Wiley & Sons, New York, 1998).

For the purposes of quantitating ischemic stroke-related proteins, abiological sample of the subject that includes cellular proteins can beused. Quantitation of an ischemic stroke-related protein can be achievedby immunoassay and the amount compared to levels of the protein found incells from a subject who has not had an ischemic stroke. A significantincrease in the amount of four or more ischemic stroke-related proteinsin the cells of a subject compared to the amount of the same ischemicstroke-related protein found in normal human cells is usually at least2-fold, at least 3-fold, at least 4-fold or greater difference.Substantial overexpression of four or more ischemic stroke-relatedprotein(s) can be indicative of an ischemic stroke. Similarly, asignificant decrease in the amount of four or more ischemicstroke-related proteins in the cells of a subject compared to the amountof the same ischemic stroke-related protein found in normal human cellsis usually at least 2-fold, at least 3-fold, at least 4-fold or greaterdifference. Substantial underexpression of four or more ischemicstroke-related protein(s) can be indicative of an ischemic stroke orpoor prognosis.

An alternative method of evaluating a stroke is to quantitate the levelof four or more ischemia-related proteins in a subject, for instance inthe cells of the subject. This diagnostic tool is useful for detectingreduced or increased levels of ischemia-related proteins, for instance,though specific techniques can be used to detect changes in the size ofproteins, for instance. Localization or coordinated expression(temporally or spatially) of ischemia-related proteins can also beexamined using well known techniques.

Example 12 Kits

Kits are provided for evaluating a stroke, for example for determiningwhether a subject has had an ischemic stroke, determining the severityor likely neurological recovery of a subject who has had an ischemicstroke, and determining a treatment regimen for a subject who has had anischemic stroke (such as kits containing ischemic stroke detectionarrays). Kits are also provided that contain the reagents need to detecthybridization complexes formed between oligonucleotides on an array andischemic stroke-related nucleic acid molecules obtained from a subject,or between proteins or antibodies on an array and proteins obtained froma subject suspected of having had (or known to have had) an ischemicstroke. These kits can each include instructions, for instanceinstructions that provide calibration curves or charts to compare withthe determined (such as experimentally measured) values. The disclosedkits can include reagents needed to determine gene copy number (genomicamplification or deletion), such as probes or primers specific for anischemia-related nucleic acid sequence.

Kits are provided to determine the level (or relative level) ofexpression or of any combination of four or more ischemic stroke-relatednucleic acids (such as mRNA) or ischemic stroke-related proteins (suchas kits containing nucleic acid probes, proteins, antibodies, or otherischemic stroke-related protein specific binding agents) listed inTables 2-5.

Kits are provided that permit detection of ischemic stroke-related mRNAexpression levels (including over- or under-expression, in comparison tothe expression level in a control sample). Such kits include anappropriate amount of one or more of the oligonucleotide primers for usein, for instance, reverse transcription PCR reactions, and can alsoinclude reagents necessary to carry out RT-PCR or other in vitroamplification reactions, including, for instance, RNA sample preparationreagents (such as an RNAse inhibitor), appropriate buffers (such aspolymerase buffer), salts (such as magnesium chloride), anddeoxyribonucleotides (dNTPs).

In some examples, kits are provided with the reagents needed to performquantitative or semi-quantitative Northern analysis of ischemicstroke-related mRNA. Such kits can include at least four ischemicstroke-related sequence-specific oligonucleotides for use as probes.Oligonucleotides can be labeled, for example with a radioactive isotope,enzyme substrate, co-factor, ligand, chemiluminescent or fluorescentagent, hapten, or enzyme.

Kits are provided that permit detection of ischemic stroke-relatedgenomic amplification or deletion. Nucleotide sequences encoding anischemic stroke-related protein, and fragments thereof, can be suppliedin the form of a kit for use in detection of ischemic stroke-relatedgenomic amplification/deletion or diagnosis of an ischemic stroke,progression of an ischemic stroke, or therapy assessment for subjectswho have suffered an ischemic stroke. In examples of such a kit, anappropriate amount of one or more oligonucleotide primers specific foran ischemic stroke-related-sequence (such as those listed in Table 1) isprovided in one or more containers. The oligonucleotide primers can beprovided suspended in an aqueous solution or as a freeze-dried orlyophilized powder, for instance. The container(s) in which theoligonucleotide(s) are supplied can be any conventional container thatis capable of holding the supplied form, for instance, microfuge tubes,ampoules, or bottles. In some applications, pairs of primers areprovided in pre-measured single use amounts in individual, typicallydisposable, tubes, or equivalent containers. With such an arrangement,the sample to be tested for the presence of ischemic stroke-relatedgenomic amplification/deletion can be added to the individual tubes andin vitro amplification carried out directly.

The amount of each primer supplied in the kit can be any amount,depending for instance on the market to which the product is directed.For instance, if the kit is adapted for research or clinical use, theamount of each oligonucleotide primer provided is likely an amountsufficient to prime several in vitro amplification reactions. Those ofordinary skill in the art know the amount of oligonucleotide primer thatis appropriate for use in a single amplification reaction. Generalguidelines can be found in Innis et al. (PCR Protocols, A Guide toMethods and Applications, Academic Press, Inc., San Diego, Calif.,1990), Sambrook et al. (In Molecular Cloning: A Laboratory Manual, ColdSpring Harbor, N.Y., 1989), and Ausubel et al. (In Current Protocols inMolecular Biology, John Wiley & Sons, New York, 1998).

A kit can include more than two primers to facilitate the in vitroamplification of ischemic stroke-related genomic sequences, such asthose listed in Tables 2-5, or the 5′ or 3′ flanking region thereof.

In some examples, kits also include the reagents needed to perform invitro amplification reactions, such as DNA sample preparation reagents,appropriate buffers (for example polymerase buffer), salts (for examplemagnesium chloride), and deoxyribonucleotides (dNTPs). Writteninstructions can also be included. Kits can further include labeled orunlabeled oligonucleotide probes to detect the in vitro amplifiedsequences. The appropriate sequences for such a probe will be anysequence that falls between the annealing sites of two providedoligonucleotide primers, such that the sequence the probe iscomplementary to is amplified during the in vitro amplification reaction(if it is present in the sample).

One or more control sequences can be included in the kit for use in thein vitro amplification reactions. The design of appropriate positive andnegative control sequences is well known to one of ordinary skill in theart.

In particular examples, a kit includes an array with oligonucleotides(or antibodies) that recognize any combination of at least four ischemicstroke-related sequences, such as any combination of at least four ofthose listed in Table 5, at least 22 of those listed in Table 5, atleast 150 of those listed in Table 3, or at least 500 of those listed inTable 2. In one example, the array includes oligonucleotides (orantibodies) that recognize at least 1, at least 2, at least 3, at least4, at least 5, or at least 6 of the following: CD163; hypotheticalprotein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; and KIAA0146. For example, the array caninclude oligonucleotides (or antibodies) that recognize at least CD163;hypothetical protein FLJ22662 Laminin A motif; BST-1; FcγRI; baculoviralIAP repeat-containing protein 1; and KIAA0146.

In some examples, the array includes agents (such as oligonucleotides,proteins, or antibodies) that can recognize any combination of at leastone gene (or protein) from each class listed in Table 5 (such as atleast 2 or at least 3 genes (or proteins) from each class). The arraycan include other oligonucleotides, for example to serve as negative orpositive controls. The oligonucleotides that recognize ischemicstroke-related and control sequences can be on the same array, or ondifferent arrays. Particular arrays are disclosed in Examples 7-9.

Kits are also provided for the detection of ischemic stroke-relatedprotein expression, for instance increased expression of any combinationof at least 4 proteins listed in Table 5. Such kits include one or moreischemic stroke-related proteins (full-length, fragments, or fusions) orspecific binding agent (such as a polyclonal or monoclonal antibody orantibody fragment), and can include at least one control. The ischemicstroke-related protein specific binding agent and control can becontained in separate containers. The kits can also include agents fordetecting ischemic stroke-related protein:agent complexes, for instancethe agent can be detectably labeled. If the detectable agent is notlabeled, it can be detected by second antibodies or protein A, forexample, either of both of which also can be provided in some kits inone or more separate containers. Such techniques are well known.

Additional components in some kits include instructions for carrying outthe assay. Instructions permit the tester to determine whether ischemicstroke-linked expression levels are elevated, reduced, or unchanged incomparison to a control sample. Reaction vessels and auxiliary reagentssuch as chromogens, buffers, enzymes, etc. can also be included in thekits.

Example 13 Gene Expression Profiles (Fingerprints)

With the disclosure of many ischemic stroke-related molecules (asrepresented for instance by those listed in Tables 2-5), gene expressionprofiles that provide information on evaluating a stroke, for examplefor determining whether a subject has had an ischemic stroke,determining the severity or likely neurological recovery of a subjectwho has had an ischemic stroke, and determining a treatment regimen fora subject who has had an ischemic stroke, are now enabled.

Ischemic stroke-related expression profiles include the distinct andidentifiable pattern of expression (or level) of sets of ischemicstroke-related genes, for instance a pattern of increased and decreasedexpression of a defined set of genes, or molecules that can becorrelated to such genes, such as mRNA levels or protein levels oractivities. The set of molecules in a particular profile can include anycombination of at least four of the sequences listed in any of Tables2-5.

Another set of molecules that could be used in a profile include anycombination of at least four sequences listed in Table 5, each of whichis overexpressed following an ischemic stroke. For example, an ischemicstroke-related gene expression profile can include one sequence fromeach of the following four classes of genes: white blood cell activationand differentiation genes, genes related to hypoxia, genes involved invascular repair, and genes related to a specific PBMC response to thealtered cerebral microenvironment. In another example, the moleculesincluded in the profile include at least CD163; hypothetical proteinFLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; and KIAA0146, or any one of these.

Yet another example of a set of molecules that could be used in aprofile would include any combination of at least 150 of the sequenceslisted in Table 3, whose expression is upregulated or downregulatedfollowing an ischemic stroke. In a particular example, a set ofmolecules that could be used in a profile would include any combinationof at least 500 of the sequences listed in Table 2, whose expression isupregulated or downregulated following an ischemic stroke.

Particular profiles can be specific for a particular stage or age ofnormal tissue (such as PMBCs). Thus, gene expression profiles can beestablished for a pre-ischemic stroke tissue (such as normal tissue notsubjected to an ischemic challenge or preconditioning) or an ischemicchallenged tissue. Each of these profiles includes information on theexpression level of at least four or more genes whose expression isaltered following an ischemic stroke. Such information can includerelative as well as absolute expression levels of specific genes.Likewise, the value measured can be the relative or absolute level ofprotein expression or protein activity, which can be correlated with a“gene expression level.” Results from the gene expression profiles of anindividual subject can be viewed in the context of a test samplecompared to a baseline or control sample fingerprint/profile.

The levels of molecules that make up a gene expression profile can bemeasured in any of various known ways, which may be specific for thetype of molecule being measured. Thus, nucleic acid levels (such asdirect gene expression levels, such as the level of mRNA expression) canbe measured using specific nucleic acid hybridization reactions. Proteinlevels can be measured using standard protein assays, usingimmunologic-based assays (such as ELISAs and related techniques), orusing activity assays. Examples for measuring nucleic acid and proteinlevels are provided herein; other methods are well known to those ofordinary skill in the art.

Examples of ischemia-related gene expression profiles can be in arrayformat, such as a nucleotide (such as polynucleotide) or protein arrayor microarray. The use of arrays to determine the presence and/or levelof a collection of biological macromolecules is now well known (see, forexample, methods described in published PCT application number WO99/48916, describing hypoxia-related gene expression arrays). Inarray-based measurement methods, an array can be contacted withpolynucleotides (in the case of a nucleic acid-based array) orpolypeptides (in the case of a protein-based array) from a sample from asubject. The amount or position of binding of the subject'spolynucleotides or polypeptides then can be determined, for instance toproduce a gene expression profile for that subject. Such gene expressionprofile can be compared to another gene expression profile, for instancea control gene expression profile from a subject known to have suffereda stroke, or known to not have suffered a stroke. Such a method could beused to determine whether a subject had an ischemic stroke or determinethe prognosis of a subject who had an ischemic stroke. In addition, thesubject's gene expression profile can be correlated with one or moreappropriate treatments, which can be correlated with a control (or setof control) expression profiles for levels of ischemia, for instance.

Example 14 Rapid Screening Assays

Prior to performing any assays to identify agents that alter theactivity (such as the expression) of an ischemic stroke-relatedmolecule, rapid screening assays can be used to screen a large number ofagents to determine if they bind to an ischemic stroke-related protein.

Rapid screening assays for detecting binding to HIV proteins have beendisclosed, for example in U.S. Pat. No. 5,230,998, which is incorporatedby reference. Briefly, an ischemic stroke-related protein (such as oneor more of those listed in Tables 2-5) is incubated with a firstantibody capable of binding to the protein, and incubated with one ormore test agents. Excess unbound first antibody is washed and removed,and antibody bound to the ischemic stroke-related protein is detected byadding a second labeled antibody which binds the first antibody. Excessunbound second antibody is then removed, and the amount of detectablelabel is quantitated. The effect of the binding is then determined inpercentages by the formula: (quantity of the label in the absence of thetest agent)−(quantity of the label in the presence of the test agent/quantity of the label in the absence of the test agent)×100.

Agents that have a high binding affinity to the ischemic stroke-relatedprotein can then be used in other assays more specifically designed todetermine the activity (such as the expression) of an ischemicstroke-related molecule.

Example 15 In vitro Screening Assay

This example describes particular in vitro methods that can be used toscreen test agents for their ability to alter the activity of anischemic stroke-related molecule. However, the disclosure is not limitedto these particular methods. One skilled in the art will appreciate thatother in vitro assays could be used.

As disclosed in the Examples above, expression of the disclosed ischemicstroke-related molecules (such as those listed in Tables 2-5) isincreased or decreased following an ischemic stroke. Therefore,screening assays can be used to identify and analyze agents thatnormalize such activity (such as decrease expression/activity of a genethat is increased following an ischemic stroke, increaseexpression/activity of a gene that is decreased following an ischemicstroke, or combinations thereof), or further enhance the change inactivity (such as further decrease expression/activity of a gene that isdecreased following an ischemic stroke, or further increaseexpression/activity of a gene that is increased following an ischemicstroke). For example, it may be desirable to further enhance the changein activity if such a change provides a beneficial effect to the subjector it may be desirable to neutralize the change in activity if such achange provides a harmful effect to the subject.

Agents identified via the disclosed assays can be useful, for example,in decreasing one or more symptoms associated with stroke, such as adecrease of at least about 10%, at least about 20%, at least about 50%,or even at least about 90%. Once identified, test agents found to alterthe activity of an ischemic stroke-related molecule can be formulated intherapeutic products (or even prophylactic products) in pharmaceuticallyacceptable formulations, and used to treat a subject who has had anischemic stroke.

Cells (such as at least 50,000 cells) that provide a model what happensin vivo following an ischemic stroke are cultured under hypoxicconditions, hypoglycemic conditions, or combinations thereof. Forexample, PBMCs can be cultured at 37° C. in hypoxic conditions of 94%N₂, 5% CO₂, and 1% O₂, for at least 1 hour, such as 4 hours or 24 hours.In another example, PBMCs are cultured at 37° C. in the absence of addedglucose for at least 1 hour, such as 4 hours or 24 hours. In yet anotherexample, PBMCs are cultured at 37° C. in at 94% N₂, 5% CO₂, and 1% 0₂ inthe absence of added glucose for at least 1 hour, such as 4 hours or 24hours.

Simultaneous to incubation in the hypoxic or hypoglycemic conditions, orat a time later, one or more test agents are incubated with the cellsunder conditions sufficient for the test agent to have the desiredeffect on the cell, for example to alter (such as normalize) theactivity of a ischemic stroke-related molecule. In one example, theagent is added at least 30 minutes after culturing the cells in thehypoxic or hypoglycemic conditions, such as at least 1 hour, at least 2hours, at least 6 hours, or at least 24 hours after culturing the cellsin the hypoxic or hypoglycemic conditions.

To determine the effect of the test agents on the activity of one ormore ischemic stroke-related molecules, RNA can be isolated from thePBMCs and labeled (see Examples 1 and 2). The labeled RNA is exposed toan array containing one or more nucleic acid molecules (such as a primeror probe) that can specifically hybridize to one or more ischemicstroke-related genes, such at least 1, at least 2, or at least 3 ofthose listed in Tables 2-5 (for example using the methods describedherein).

Alternatively, to determine the effect of the test agents on theactivity of one or more ischemic stroke-related molecules, proteins areisolated from the PBMCs. The isolated proteins can be analyzed to detectdifferential expression of one or more ischemic stroke-related proteins,such at least 1, at least 2, or at least 3 of those listed in Tables2-5, such as using the methods described in Example 9

Example 16 In vivo Screening Assay

This example describes particular in vivo methods that can be used toscreen test agents for their ability to alter the activity of anischemic stroke-related molecule. However, the disclosure is not limitedto these particular methods. One skilled in the art will appreciate thatother in vivo assays could be used (such as other mammals or other meansof inducing an ischemic stroke).

A mammal is exposed to conditions that induce an ischemic stroke. In aparticular example, an ischemic stroke is induced in a mouse byocclusion of the middle cerebral artery (MCA) under anesthesia (forexample 1 mL/kg of a mixture of ketamine (75 mg/mL) and xylazine (5mg/mL)). The mouse is anesthetized and a U-shape incision made betweenthe left ear and left eye. The top and back segments of the temporalmuscle are transected, and the skull exposed by retraction of thetemporal muscle. A small opening (1 to 2 mm in diameter) is made in theregion over the MCA with saline superfusion to prevent heat injury. Themeninges can be removed, and the MCA occluded by ligation, for examplewith 10-0 nylon thread (Ethylon). Occlusion of the MCA can be persistent(for example by transecting the MCA distally to the ligation point), orreversible, for example by occluding for a finite period of time, suchas at least 10 minutes, at least 30 minutes, or at least 60 minutes.Alternatively or in addition, the mouse is exposed hypoxic conditions,such as 8-11% oxygen for 2 hours.

Simultaneous to inducing the ischemic stroke, or at a time later, one ormore test agents are administered to the subject under conditionssufficient for the test agent to have the desired effect on the subject.Any appropriate method of administration can be used, such asintravenous, intramuscular, or transdermal. In one example, the agent isadded at least 30 minutes after the ischemic stroke, such as at least 1hour, at least 2 hours, at least 6 hours, or at least 24 hours after theischemic stroke.

The effect of the test agents on the activity of one or more ischemicstroke-related molecules can be determined using methods described inExample 15. For example, PBMCs can be isolated from the subjectfollowing exposure to the test agent. RNA or proteins isolated from thePBMCs can be analyzed to determine the activity of one or more ischemicstroke-related molecules.

Example 17 Assays for Determining Effective Dose and Effect on IschemicStroke

This example describes methods that can be used to further evaluate testagents that alter the activity of an ischemic stroke-related molecule,such as those identified using the methods described in Examples 15 and16. For example, effective doses of the test agents, and the ability ofthe agent to treat an ischemic stroke can be determined in vitro or invivo.

Cell-Based Assays

Cells (such as 20,000 to 500,000 cells) are exposed to conditions thatmimic an ischemic stroke, such as hypoxic or hypoglycemic conditions (orboth), and the incubation continued for at least 1 hour (such as atleast 4 hours or at least 24 hours). The test agent can be applied tothe cells before, during, or after mimicking an ischemic stroke. In someexamples, several different doses of the potential therapeutic agent areadministered, to identify optimal dose ranges. For example, milligram,microgram, and nanogram concentrations can be used. Subsequently, assaysare conducted to determine the activity of one or more ischemicstroke-related molecules.

Animal Model Assays

The ability of an agent, such as those identified using the methodsprovide above, to treat an ischemic stroke, can be assessed in animalmodels. Several methods of inducing an ischemic stroke in a mammal areknown, and particular examples are provided herein. Mammals of anyspecies, including, but not limited to, mice, rats, rabbits, dogs,guinea pigs, pigs, micro-pigs, goats, and non-human primates, such asbaboons, monkeys, and chimpanzees, can be used to generate an animalmodel of ischemic stroke. Such animal models can also be used to testagents for an ability to ameliorate symptoms associated with ischemicstroke. In addition, such animal models can be used to determine theLD50 and the ED50 in animal subjects, and such data can be used todetermine the in vivo efficacy of potential agents.

An ischemic stroke is induced in the mammal, and one or more test agentsidentified in the examples above administered. The amount of test agentadministered can be determined by skilled practitioners. In someexamples, several different doses of the potential therapeutic agent canbe administered to different test subjects, to identify optimal doseranges. The therapeutic agent can be administered before, during, orafter inducing the ischemic stroke. Subsequent to the treatment, animalsare observed for one or more symptoms associated with ischemic stroke. Adecrease in the development of symptoms associated with ischemic strokein the presence of the test agent provides evidence that the test agentis a therapeutic agent that can be used to decrease or even inhibitischemic stroke in a subject.

Example 18 Differential Expression Associated with Ischemic Stroke

This example describes particular changes in expression, such as gene orprotein expression, that are associated with ischemic stroke. Althoughparticular ischemic stroke-related molecules are listed in this example,one skilled in the art will appreciated that other molecules can be usedbased on the teachings in this disclosure.

In particular examples detecting differential expression includesdetecting differences in expression (such as an increase, decrease, orboth). The method can further include determining the magnitude of thedifference in expression, wherein the magnitude of the change isassociated with ischemic stroke. Particular examples of ischemicstroke-related molecules that are differentially expressed inassociation with the diagnosis of an ischemic stroke, and theirdirection of change (upregulated or downregulated), and the magnitude ofthe change (as expressed as a percent, t-statistic, and fold change) areprovided in Table 10.

TABLE 10 Exemplary patterns of expression associated with ischemicstroke Ischemic Stroke Molecule Change in Expression Magnitude of thechange CD163 Upregulated t-statistic of at least 7 (such as at least7.8) at least 50% at least 4-fold hypothetical protein FLJ22662upregulated t-statistic of at least 7.5 (such as Laminin A motif atleast 7.8) at least 50% at least 4-fold BST-1 upregulated t-statistic ofat least 6 (such as at least 6.4) at least 50% at least 4-fold FcγRIupregulated t-statistic of at least 4.5 (such as at least 5.7) at least50% at least 4-fold baculoviral IAP repeat- upregulated t-statistic ofat least 4 (such as at containing protein 1 least 4.4) at least 50% atleast 4-fold KIAA0146 upregulated t-statistic of at least 5 (such as atleast 6.5) at least 50% at least 4-fold intercellular adhesion molecule2 downregulated t-statistic of no more than −5.0 (such as no more than−5.4) at least 50% at least 4-fold protein kinase D2 downregulatedt-statistic of no more than −5.0 (such as no more than −5.5) at least50% at least 4-fold GATA binding protein 3 downregulated t-statistic ofno more than −5.5 (such as no more than −5.9) at least 50% at least4-fold hypothetical protein FLJ20257 downregulated t-statistic of nomore than −5.5 (such as no more than −5.9) at least 50% at least 4-foldprotein kinase C, theta downregulated t-statistic of no more than −6(such as no more than −6.1) at least 50% at least 4-fold

Therefore, CD163; hypothetical protein FLJ22662 Laminin A motif; BST-1;FcγRI; baculoviral IAP repeat-containing protein 1; and KIAA0146 areupregulated by a magnitude of at least 50%, at least 4-fold or have at-statistic of at least 4. That is, CD163; hypothetical protein FLJ22662Laminin A motif; BST-1; FcγRI; baculoviral IAP repeat-containing protein1; and KIAA0146 are upregulated by an amount associated with ischemicstroke, for example at least 50% or at least 4-fold (or have at-statistic of at least 4). In addition, intercellular adhesion molecule2, protein kinase D2, GATA binding protein 3, hypothetical proteinFLJ20257, and protein kinase C, theta are downregulated by a magnitudeof at least 50%, at least 4-fold or have a t-statistic of no more than−5. That is, intercellular adhesion molecule 2, protein kinase D2, GATAbinding protein 3, hypothetical protein FLJ20257, and protein kinase C,theta are downregulated by an amount associated with ischemic stroke,for example at least 50% or at least 4-fold (or have a t-statistic of nomore than −5).

One example of a pattern of expression of proteins that have been foundto be associated with ischemic stroke, such as upregulation of CD163;hypothetical protein FLJ22662 Laminin A motif; and BST-1, wherein themagnitude of change is at least 4-fold for each of CD163; hypotheticalprotein

FLJ22662 Laminin A motif; and BST-1. Another example of a pattern ofexpression of proteins that have been found to be associated withischemic stroke is as upregulation of CD163; hypothetical proteinFLJ22662 Laminin A motif; BST-1; FcγRI; baculoviral IAPrepeat-containing protein 1; and KIAA0146, for example wherein themagnitude of change is at least 4-fold for each of these proteins.

In view of the many possible embodiments to which the principles of ourinvention may be applied, it should be recognized that the illustratedembodiment is only a preferred example of the invention and should notbe taken as a limitation on the scope of the invention. Rather, thescope of the invention is defined by the following claims. We thereforeclaim as our invention all that comes within the scope and spirit ofthese claims.

1. A method of determining whether a human subject has had an ischemicstroke, comprising: detecting expression of ischemic stroke-relatednucleic acid molecules of the subject obtained from a blood sample,wherein the ischemic stroke-related molecules comprise at least fourischemic stroke-related molecules represented by any combination of atleast four molecules listed in any of Tables 2-5; comparing expressionof the ischemic stroke-related nucleic acid molecules to a controlrepresenting expression of the ischemic stroke-related nucleic acidmolecules expected in a subject who has not had an ischemic stroke; anddetermining that the subject has had an ischemic stroke when thepresence of an at least 4-fold change in expression of the ischemicstroke-related nucleic acid molecules in the subject relative to thecontrol is detected.
 2. The method of claim 1, wherein expression ofischemic stroke-related nucleic acid molecules is detected within 24hours of onset of clinical signs and symptoms that indicate a potentialstroke.
 3. The method of claim 1, wherein expression of ischemicstroke-related nucleic acid molecules is detected within 7-14 days ofonset of clinical signs and symptoms that indicate a potential stroke.4. The method of claim 1, wherein expression of ischemic stroke-relatednucleic acid molecules is detected within 90 days of onset of clinicalsigns and symptoms that indicate a potential stroke.
 5. The method ofclaim 1, wherein the at least four ischemic-stroke related moleculescomprise CD163, hypothetical protein FLJ22662 Laminin A motif;adrenomedullin; KIAA0146 protein; amyloid β(A4) precursor-like protein;CD36; baculoviral IAP repeat-containing protein 1; or combinationsthereof.
 6. The method of claim 1, wherein the method comprisesdetermining whether there is increased expression any combination of atleast four ischemic stroke-related genes, wherein the presence ofincreased expression of the at least four ischemic stroke-relatedmolecules indicates that the subject has had an ischemic stroke.
 7. Themethod of claim 1, wherein the method has a sensitivity of at least 78%and accuracy of at least 80%.
 8. The method of claim 1, wherein thesubject had an onset of clinical signs and symptoms of an ischemicstroke no more than 72 hours prior to detecting expression of the atleast four ischemic stroke-related molecules.
 9. The method of claim 1,where the nucleic acid molecules comprise mRNA or cDNA.
 10. The methodof claim 1, wherein the nucleic acid molecules are isolated from thesubject, thereby generating isolated nucleic acid molecules, and whereinthe isolated nucleic acid molecules are hybridized with oligonucleotidesthat detect the at least four ischemic stroke-related molecules.
 11. Themethod of claim 10, wherein the oligonucleotides are present on an arraysubstrate.
 12. The method of claim 1, wherein the nucleic acid moleculesisolated from the blood sample are obtained from peripheral bloodmononuclear cells (PBMCs).
 13. The method of claim 1, wherein theisolated nucleic acid molecules are labeled with a detectable label. 14.The method of claim 11, wherein the oligonucleotides are labeled with adetectable label.
 15. The method of claim 1, wherein the blood sample isobtained from the subject within 24 hours of onset of clinicalindications of stroke.
 16. The method of claim 1, further comprisingadministering to the subject a treatment to avoid or reduce ischemicinjury if the expression indicates that the subject has had an ischemicstroke.
 17. The method of claim 16, wherein the selected treatmentcomprises treating the subject with an anticoagulant agent, athrombolytic agent, or combinations thereof.
 18. The method of claim 1,wherein detecting expression comprises quantifying expression of the atleast four ischemic stroke-related molecules.
 19. An array comprisingoligonucleotides complementary to ischemic stroke-related genesequences, wherein the ischemic stroke-related gene sequences compriseany combination of at least four of the genes listed in Tables 2-5. 20.A method of determining whether a human subject has had an ischemicstroke, comprising: applying isolated nucleic acid molecules obtainedfrom PBMCs of the subject to an array, wherein the array consists ofoligonucleotides complementary to at least four ischemic stroke-relatedmolecules represented by any combination of at least four moleculeslisted in any of Tables 2-5; incubating the isolated nucleic acidmolecules with the array for a time sufficient to allow hybridizationbetween the isolated nucleic acid molecules and oligonucleotide probes,thereby forming isolated nucleic acid molecule:oligonucleotidecomplexes; and analyzing the isolated nucleic acidmolecule:oligonucleotide complexes to determine if expression of theisolated nucleic acid molecules is altered, wherein the presence ofdifferential expression in the at least four ischemic stroke-relatedmolecules indicates that the subject has had an ischemic stroke.